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Abstract 
 
Background: Polyunsaturated fatty acid (PUFA) intake is low throughout Latin 
America, but sociodemographic patterning and dietary sources of PUFA status in the region are 
poorly characterized. PUFA may be related to the development of early-life risk factors for 
cardiometabolic diseases, which have reached epidemic proportions in Latin America. However, 
the relations between these nutrients and cardiometabolic risk in children are poorly understood. 
Objectives: To identify sociodemographic, anthropometric, and dietary correlates of 
PUFA status in Mesoamerica (aim 1), and to examine the relations of n-3 and n-6 PUFA with 
metabolic syndrome (MetS) (aim 2) and development of adiposity in children (aim 3). 
Methods: Aims 1 and 2 were completed using data from the Nine Mesoamerican 
Countries Metabolic Syndrome (NiMeCoMeS) study, a cross-sectional investigation of school-
age children and their parents from the capital cities of Guatemala, Honduras, El Salvador, 
Nicaragua, Costa Rica, Belize, Panama, the Dominican Republic, and the city of Tuxtla 
Gutíerrez in Chiapas, Mexico. Researchers collected information on sociodemographic 
characteristics; food intake and the type of cooking oil used in the home were measured by food 
frequency questionnaire. PUFA concentrations were quantified in adipose tissue by gas 
chromatography. 
In aim 1, we assessed correlates of adipose tissue PUFA biomarkers by estimating 
percent mean differences in each PUFA between levels of predictors using multivariable-
adjusted linear regression models. 
 xiii 
In aim 2, we examined associations between PUFA and MetS in parents, and between 
PUFA and a continuous metabolic risk score in children. We estimated prevalence ratios of MetS 
in adults and mean differences in metabolic score in children across quartiles of PUFA using 
multivariable-adjusted Poisson and linear regression models, respectively. 
Aim 3 was conducted in the context of a cohort of children from Santiago, Chile who 
were recruited in infancy and followed through adolescence. PUFA were quantified in serum at 5 
and 10 y of age. Body mass index (BMI) was measured at 5, 10, and 16 y. We compared the 
change in BMI-for-age Z scores through 16 y of age between PUFA quartiles at 5 or 10 y and 
between quartiles of PUFA change from 5 to 10 y by fitting growth curves from multivariable 
linear mixed models with restricted cubic splines. 
Results: Country of origin was the strongest predictor of all essential and long-chain 
PUFA biomarkers. The type of cooking oil used in the home was the strongest dietary correlate 
of PUFA status. Among adults, MetS prevalence was inversely associated with adipose tissue 
alpha-linolenic acid (ALA) and gamma-linolenic acid (GLA), and positively associated with 
eicosapentaenoic acid (EPA), dihomo-gamma-linolenic acid (DGLA), and the Δ6-desaturase 
activity index. Among children, metabolic risk score was positively associated with 
docosapentaenoic acid (DPA). Serum concentrations of some long-chain n-3 PUFA in middle 
childhood were associated with less weight gain through adolescence whereas the n-6 PUFA 
arachidonic acid (AA) and estimated Δ5-desaturase activity are related to increased weight gain. 
Conclusions and significance: PUFA status within Latin America is heterogeneous and 
is related to the type of vegetable oil used for cooking. ALA is inversely associated with MetS 
among adults but long-chain n-3 PUFA do not appear to be protective against MetS in children 
or adults. However, they may be protective against development of adiposity in middle 
 xiv 
childhood. These results suggest that PUFA are related to cardiometabolic risk in early life and 
could serve as modifiable targets for intervention.  
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Chapter 1. Introduction 
Overview 
Polyunsaturated fatty acids (PUFA) are vital nutrients with roles in many different 
physiological processes. In Latin America, information on the state of PUFA nutrition is sparse. 
However, available evidence suggests that intake of n-3 and n-6 PUFA is inadequate (1,2). 
 Cardiometabolic diseases such as cardiovascular disease (CVD) and diabetes have 
become some of the leading causes of death in Latin America (3). Risk factors for these 
conditions can develop in childhood (4) and persist to adulthood (5), underscoring the 
importance of early prevention. The prevalence of some of these early-life risk factors including 
childhood obesity and metabolic syndrome (MetS) in Latin American countries is alarmingly 
high (6). Nutrition in childhood is related to the development of cardiometabolic risk (7) and 
potentially modifiable, yet the relations between early-life PUFA nutrition and these risk factors 
are poorly understood.  
Specific PUFA are related to lower risk of CVD (8,9) and diabetes (10,11). Among 
adults, PUFA are also associated with risk factors for these diseases such as MetS and its 
components (12,13) and obesity (14), although not all studies are consistent. Investigations of 
these associations in children are very limited, and the results are inconclusive (15–19). In 
addition, very few studies have been conducted in Latin American populations and results from 
high-income countries may not be generalizable to this region. This dissertation seeks to address 
gaps in knowledge regarding PUFA and cardiometabolic risk in Latin America, with a particular 
focus on children.   
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Specific aims 
This work aims to describe sociodemographic and dietary correlates of PUFA status in 
Mesoamerica, and to characterize associations between specific PUFA and cardiometabolic risk 
factors in early life. 
Aim 1. To identify sociodemographic, anthropometric, and dietary factors that are 
associated with adipose tissue PUFA concentrations among school-age children and their parents 
from Mesoamerica. We will examine characteristics such as sex, age, height, body mass index 
(BMI), socioeconomic status indicators, and country of origin. Potential dietary correlates 
include the type of cooking oil used in the home and frequency of intake of foods high in PUFA. 
Aim 2. To examine the relations between PUFA in adipose tissue and MetS among 
Mesoamerican parents and their children. As a secondary aim, we will also examine the 
associations of PUFA biomarkers with the individual MetS components: abdominal obesity, high 
fasting glucose, hypertension, low high-density lipoprotein (HDL) cholesterol, and high serum 
triglycerides. 
Aim 3. To investigate associations between serum PUFA concentrations at 5 and 10 y of 
age and change in BMI-for-age-and-sex Z scores through adolescence in a cohort of children 
from Santiago, Chile. 
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Polyunsaturated fatty acids in Latin America 
Overview of polyunsaturated fatty acids 
Fatty acids are the basic molecular components of fat. In the diet, they serve both as a 
source of energy and as nutrients with specific physiological roles. Polyunsaturated fatty acids 
(PUFA) are those that contain more than one double bond in their aliphatic chain, and they are 
classified primarily into the n-3 and n-6 families. Each of these families contains a precursor 
fatty acid considered essential because it can only be obtained from the diet. Endogenous 
conversion of essential fatty acids into downstream long-chain PUFA occurs through the action 
of desaturase and elongase enzymes. The efficiency of this conversion is, however, highly 
variable and generally low (20). 
The n-3 essential fatty acid is alpha-linolenic acid (ALA, 18:3 n-3), and long-chain n-3 
PUFA include eicosapentaenoic acid (EPA; 20:5 n-3), docosapentaenoic acid (DPA, 22:5 n-3), 
and docosahexaenoic acid (DHA; 22:6 n-3). ALA can be obtained from vegetable oils made 
from soyabean, rapeseed (canola), and flaxseed. EPA and DHA are found preformed in fatty fish 
and other marine sources, in addition to their endogenous conversion from ALA. In the n-6 
family, the essential fatty acid is linoleic acid (LA; 18:2 n-6) and its products include gamma-
linolenic acid (GLA; 18:3 n-6), dihomo-gamma-linolenic acid (DGLA; 20:3 n-6), and 
arachidonic acid (AA; 20:4 n-6). LA is found in vegetable oils, particularly safflower, sunflower, 
corn, and cottonseed oils. In addition to endogenous production from LA, some AA is obtained 
in the diet from animal products such as meat and eggs. N-3 and n-6 PUFA are crucial to health 
and development through their roles as structural components of cell membranes and as 
precursors for the synthesis of eicosanoids, a class of local signaling molecules that regulate gene 
expression, cardiovascular function, and immune response (21). 
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Polyunsaturated fatty acid nutrition in Latin America 
Despite the physiologic importance of PUFA, little is known about fatty acid nutrition 
and status in Latin American countries. 
In a meta-analysis of national nutrition surveys, the estimated average intakes of n-6 
PUFA in percentage of total energy (%E) among adults in 2010 in central, Andean, tropical, and 
southern Latin America were 5.5, 4.7, 6.9, and 6.2%E, respectively (2). While these averages are 
in line with the World Health Organization's (WHO) Acceptable Macronutrient Distribution 
Range (AMDR) for LA of 2.5-9%E (22), there is evidence that a much higher intake of 12%E 
from n-6 PUFA is optimal for prevention of chronic disease and mortality, and that 10% of all 
coronary heart disease deaths in Latin America were attributable to n-6 PUFA intake below this 
level in 2010 (23). Intakes of seafood-based long-chain n-3 PUFA in central, Andean, tropical, 
and southern Latin America (in mg/d) were estimated to be 62, 94, 57, and 150 mg/d, and intakes 
of plant-based n-3 PUFA were 552, 824, 1742, and 1288 mg/d (2). The lower limit of the AMDR 
set by the WHO is 250 mg/d for long-chain n-3 PUFA and 0.5%E for ALA, equivalent to 1100 
mg/d in a 2000 cal/d diet (22); however, optimal intake of ALA for disease prevention is 
estimated to be 1-2%E (24). None of the estimated intakes of long-chain n-3 PUFA achieve this 
minimum, and only the estimated intakes in tropical and southern Latin America meet the 
minimum for ALA. Furthermore, while these results generally suggest low PUFA intake in many 
parts of Latin America, the only national surveys available for analysis were from Mexico, 
Colombia, Brazil, and Argentina. Intake for all other countries was estimated based on data from 
these and other data sources; the true intake levels are unknown. Another analysis using food 
balance sheets from the Food and Agriculture Organization also concluded that fish availability 
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was low throughout Latin America, and that availability of vegetable oils high in ALA was low 
in some countries as well (1). Information on PUFA intake among children specifically is 
generally consistent with studies of adults. Data from the Mexican National Health and Nutrition 
Survey from 2006 indicate a mean intake of 4.5%E and 0.3%E from n-6 and n-3 PUFA among 
school-age children, and 5.5%E and 0.3%E among adolescents (25). In a study of Costa Rican 
adolescents in 2006, mean intakes of LA and ALA were 7.8%E and 0.9%E, respectively (26). 
Mean intake of EPA+DHA was 82 mg/d, having decreased from 120 mg/d a decade earlier. In a 
group of Guatemalan children, mean intakes of LA, ALA, and EPA+DHA were 5.3%E, 0.5%E, 
and 42 mg/d among children of high socioeconomic status, and 5.9%E, 0.5%E, and 40 mg/d 
among children of low socioeconomic status (27). 
Countries in Latin America are at varying stages of the nutrition transition (28). This 
transition describes the process through which countries undergoing economic development 
experience a shift from undernutrition-related conditions towards obesity-related chronic disease 
as diets become Westernized (29). This Western diet is characterized in part by a high intake of 
fat, but with an increase in the proportion of saturated relative to unsaturated fats. The transition 
typically first affects the better-off who can afford access to Westernized diets, and then shifts 
toward poorer people as access to these lifestyle patterns becomes widespread. The nutrition 
transition may be contributing to higher intakes of saturated fat at the expense of PUFA among 
specific demographic and socioeconomic populations within Latin American (30), but current 
data are lacking. Information on the dietary sources of PUFA in Latin American contexts is also 
limited. Evidence from Costa Rica and Colombia suggests that vegetable oils used for cooking 
are the primary source of dietary PUFA (26,31) and are influential in determining PUFA status 
(32). Based on data from Costa Rica (26), Mexico (25), and Guatemala (27), other dietary 
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sources of n-3 and n-6 PUFA include beans, baked goods, fast food, dairy, chicken, fish, and 
eggs. 
Limited available evidence suggests that PUFA intake is generally inadequate throughout 
Latin America. While this potentially represents a significant public health concern, it is difficult 
to design and implement effective interventions aimed at increasing dietary PUFA without better 
information about the current state of PUFA status and its sociodemographic and dietary 
correlates. 
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Cardiometabolic disease in Latin America 
Cardiometabolic diseases including CVD and diabetes are among the leading causes of 
death in Latin America (3). Although these conditions typically manifest later in life, their risk 
factors can develop during childhood (4) and persist into adulthood (5,33,34). In conjunction 
with the high burden of cardiometabolic disease, the prevalence of related risk factors is high 
among children and adolescents in Latin America (6). 
Risk factors among children 
Childhood obesity is perhaps the strongest and most prevalent early-life risk factor for 
chronic diseases in adulthood, including type 2 diabetes, hypertension, and coronary heart 
disease (5). Childhood obesity is highly prevalent in Latin America and has been increasing in 
many countries over the past decade (35). Based on data from the WHO Global Database on 
Child Growth and Malnutrition (36), the prevalences of overweight and obesity in children under 
5 years of age in 1990 in Central and South America were 5.1% and 7.3% respectively, and in 
2011 they were 6.4% and 7.4% (35). Among school-age children, the prevalences of 
overweight/obesity estimated from recent national surveys (2009 onwards) in Brazil, Colombia, 
and Mexico were 33.5%, 18.9%, and 34.5%, with increases of about 1% per year between 2005 
and 2010 in Colombia and between 1999 and 2006 in Mexico (35).  
Metabolic syndrome (MetS) is a cluster of typically co-occurring cardiovascular risk 
factors including abdominal obesity, high fasting glucose, hypertension, low HDL cholesterol, 
and high serum triglycerides (37). These risk factors can be present in childhood and track into 
adulthood (38,39), when they are associated with high risk of CVD or diabetes (40) and CVD-
related mortality (41). Adverse metabolic profiles in childhood predict the development of 
cardiometabolic outcomes in adulthood, including type 2 diabetes and atherosclerosis (38,42). 
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Information on the prevalence of pediatric MetS in Latin America is scarce, and assessment is 
complicated by the fact that there is no widely agreed-upon definition of the syndrome in 
children. Evidence from some low- and middle-income countries suggests that metabolic 
abnormalities are highly prevalent among children (43). One study of 61 Bolivian children and 
adolescents defined MetS using a modified version of the National Cholesterol Education 
Program’s Adult Treatment Panel III (ATP III) definition and found a prevalence of 36% (44). 
The Nine Mesoamerican Countries Metabolic Syndrome (NiMeCoMeS) Study, a cross-sectional 
study of 267 children and their parents from urban areas in Mesoamerica, used a continuous 
metabolic score rather than a dichotomous definition of metabolic syndrome (45). Higher 
metabolic scores were associated with having parents with metabolic syndrome. The prevalence 
of metabolic syndrome among parents was high (37.9% in mothers and 35.3% in fathers). 
Risk factors among adults 
Prevalence of cardiometabolic risk factors is also high among Latin American adults. The 
Latin American Consortium of Studies on Obesity combined data on obesity from 11 studies 
conducted between 2000 and 2008 in urban and rural populations from 8 countries (46). The 
overall prevalence of obesity was 16.1%; abdominal obesity, 35.8%; hypertension, 20.2%; low 
HDL, 53.3%; and high triglycerides, 26.5% (47). The CARMELA study of adults in 7 Latin 
American cities found similar results: the prevalence of obesity was 23%; hypertension, 18%; 
and MetS, 20% (48). In the NiMeCoMeS study, the prevalence of obesity was 34.2% overall; in 
women and men respectively, the prevalence of abdominal obesity was 70.0% and 24.1%; high 
fasting glucose, 9.8% and 8.1%; hypertension, 15.4% and 29.4%; low HDL, 83.3% and 78.9%; 
high triglycerides, 39.8% and 63.2%; and MetS, 37.9% and 35.3% (45).  
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Taken together, these findings indicate that cardiometabolic disease and early 
development of cardiometabolic risk factors are of great public health concern in Latin America. 
Risk factors in childhood represent a key point of intervention against these conditions, when the 
cumulative impact on health is still limited. Childhood nutrition, which is related to early 
development of cardiometabolic risk factors (7), is a potentially modifiable and influential target 
for intervention. 
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Polyunsaturated fatty acids and cardiometabolic risk factors 
PUFA may influence the development of cardiometabolic risk factors in adults 
(12,14,49), although studies conducted among Latin American populations are limited (50,51). 
Intervening on PUFA nutrition could be a promising means of reducing the burden of childhood 
obesity and MetS, but associations between PUFA and these conditions in children are poorly 
understood. 
PUFA and development of adiposity 
In vitro and animal studies indicate that n-6 PUFA promote adipogenesis, while n-3 
PUFA inhibit it (52). Prostacyclin, an eicosanoid product of AA, promotes adipocyte 
differentiation from preadipocytes (53) through up-regulation of transcription factors that 
promote expression of peroxisome proliferation-activated receptor gamma (PPARγ), a necessary 
receptor for adipocyte formation (52,54). Long-chain n-3 fatty acids increase satiety and thus 
decrease total calorie intake (55). They also regulate lipid metabolism by promoting expression 
of genes involved in lipolysis and -oxidation and inhibiting lipogenesis, thus reducing fat 
deposition (56). 
In children, most research on PUFA and adiposity is cross-sectional in nature (16,17,57–
64). These studies have examined PUFA biomarkers mainly in blood components in relation to 
BMI or to obesity, and have generally not found consistent associations between specific PUFA 
and adiposity. DGLA was positively associated with either BMI or obesity in several 
(17,60,62,64) but not all studies (58,61,63). Results related to all other PUFA were inconclusive. 
Two longitudinal studies have examined associations between adiposity and PUFA. In 
one, ALA was inversely associated with estimated BMI-for-age Z score gain between ages 6 and 
14 y among 668 children from Bogotá, Colombia who were 5-12 y old at baseline and followed 
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for a median of 30 months (15). In the other, 3 y changes in plasma DHA and DGLA were each 
positively associated with concomitant change in standardized weight, whereas change in LA 
was inversely associated with weight change among 77 Japanese children who were 10 y old at 
baseline (18). 
PUFA and development of MetS and its components 
There are several mechanisms by which PUFA may affect development of metabolic 
syndrome. Generally, the eicosanoid products of n-6 PUFA such as AA are pro-inflammatory, 
whereas eicosanoids derived from n-3 PUFA are anti-inflammatory (65,66), and displacement of 
AA in cell membranes by EPA and DHA or vice versa alters the levels of production of these 
different classes of eicosanoids and therefore affects inflammatory processes. N-3 PUFA may 
also reduce inflammation through other mechanisms including conversion into pro-resolving 
mediators such as resolvin that end acute inflammatory response, and down-regulation of pro-
inflammatory transcription factors (66). N-3 PUFA alter lipid profiles; the mechanisms include 
up-regulation of triglyceride oxidation rather than storage, and lowered secretion of very low 
density lipoprotein (VLDL) (67). They also promote vasodilation through activation of nitric 
oxide synthase, and reduce production of vasoconstrictive prostaglandins, which are synthesized 
from AA (66). N-3 PUFA may reduce insulin resistance through lowered inflammation, up-
regulation of the insulin-sensitizing hormones leptin and adiponectin, and regulation of gene 
expression for several proteins involved in carbohydrate metabolism (68). 
Several cross-sectional studies have examined PUFA and pediatric MetS or its 
components (16,17,63,69,70). Circulating ALA biomarkers were not associated with MetS in 
these studies (17,63,70), but results for other PUFA were inconsistent. In one longitudinal study 
of 1267 2-10 y old European children, ALA and EPA at baseline were inversely associated with 
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blood pressure at follow up among normal weight children, but positively associated among 
those with overweight or obesity (71). GLA and AA were each positively associated with blood 
pressure. A few trials of long-chain n-3 PUFA supplementation have been conducted among 
children. Of these, some found a protective effect of EPA, DHA, or both on blood pressure, HDL 
cholesterol (72,73), triglycerides (73,74), or measures of insulin sensitivity (73–75); two of these 
studies were conducted in Mexican children (73,75). One additional trial of EPA+DHA+GLA 
found no effect on any MetS components (76). Finally, in a review of trials and observational 
studies of PUFA during pregnancy, lactation, and infancy, there were inconsistent associations 
between these exposures and MetS components during early childhood and adolescence (19). 
Summary 
The literature on PUFA and cardiometabolic risk factors in childhood has many 
limitations. The majority of existing studies are cross-sectional, which prevents causal inference 
and allows for the possibility of reverse causation if adiposity and metabolic dysregulation affect 
PUFA levels. Many of these studies are also small, and several did not conduct analyses adjusted 
for confounders. Most studies relied on PUFA concentrations measured in blood components; 
only one (62) used adipose tissue biomarkers, which are the gold standard biomarker of fatty 
acid status because they reflect long-term intake (77). Finally, very few studies have been 
conducted in Latin American populations, and results may not be generalizable to this region. 
More research is needed in order to clarify the relation of PUFA status to cardiometabolic risk in 
childhood.  
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Summary of chapters 
This dissertation seeks to generate knowledge regarding the associations between PUFA 
status and cardiometabolic risk in Latin American contexts, particularly among children. The 
sociodemographic patterning and dietary sources of PUFA in Latin America is largely unknown, 
and more information is needed in order to design effective interventions aimed at increasing 
PUFA intake. To this end, chapter 2 identifies sociodemographic, anthropometric, and dietary 
correlates of adipose tissue PUFA biomarkers among a group of school-age children and their 
parents from Mesoamerica. Next, the work in chapters 3 and 4 focuses on the relations between 
specific PUFA and cardiometabolic risk factors in children. In chapter 3, we examine 
associations between adipose tissue PUFA and MetS among the Mesoamerican families.  In 
chapter 4 we assess whether serum PUFA in middle childhood are related to BMI-for-age Z 
score trajectories through adolescence. Finally, chapter 5 summarizes the main findings from 
previous chapters and provides a discussion of the significance of the work for public health.  
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Chapter 2. Sociodemographic, anthropometric, and dietary predictors of polyunsaturated 
fatty acids in adipose tissue among Mesoamerican children and their parents 
 
Kerry S. Flannagan, Manuel Ramirez-Zea, Ana Victoria Roman,  
Arun K. Das, Eduardo Villamor 
 
Abstract 
Objective: To characterize sociodemographic, anthropometric, and dietary predictors of 
polyunsaturated fatty acid (PUFA) status biomarkers in adipose tissue among children and their 
parents from Mesoamerica. 
Design: Cross-sectional study. Concentrations of linoleic acid (LA), total long-chain n-6 PUFA 
(n-6 LCPUFA), alpha-linolenic acid (ALA), and total long-chain n-3 PUFA (n-3 LCPUFA) from 
gluteal adipose tissue were quantified with the use of gas chromatography. Dietary information 
was measured with a food frequency questionnaire. We estimated percent mean differences in 
each PUFA between levels of predictors using multivariable-adjusted linear regression models. 
Setting: Capitals of Guatemala, El Salvador, the Dominican Republic, Honduras, Nicaragua, 
Panama, Costa Rica, and Belize, and Tuxtla Gutiérrez in Mexico. 
Subjects: Children (n=220) aged 7-12 y and 471 parents. 
Results: Country was the strongest predictor of each PUFA while BMI was positively associated 
with n-6 LCPUFA in children and adults. Cooking primarily with soyabean oil was positively 
associated with LA and ALA concentrations, whereas cooking with canola oil was related to n-6 
 22 
and n-3 LCPUFA concentrations. Adipose tissue ALA concentrations were 25.1% (95% CI: 
0.4%, 55.9%) higher among children in the 90th percentile of intake frequency of cream, 
compared to those in the 10th percentile. N-3 LCPUFA concentrations among adults in the 90th 
percentile of fish and canned fish intake frequency were 12.1% (95% CI: -4.0%, 30.9%) and 
16.1% (95% CI: -1.3%, 36.5%) higher, respectively, than among those in the 10th percentiles. 
Conclusions: Adipose tissue PUFA status in Mesoamerica is associated with country of origin, 
the type of oil used for cooking, and intake of specific foods.  
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Introduction 
Polyunsaturated fatty acids (PUFA) are nutrients that are required for a wide range of 
physiologic functions and that exert many important health effects. The n-6 PUFA linoleic acid 
(18:2 n-6; LA) and the n-3 PUFA alpha-linolenic acid (18:3 n-3; ALA) are essential because 
they cannot be synthesized in the human body and must be obtained through diet, primarily from 
plant oils. Long-chain n-6 and n-3 PUFA (n-6 and n-3 LCPUFA) are produced through 
endogenous metabolism of LA and ALA (1), and can also be obtained preformed in the diet from 
meat or eggs (n-6 LCPUFA) and fatty fish (n-3 LCPUFA). LCPUFA serve as precursors for 
eicosanoids, a class of signaling molecules that regulate immune and cardiovascular function. 
Many of the eicosanoids derived from n-6 LCPUFA are pro-inflammatory, while those derived 
from n-3 LCPUFA are generally anti-inflammatory (1). 
In adults, n-3 LCPUFA intake is associated with reduced risk of cardiovascular disease, 
some cancers, and mood or cognitive disorders (2). ALA may also be cardioprotective (3). 
Evidence for the effects of LA and n-6 LCPUFA on cardiovascular disease and its risk factors is 
less conclusive (4). PUFA intake has also been related to cardiometabolic risk factors in children 
(5,6). 
In Latin America, available evidence suggests that PUFA intake in adults and children 
may be inadequate (7–9). Fish and vegetable oils high in ALA are scarce in many countries (10). 
Low PUFA intake in this region is of particular concern because the rates of cardiovascular 
disease (11), childhood obesity (12), and childhood metabolic dysregulation (13) are high. 
Improving PUFA status through dietary interventions might be a useful public health measure 
against chronic disease (14). However, current and detailed information about PUFA status in 
Latin American populations is lacking. It is unclear whether PUFA status varies according to 
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demographic, socioeconomic, anthropometric, or dietary characteristics. The type of oil used for 
cooking is an important predictor of PUFA status (7,14,15), and most dietary PUFA is in the 
form of essential fatty acids while intake of preformed LCPUFA is low (7–9). Many previous 
studies of PUFA status relied on dietary methods that may be subject to errors due to recall or 
inaccurate estimation of the fatty acid content of foods. Moreover, these measures may not 
accurately reflect physiological PUFA status especially with respect to LCPUFA which can be 
endogenously metabolized. Adipose tissue fatty acids are the gold standard biomarkers of fatty 
acid status because they reflect intake over several years (16); nevertheless, they are seldom 
ascertained in population studies. 
We conducted a cross-sectional study to examine sociodemographic, anthropometric, and 
dietary correlates of adipose tissue PUFA concentrations among school-aged children and their 
parents in nine Mesoamerican countries.  
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Methods 
Study design and population 
We conducted a cross-sectional investigation of school children and their parents in the 
context of the Nine Mesoamerican Countries Metabolic Syndrome (NiMeCoMeS) Study. Details 
of the study design have been described previously (13). In brief, between July 2011 and 
November 2013 we identified families from the capital cities of Guatemala, El Salvador, the 
Dominican Republic, Honduras, Nicaragua, Panama, Costa Rica, and Belize, and the city of 
Tuxtla Gutiérrez in Chiapas, Mexico, with use of public primary school enrollment lists in each 
city.  From these lists, study teams randomly selected potentially eligible students who were 7-12 
y of age. Additional eligibility criteria were assessed at school visits; these included that the child 
lived with both biological parents, that neither the child nor their mother was pregnant, and that 
the child did not have any siblings already invited to participate. Parents of children who met all 
inclusion criteria were offered enrollment. The final sample comprised 267 families (Guatemala, 
31; El Salvador, 30; the Dominican Republic, 30; Honduras, 30; Nicaragua, 31; Panama, 26; 
Costa Rica, 27; Belize, 31; and Mexico, 31).  
This study was conducted according to the guidelines laid down in the Declaration of 
Helsinki. All procedures involving human subjects/patients were approved by the Institutional 
Review Boards (IRB) of collaborating institutions in each of the nine countries and by the 
University of Michigan Health and Behavioral Sciences IRB. All parents provided written 
informed consent to participate for themselves and their children. Assent to participate was 
confirmed from the children before enrollment. 
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Data collection 
All data collection procedures took place at home or at a family visit to a health center. 
Participants were asked to fast for at least 6 hours before the appointment. At this visit, mothers 
completed a background questionnaire that included questions on each participant's age, 
education level, and smoking status, as well as socioeconomic status (SES) indicators. Food 
security was assessed with the Latin American and Caribbean Food Security Scale, an instrument 
that has been validated for use in this region (17). The scale consists of 16 yes/no questions about 
experiences of food insecurity over the previous 3 months. 
Trained research assistants administered a 97-item food frequency questionnaire (FFQ) to 
each family member, adapted closely from an FFQ that was validated for use among Costa Rican 
adults (18). The FFQ incorporated appropriate country-specific adjustments of food names. It 
inquired about habitual intake frequency over the previous 12 months of foods and food groups 
commonly eaten in the region, including dairy, fruit, vegetables, eggs and meat, bread, flour, 
cereal, juice, caffeinated and alcoholic beverages, fast food, desserts, dressings and sauces, and 
cooking fats. There were also questions on the brand of butter, margarine, lard/shortening, or 
vegetable oil used if participants indicated that they consumed any of these fats, and a question 
about the composition of the vegetable oil most frequently used for cooking, from a list that 
included soyabean, sunflower, corn, palm, olive, canola, mixed oils, or other. Intake frequency 
options were >6 times/d, 4-5 times/d, 2-3 times/d, 1 time/d, 5-6 times/wk, 2-4 times/wk, 1 
time/wk, 1-3 times/mo, and <1 time/mo or never. Portion sizes were described in natural units or 
with the use of typical measures of volume.  
Anthropometric measures were obtained from each participant with use of standardized 
procedures and calibrated instruments. Height was measured without shoes to the nearest 
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millimeter with the use of portable Seca stadiometers (Seca, Hamburg, Germany). Weight was 
measured in light clothing to the nearest 100 g with use of Tanita scales (Tanita, Tokyo, Japan). 
All measures were obtained in triplicate. 
At the end of the visit, researchers obtained samples of subcutaneous adipose tissue from 
each family member. After numbing the upper external area of the left gluteus with an ice pack 
and a local anesthetic spray, a 16-gauge needle was inserted at a 45˚ angle and adipose tissue was 
aspirated into the syringe (19). Samples were transported on ice to laboratories in each country 
where they were stored in a 3:2 hexane:isopropanol solution in amber vials at -70˚C. The 
samples were transported frozen from their respective countries to the Institute of Nutrition of 
Central America and Panama (INCAP) in Guatemala City, and from there to the University of 
Michigan for fatty acid analysis. 
Laboratory methods 
Analysis of adipose tissue fatty acids was completed at the University of Michigan 
Regional Comprehensive Metabolomics Resource Core. Total lipids were extracted from 20-25 
mg of adipose tissue according to the method described by Bligh and Dyer (20), with 10 μL of 4 
mM nonadecanoic acid (C19:0) added as an internal standard. The fatty acid components of the 
total lipids were then derivatized into their methyl esters using boron trifluoride-methanol (21). 
The methyl esters were extracted with a 2:1 hexane-water mixture and centrifugation. The 
hexane layer was removed and dried and the methyl esters were re-dissolved in 100-200 μL of 
hexane, depending on the volume of the original sample. Fatty acids were analyzed by gas 
chromatography (GC). One to two μL of sample was injected via auto sampler onto an Agilent 
6890N gas chromatograph (Agilent, Santa Clara CA, USA) equipped with a flame ionization 
detector, a 100 m x 0.25 mm x 0.2 μm SP-2560 column (Sigma-Aldrich, Bellefonte PA, USA), 
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and Chemstation software for data analysis. Fatty acids were quantified using a calibration curve 
prepared from known amounts of C19:0 (the internal standard) and other authentic methyl esters. 
The authentic methyl esters were also used to identify the fatty acids in samples by comparing 
retention times. The coefficient of variation for GC analyses was between 2.5-3.6%.  
Data analyses 
Adipose tissue samples were available in 220 children and 471 parents; these constituted 
the analytic sample. The primary outcomes were four adipose tissue biomarkers of 
polyunsaturated fatty acids, expressed as mass percentages of the total fatty acids measured in a 
sample: LA, n-6 LCPUFA (sum of eicosadieneoic acid, dihomogamma-linolenic acid, 
arachidonic acid, and adrenic acid), ALA, and n-3 LCPUFA (sum of eicosapentaenoic acid, 
docosapentaenoic acid, and docosahexaenoic acid). 
Sociodemographic exposures included sex, age, education level, smoking status, number 
of household assets, food security, and country of origin. Parental education was categorized 
according to the number of completed school years (incomplete elementary, 1–5; complete 
elementary, 6; incomplete secondary, 7–11; complete secondary, 12; or post-secondary, ≥13). 
Adults were classified as never, past, or current smokers. We determined the number of assets 
each family had from a list that included a car, bicycle, refrigerator/freezer, gas stove, electric 
stove, blender, microwave, washing machine, color TV, sound set, computer, and internet. We 
created a household food insecurity score as the sum of all affirmative answers to the survey and 
categorized it as none (0), mild (1-5), moderate (6-10), or severe (11-16) (22). Anthropometric 
exposures included height and body mass index (BMI, calculated as kg/m2). We estimated the 
median of the three replicate measures obtained (23). In the adults, height was categorized into 
sex-specific quartiles and BMI was categorized as <25, 25 - <30, or ≥30 (24). For children, we 
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considered sex, age, height, BMI, the mother's age at the child's birth, maternal height, maternal 
BMI, maternal education level, parental smoking history (the number of parents who ever 
smoked: none, 1, or 2), number of household assets, food security, and country of origin. 
Children's height and BMI were converted into age-and-sex-specific Z scores using the World 
Health Organization Growth Reference for children ages 5-19 y (25). 
The main dietary exposure was the composition of the household's primary cooking oil 
(soyabean, canola, corn, sunflower, palm, vegetable mixtures, or other) as reported in the FFQ. 
Oil composition was derived from manufacturers' information about the reported brand of oil in 
40% of participants and from directly reported oil composition in the rest. 
We also examined intake frequencies of specific foods from the FFQ as additional dietary 
exposures. In order to select these foods, we matched each item on the FFQ to its closest 
corresponding item in a set of nutrient composition tables of Costa Rican foods (26). We then 
used the food composition tables to identify those foods from the FFQ with the highest 
concentration of each PUFA (LA, n-6 LCPUFA, ALA, and n-3 LCPUFA) per 100 g. Some items 
(e.g. fish) were more broadly defined in the FFQ than they were in the food composition tables 
(e.g. tilapia, haddock, etc.). In those cases, we calculated the mean PUFA concentrations across 
all matches in the food composition tables. In addition to the foods identified from the 
composition tables, we included others that have previously been reported as important dietary 
sources of PUFA in Mesoamerican populations (7–9). The final list of foods is presented in 
Supplemental Table 2. We estimated intake frequencies in servings/d using as weights the 
average frequency corresponding to each categorical response on the FFQ. Weights for <1/mo 
and ≥6/d were 0 and 6, respectively. 
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We conducted analyses separately among children and adults. In bivariate analyses, we 
compared the distribution of each outcome between categories of sociodemographic, 
anthropometric, and cooking oil type variables with the use of means ± SD. For ordinal 
predictors, we performed tests for linear trend by introducing a variable representing categories 
of the predictor as a continuous covariate in a linear regression model. For nominal predictors, 
we conducted χ2 score tests. For analyses of intake frequencies as exposures, we first log-
transformed the PUFA outcomes because their distributions were skewed, and then estimated 
percent differences in mean PUFA concentrations with 95% confidence intervals comparing the 
90th and 10th percentiles of intake frequency in servings/d of each food item using linear 
regression. 
In multivariable analyses we first fitted linear regression models to estimate adjusted 
percent mean differences in each outcome by levels of sociodemographic and anthropometric 
characteristics. All models included sex, age, and country of origin, plus additional predictors 
that were relevant to each outcome per bivariate analyses. Next, we estimated percent mean 
differences in each outcome by cooking oil type and food intake frequency adjusted for sex, age, 
education level (adults) or maternal education level (children), and other sociodemographic 
characteristics that were relevant for the outcome in multivariable analyses. Foods were retained 
in the model for each outcome when they remained statistically significant at P <0.05 or were 
considered important from a theoretical viewpoint. In the main analyses, country was excluded 
from these models because it is likely a substantial source of true variability in the exposures; 
nevertheless, in supplemental analyses we also fit models in which country was included. BMI 
was also excluded because it could be on the causal path between cooking oil or food intake 
frequency and PUFA in adipose tissue. In additional supplemental analyses, we examined the 
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associations of cooking oil type with Δ6-desaturase activity, one of the enzymes involved in 
endogenous conversion of essential fatty acids into LCPUFA. The outcome of these models was 
the ratio of dihomogamma-linolenic acid to LA; because Δ6-desaturase is the rate-limiting step 
in converting LA to dihomogamma-linolenic acid, a higher ratio should indicate higher enzyme 
activity. Predictors included cooking oil type, age, sex, and education or maternal education. All 
regression models were fitted using generalized estimating equations and empirical standard 
errors, which are robust to heteroskedasticity and non-normality (27). An exchangeable 
correlation structure was specified in all models for adults to account for clustering by family 
membership.  
We conducted all analyses using Statistical Analysis Software version 9.4 (SAS Institute, 
Cary NC, USA).  
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Results 
Children. The mean (±SD) age of participating children was 10.0 ± 1.2 y and 52.3% 
were girls. Unadjusted means (±SD) of adipose tissue PUFA in children varied by 
sociodemographic and anthropometric characteristics (Table 1), cooking oil type (Supplemental 
Table 1), and food intake frequency (Supplemental Table 2). The proportion of households 
using each type of cooking oil differed by country (Supplemental Figure 1), and intake 
frequency of specific foods varied between children and adults (Supplemental Table 5). 
Linoleic acid. Mean (±SD) LA weight percentage was 14.02 ± 4.84. In adjusted analysis, 
LA was positively associated with female sex and age (Table 2). Children from the Dominican 
Republic and Panama had the highest LA concentrations while children from El Salvador and 
Honduras had the lowest (P<0.0001). LA was highest among children whose families used 
soyabean or other oils and lowest among those whose families used palm oil (P=0.001) (Figure 
1A). Simultaneous adjustment for country and cooking oil type attenuated the associations with 
cooking oil, while the associations with country remained similar. LA was positively associated 
with intake frequencies of corn tortillas, butter/margarine added to food, dressing/mayonnaise, 
cake, and fried chicken, and inversely associated with that of hamburger, cream, and fish (Figure 
1A). 
Total long-chain n-6 PUFA. After adjustment, n-6 LCPUFA was positively associated 
with height- and BMI-for-age Z scores (Table 2). Children from Costa Rica and the Dominican 
Republic had the highest n-6 LCPUFA concentrations, while children from Belize and Honduras 
had the lowest (P<0.0001). N-6 LCPUFA concentrations were highest in children whose families 
used mainly canola oil and lowest in those whose families used palm oil (P=0.08) (Figure 1B). 
Cooking oil type was not associated with Δ6-desaturase activity. When country and cooking oil 
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type were included in the model together, the associations with cooking oil type were attenuated. 
N-6 LCPUFA in adipose tissue was positively associated with intake frequencies of 
butter/margarine added to food and cake and inversely associated with frequency of hamburger 
intake (Figure 1B). 
Alpha-linolenic acid. Mean (±SD) ALA weight percentage was 0.74 ± 0.35. ALA was 
inversely associated with the mother's age at the child's birth after multivariable adjustment 
(Table 2). ALA was highest among children from the Dominican Republic and Mexico and 
lowest among children from El Salvador and Costa Rica (P<0.0001). ALA was highest among 
children whose families used other oils and lowest among those whose families used palm oil 
(P=0.04) (Figure 1C). Inclusion of country in the model attenuated the associations with oil 
type, but did not appreciably change the associations with country. ALA was positively 
associated with intake frequencies of cream, dressing/mayonnaise, butter/margarine added to 
food, cake, and corn tacos/tostadas, and inversely associated with those of white bread, 
hamburger, avocado, refried beans, and fish (Figure 1C). 
Total long-chain n-3 PUFA. In adjusted analysis, n-3 LCPUFA was positively associated 
with age and height-for-age Z score (Table 2). Children from the Dominican Republic and 
Mexico had the highest n-3 LCPUFA concentrations whereas children from Honduras and Costa 
Rica had the lowest (P<0.0001). Children whose families used primarily canola oil had the 
highest n-3 LCPUFA concentrations while those whose families used corn oil had the lowest 
(P=0.004) (Figure 1D). When country and oil type were included in the model simultaneously, 
the associations with oil type were attenuated. Adipose tissue n-3 LCPUFA was positively 
associated with intake frequencies of dressing/mayonnaise and hot dogs and inversely associated 
with intake frequencies of refried beans (Figure 1D). 
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Adults. Mean (±SD) age of adult participants was 38.3 ± 7.3 y and 52% were women. 
Unadjusted means (±SD) of adipose tissue PUFA varied by sociodemographic characteristics 
(Table 3), cooking oil type (Supplemental Table 3), and food intake (Supplemental Table 4).  
Linoleic acid. Mean (±SD) LA weight percentage was 14.78 ± 4.82 in men and 15.26 ± 
4.95 in women. In adjusted analysis, age and smoking were inversely associated with adipose 
tissue LA (Table 4). LA concentrations were highest among participants from the Dominican 
Republic and Costa Rica and lowest among those from Honduras and El Salvador (P<0.0001). 
Adipose tissue LA was highest among participants who used soyabean oil as their primary 
cooking oil and lowest among those who used palm oil (P<0.0001) (Figure 2A). When country 
and cooking oil type were included in the model simultaneously, the associations with cooking 
oil were attenuated while the associations with country remained mostly unchanged. LA was 
positively associated with intake frequencies of butter/margarine added to food, canned 
tuna/sardines, white bread, and viscera, and inversely associated with intake frequencies of 
cream, corn products, and fresh cheese, after multivariable adjustment (Figure 2A).  
Total long-chain n-6 PUFA. After adjustment, adipose tissue n-6 LCPUFA was lower in 
men compared with women and positively associated with BMI (Table 4). N-6 LCPUFA 
concentrations were highest among participants from Costa Rica and Guatemala, and lowest 
among those from Honduras and El Salvador (P<0.0001). People who used canola oil had the 
highest n-6 LCPUFA concentrations whereas those who primarily used palm oil had the lowest 
(P=0.002) (Figure 2B). Cooking oil type was not associated with Δ6-desaturase activity. 
Including both country and cooking oil type in the model attenuated the associations with 
cooking oil type. N-6 LCPUFA was positively associated with intake frequencies of 
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butter/margarine added to food and hamburger, and inversely associated with those of cream, 
chorizo, fried chicken, and corn products (Figure 2B). 
Alpha-linolenic acid. Mean (±SD) ALA weight percent was 0.75 ± 0.34 in men and 0.75 
± 0.33 in women. ALA was inversely associated with BMI in multivariable analysis (Table 4). 
Dominican and Nicaraguan participants had the highest concentrations while those from El 
Salvador and Honduras had the lowest (P<0.0001). Users of soyabean oil had the highest ALA 
concentrations whereas users of palm oil had the lowest (P<0.0001) (Figure 2C). Inclusion of 
country in the model attenuated the associations with cooking oil type. Intake frequency of 
salami was positively associated with ALA concentrations, while those of cream, corn tortillas, 
corn products, and sausage were inversely associated (Figure 2C). 
Total long-chain n-3 PUFA. N-3 LCPUFA concentration in adipose tissue was lower in 
men compared with women in multivariable analysis (Table 4). N-3 LCPUFA was highest 
among participants from Costa Rica and Guatemala and lowest among those from Honduras and 
Nicaragua (P<0.0001). Concentrations were highest in canola oil users and lowest among users 
of palm or corn oils (P=0.03) (Figure 2D). When country was included in the model, the 
associations with oil type were attenuated. N-3 LCPUFA was positively associated with intake 
frequency of corn tortillas and inversely associated with intake frequencies of hard cheese, 
cream, beef/pork in soups or stews, and cooked eggs (Figure 2D).  
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Discussion 
In this cross-sectional study of Mesoamerican families, adipose tissue concentrations of 
LA, n-6 LCPUFA, ALA, and n-3 LCPUFA were associated with demographic and 
anthropometric characteristics, the main type of oil used for cooking in the home, and intake 
frequencies of specific foods. 
The overall means of adipose tissue LA and ALA in our study are similar to those from a 
meta-analysis of 19 studies conducted in healthy adult populations, primarily from Europe and 
the United States (16). In that review, mean mole percentages of LA and ALA in adipose tissue 
were 13.9% and 0.8%, respectively, compared with 15.0% and 0.8% in adults and 14.0% and 
0.7% in children from Mesoamerica. However, LA and ALA concentrations in some countries in 
our study, including El Salvador and Honduras, were much lower than those reported in other 
populations. This suggests that intake of essential fatty acids is low in parts of Mesoamerica as 
compared to high-income countries, and that there is heterogeneity within the region. The only 
estimates previously available for Mesoamerica are from a study of Costa Rican adults evaluated 
between 1994 and 1998. In that study, mean LA and ALA weight percentages were 13.37% and  
0.55%, respectively (28); compared with 17.60% and 0.86% in Costa Rican adults from our 
study. The higher values measured in our study may indicate differences in diet by area of 
residence or an increase in PUFA intake over the previous decades.  
BMI was positively associated with n-6 LCPUFA in all participants, and inversely 
associated with ALA in adults. Several previous studies of PUFA biomarkers have found 
positive associations between BMI and specific n-6 LCPUFA, but associations between BMI and 
ALA are inconsistent (6,29–31). Intake of ALA may inhibit the promotion of adipogenesis by n-
6 LCPUFA (32), which could explain both of our findings. However, these associations may also 
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be attributable to reverse causation as a result of altered PUFA metabolism in adipose tissue of 
persons with obesity (33). 
Country of origin was the strongest predictor of all PUFA in both children and adults. 
This is consistent with a European study in which region was the strongest predictor of plasma 
PUFA concentrations (34). Differences by country likely mainly reflect differences in lifestyle 
and diet, especially in the case of adipose tissue LA and ALA, which do not appear to be 
genetically determined (35). Country-specific distributions of cooking oil usage were consistent 
with some differences in PUFA by country: soyabean oil use was highest in Dominican 
households, corresponding to high LA and ALA among Dominican participants, and palm oil 
usage was highest in Honduras and El Salvador, corresponding to low levels of all PUFA among 
participants from these countries. Adjustment for cooking oil type did not appreciably change the 
associations of any PUFA with country, while the associations with cooking oil type were 
attenuated. We believe the reason for the attenuation is that country is the main source of 
variability in type of oil used. Previous studies in Costa Rica suggest that cooking oil is a 
significant predictor of PUFA intake (7,15), and we cannot rule out that usage of different types 
of oils explains at least in part the differences in PUFA by country in the present study. These 
associations may also reflect differences in intake of specific foods or variation in the PUFA 
content of oils and foods according to the country in which they are produced (36). 
The primary type of oil used for cooking in the home was a significant predictor of 
essential n-6 and n-3 PUFA in children and adults. Some of these associations are expected 
according to the fatty acid composition of cooking oils in Latin American countries (37–39). 
Soyabean and canola oils are high in ALA, whereas palm oil is low in all n-6 and n-3 PUFA; 
correspondingly, in our study soyabean and canola oil users had among the highest ALA levels, 
 38 
whereas palm oil users had among the lowest levels of all PUFA. LA content is highest in corn 
and sunflower oils (37–39), but we observed the highest adipose LA concentrations among users 
of soyabean oil. This is consistent with previous findings from Costa Rica, where use of 
soyabean oil low in trans fatty acids was associated with higher adipose tissue LA concentrations 
(15).  
We also found that cooking oil usage predicted LCPUFA status, despite the low levels of 
preformed LCPUFA typically found in vegetable oils (37–39). This is in line with the results of 
an intervention study among Colombian families in which soyabean or sunflower oil increased 
whole blood LCPUFA concentrations in school-age children (14). In our study, canola oil users 
had among the highest levels of both n-6 and n-3 LCPUFA, despite not having the highest levels 
of LA and ALA. The conversion of essential fatty acids into LCPUFA by desaturase enzymes is 
inhibited by high essential fatty acid intake (40), and total essential fatty acid content is higher in 
soyabean and corn oils than in canola oil (37–39). However, Δ6-desaturase activity did not differ 
significantly between users of different oil types; thus, these findings cannot be explained by 
higher Δ6-desaturase activity among canola oil users as a result of lower total essential fatty acid 
intake. Canola oil is a rich source of ALA, which could explain the higher levels of n-3 
LCPUFA, but has relatively less LA compared to the other oil types. The reason for higher levels 
of n-6 LCPUFA among canola users is unclear. 
The specific foods associated with each PUFA differed somewhat between children and 
adults, possibly as a result of different dietary patterns or preparations. LA and ALA were each 
associated with a mix of plant- and animal-source foods; however, for almost all foods, the 
difference associated with nearly the entire range of intake frequency in the population was 
smaller than the range of essential fatty acid levels associated with different oil types. Two of the 
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strongest positive associations were between ALA and milk and cream among children, which is 
consistent with a study that found whole milk to be one of the main dietary sources of total n-3 
PUFA among Guatemalan children (9). Even at the low frequency of intake in this population, 
fish intake was positively associated with n-3 LCPUFA among adults and children, and intake of 
canned tuna/sardines was positively associated among adults. Unexpectedly, we found that 
canned tuna/sardine intake was inversely associated with n-3 LCPUFA in children, despite a 
similar range of intake as that among adults. Habitual intake of this food may be measured with 
greater error in children than adults, or the association may be due to chance. 
We did not find significant associations between SES indicators and adipose tissue 
PUFA. This could be because social determinants of PUFA intake, such as access to or 
preference for certain cooking oils among people of different SES, vary substantially by country 
(38,41). Our sample sizes per country precluded within-country analyses. 
Our study has several strengths. We examined associations that have not been well-
characterized in Mesoamerican populations, and that are relevant to public health concerns in the 
region, including the low intake of dietary sources of n-3 LCPUFA (10). PUFA were measured 
in adipose tissue, the gold standard biomarker of fatty acid intake. We had available measures of 
sociodemographic, anthropometric, and dietary characteristics, which allowed us to assess a wide 
range of correlates of PUFA status and control for many confounders. Finally, the family design 
provided an opportunity to investigate associations separately for adults and children. 
The primary limitation of this study is its cross-sectional design, which prevents causal 
inference. Reverse causation could explain some of the results, including the association between 
BMI and n-6 LCPUFA. The study population was not intended to be representative of any 
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particular group, which may limit the generalizability of our findings. In addition, the small 
sample sizes within each country prevented us from fully assessing country-specific associations. 
In conclusion, we found that country of origin, type of oil used for cooking, and intake 
frequency of specific foods are important correlates of adipose tissue PUFA concentrations in 
Mesoamerican adults and children. Our results suggest that cooking oil type is a predictor not 
only of essential fatty acid status but of LCPUFA as well, and that some dietary correlates of 
PUFA status differ between adults and children. Future studies should assess whether and which 
dietary interventions could improve the PUFA status of this population.  
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Table 2.1. Mean (± SD) of adipose tissue n-6 and n-3 polyunsaturated fatty acid weight percent 
concentrations by sociodemographic characteristics among children from Mesoamerica 
Characteristics N LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Overall 220 14.02 ± 4.84 0.94 ± 0.73 0.74 ± 0.35 0.18 ± 0.17 
  
 
            Sex 
 
            Female 115 14.65 ± 4.98 0.90 ± 0.40 0.76 ± 0.34 0.15 ± 0.12 
Male 105 13.33 ± 4.61 0.99 ± 0.97 0.71 ± 0.36 0.20 ± 0.21 
Pb 
 
0.04 0.40 0.29 0.05 
     
   
      
Age (years) 
             
<9 67 13.27 ± 4.20 0.87 ± 0.36 0.70 ± 0.25 0.16 ± 0.19 
9 - <11 79 14.27 ± 4.74 0.96 ± 1.04 0.77 ± 0.40 0.16 ± 0.16 
≥11 74 14.43 ± 5.45 1.00 ± 0.54 0.74 ± 0.37 0.21 ± 0.16 
P, trenda 
 
0.16 0.10 0.44 0.09 
              
Height-for-age Z score 
             
<-2 11 13.39 ± 7.21 0.81 ± 0.50 0.65 ± 0.44 0.17 ± 0.19 
-2 - <-1 41 14.25 ± 4.48 0.85 ± 0.46 0.72 ± 0.31 0.15 ± 0.15 
-1 - <0 80 13.05 ± 4.32 0.93 ± 1.03 0.72 ± 0.36 0.17 ± 0.18 
0 - <1 56 15.01 ± 5.33 0.95 ± 0.46 0.80 ± 0.35 0.18 ± 0.13 
≥1 32 14.62 ± 4.51 1.14 ± 0.49 0.73 ± 0.35 0.22 ± 0.23 
P, trend 
 
0.23 0.01 0.30 0.15 
              
BMI-for-age Z score 
             
<-1 34 13.65 ± 4.47 0.75 ± 0.35 0.73 ± 0.34 0.18 ± 0.19 
-1 - <0 44 13.93 ± 5.85 0.81 ± 0.47 0.76 ± 0.40 0.15 ± 0.15 
0 - <1 66 13.40 ± 4.72 1.07 ± 1.17 0.73 ± 0.36 0.20 ± 0.21 
≥1 76 14.77 ± 4.46 1.00 ± 0.37 0.75 ± 0.32 0.17 ± 0.13 
P, trend 
 
0.24 0.0001 0.91 0.79 
              
Maternal age at child's birth (years) 
            
<20 29 14.75 ± 5.83 1.05 ± 1.60 0.93 ± 0.49 0.22 ± 0.21 
20 - <25 54 14.19 ± 5.17 0.92 ± 0.47 0.73 ± 0.32 0.19 ± 0.19 
25 - <30 75 13.42 ± 4.48 0.90 ± 0.50 0.68 ± 0.33 0.15 ± 0.12 
30 - <35 41 15.16 ± 4.44 0.97 ± 0.37 0.79 ± 0.30 0.14 ± 0.13 
≥35 21 12.47 ± 4.20 0.98 ± 0.63 0.60 ± 0.24 0.22 ± 0.26 
P, trend 
 
0.41 0.89 0.02 0.32 
              
Maternal height (cm) 
             
140.6 - 151.9 58 13.30 ± 4.99 0.89 ± 0.48 0.70 ± 0.34 0.20 ± 0.24 
152.0 - 155.7 50 13.89 ± 4.59 1.11 ± 1.28 0.78 ± 0.39 0.16 ± 0.17 
155.8 - 159.2 58 13.98 ± 4.37 0.88 ± 0.43 0.70 ± 0.27 0.16 ± 0.11 
159.3 - 181.9 54 14.95 ± 5.35 0.92 ± 0.44 0.79 ± 0.40 0.18 ± 0.13 
P, trend 
 
0.10 0.73 0.43 0.68 
 
             
 43 
Table 2.1. Mean (± SD) of adipose tissue n-6 and n-3 polyunsaturated fatty acid weight percent 
concentrations by sociodemographic characteristics among children from Mesoamerica 
Characteristics N LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
 
Maternal body mass index (kg/m2) 
            
<25 54 14.49 ± 3.94 0.92 ± 0.36 0.73 ± 0.25 0.16 ± 0.16 
25 - <30 79 14.55 ± 5.65 0.95 ± 1.04 0.81 ± 0.44 0.16 ± 0.15 
≥30 87 13.25 ± 4.50 0.95 ± 0.54 0.68 ± 0.30 0.20 ± 0.19 
P, trend 
 
0.06 0.69 0.19 0.24 
              
Maternal education level 
             
Incomplete elementary 40 13.71 ± 6.11 0.85 ± 0.47 0.72 ± 0.40 0.19 ± 0.17 
Complete elementary 26 12.61 ± 3.69 1.07 ± 0.61 0.64 ± 0.23 0.23 ± 0.29 
Incomplete secondary 56 13.68 ± 4.70 1.00 ± 1.23 0.76 ± 0.41 0.17 ± 0.17 
Complete secondary 39 14.14 ± 4.29 0.88 ± 0.36 0.78 ± 0.26 0.15 ± 0.11 
Post secondary 53 15.14 ± 4.72 0.96 ± 0.40 0.76 ± 0.37 0.17 ± 0.13 
P, trend 
 
0.09 0.71 0.30 0.24 
 
             
Parental smoking history 
             
Neither parent ever smoked 84 15.08 ± 5.97 0.92 ± 0.42 0.82 ± 0.40 0.19 ± 0.17 
One parent ever smoked 99 13.48 ± 3.98 1.02 ± 0.98 0.71 ± 0.31 0.18 ± 0.18 
Both parents ever smoked 31 12.77 ± 3.04 0.81 ± 0.37 0.61 ± 0.25 0.15 ± 0.15 
P 
 
0.03 0.18 0.008 0.48 
              
Number of household assetsc 
             
0-4 42 15.50 ± 5.89 0.86 ± 0.33 0.82 ± 0.44 0.16 ± 0.12 
5-7 87 12.75 ± 4.46 0.93 ± 1.03 0.68 ± 0.33 0.21 ± 0.22 
8-9 40 14.89 ± 4.64 0.94 ± 0.50 0.76 ± 0.36 0.13 ± 0.12 
10-12 51 14.28 ± 4.24 1.04 ± 0.44 0.75 ± 0.28 0.16 ± 0.13 
P, trend 
 
0.99 0.08 0.76 0.21 
  
            Food insecurity 
 
            No insecurity 65 14.11 ± 4.99 1.00 ± 0.46 0.75 ± 0.34 0.15 ± 0.15 
Mild insecurity 58 13.36 ± 4.09 0.89 ± 0.44 0.69 ± 0.30 0.19 ± 0.19 
Moderate insecurity 56 13.48 ± 4.52 0.90 ± 1.18 0.73 ± 0.36 0.18 ± 0.19 
Severe insecurity 40 15.63 ± 5.81 1.02 ± 0.58 0.82 ± 0.42 0.19 ± 0.16 
P, trend 
 
0.28 >0.99 0.41 0.25 
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Table 2.1. Mean (± SD) of adipose tissue n-6 and n-3 polyunsaturated fatty acid weight percent 
concentrations by sociodemographic characteristics among children from Mesoamerica 
Characteristics N LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
 
Country of origin 
 
            Guatemala 27 15.18 ± 3.75 0.94 ± 0.30 0.66 ± 0.16 0.19 ± 0.20 
El Salvador 30 10.56 ± 2.34 1.20 ± 1.69 0.50 ± 0.39 0.15 ± 0.20 
Dominican Republic 28 22.04 ± 4.83 1.03 ± 0.21 1.23 ± 0.41 0.25 ± 0.11 
Honduras 27 10.87 ± 1.95 0.72 ± 0.27 0.76 ± 0.19 0.06 ± 0.07 
Nicaragua 27 12.64 ± 3.02 0.75 ± 0.27 0.66 ± 0.22 0.15 ± 0.11 
Panama 20 15.49 ± 2.00 0.84 ± 0.32 0.71 ± 0.19 0.17 ± 0.11 
Costa Rica 16 12.44 ± 4.55 1.56 ± 0.65 0.58 ± 0.35 0.15 ± 0.22 
Mexico 19 14.80 ± 3.36 0.99 ± 0.39 0.82 ± 0.25 0.29 ± 0.25 
Belize 26 12.15 ± 3.79 0.67 ± 0.29 0.71 ± 0.29 0.19 ± 0.15 
P 
 
<0.0001 <0.0001 <0.0001 <0.0001 
aWald test from linear regression models with each fatty acid as the outcome and a variable representing 
ordinal categories of each characteristic introduced as a continuous predictor. An exchangeable 
covariance structure was specified in all models to account for clustering by family membership. 
bχ2 score statistic from linear regression models with each fatty acid as the outcome and indicator 
variables for each level of the characteristic as predictors. 
cFrom a list that included car, bicycle, refrigerator/freezer, gas stove, electric stove, blender, microwave, 
washing machine, color TV, sound set, computer, and internet. 
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Table 2.2. Adjusted percent differences (95% CI)a in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by sociodemographic characteristics among children from 
Mesoamerica 
Characteristics LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Sex 
        
Female Reference Reference Reference Reference 
Male -8.2 (-14.6, -1.3) 3.6 (-7.2, 15.5) -4.6 (-15.2, 7.3) 13.0 (-6.5, 36.5) 
Pb 0.02 0.53 0.43 0.21 
         
Age 
        
Per 1 year 3.0 (0.6, 5.5) 2.7 (-0.7, 6.2) 0.7 (-2.3, 3.9) 10.4 (4.0, 17.2) 
Pb 0.01 0.12 0.64 0.001 
  
        
Height-for-age Z score 
        
Per 1 Z score 2.3 (-0.9, 5.6) 9.1 (3.5, 14.9) 1.7 (-3.7, 7.4) 10.3 (0.9, 20.7) 
Pb 0.16 0.001 0.55 0.03 
         
BMI-for-age Z score 
        
Per 1 Z score 2.1 (-0.1, 4.3) 5.4 (1.4, 9.6) 0.8 (-2.8, 4.5) 0.4 (-6.9, 8.2) 
Pb 0.06 0.007 0.68 0.92 
         
Maternal age at child's birth 
        
Per 1 year -0.1 (-0.6, 0.5) 0.3 (-0.8, 1.4) -0.9 (-1.7, -0.1) -0.5 (-2.2, 1.3) 
Pb 0.80 0.59 0.03 0.60 
         
Maternal education level 
        
Per 1 year 0.6 (-0.2, 1.3) -0.4 (-1.8, 1.1) -0.5 (-1.9, 1.0) -1.9 (-4.0, 0.3) 
Pb 0.13 0.62 0.51 0.09 
         
Country of origin 
        
Guatemala Reference Reference Reference Reference 
El Salvador -29.9 (-38.4, -20.2) -15.1 (-36.2, 13.1) -32.2 (-45.1, -16.3) -24.8 (-50.7, 14.7) 
Dominican Republic 44.5 (27.2, 64.1) 1.8 (-12.2, 18.0) 77.1 (51.8, 106.6) 50.3 (2.8, 119.8) 
Honduras -27.7 (-36.1, -18.2) -28.5 (-40.2, -14.4) 11.1 (-9.2, 35.9) -53.2 (-67.9, -31.8) 
Nicaragua -16.9 (-27.6, -4.7) -26.8 (-38.9, -12.4) -5.4 (-19.3, 10.7) -10.8 (-40.1, 33.0) 
Panama 5.8 (-5.7, 18.7) -21.3 (-37.1, -1.5) 7.1 (-7.6, 24.1) -4.5 (-37.4, 45.8) 
Costa Rica -25.2 (-41.5, -4.4) 45.5 (15.5, 83.4) -32.0 (-56.7, 6.6) -37.0 (-65.3, 14.3) 
Mexico -3.0 (-16.5, 12.8) -4.0 (-20.8, 16.4) 19.6 (0.8, 41.8) 56.7 (2.9, 138.8) 
Belize -21.7 (-33.9, -7.3) -35.8 (-47.2, -22.0) 1.9 (-14.5, 21.4) 4.2 (-32.1, 59.8) 
Pc <0.0001 <0.0001 <0.0001 <0.0001 
aFrom multivariable linear regression models with the log-transformed concentration of each fatty acid as the 
outcome. Estimates are adjusted for age, sex, and country of origin. In addition, the model for long-chain n-6 was 
adjusted for height-for-age Z score, the model for ALA was adjusted for maternal age at the child's birth, and the 
model for long-chain n-3 was adjusted for height-for-age Z score. 
bWald test from multivariable linear regression models with each fatty acid as the outcome. 
cχ2 score statistic from multivariable linear regression models with each fatty acid as the outcome and indicator 
variables for each level of the characteristic as predictors. 
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Figure 2.1. Adjusted percent differences (95% CI) in means of adipose tissue n-6 and n-3 polyunsaturated fatty acid concentrations by 
main oil type used at home for cooking and by food intake frequency (90th vs. 10th percentiles of servings/d) among children from 
Mesoamerica. 
Estimates and confidence intervals are plotted on the log scale. Estimates are from multivariable linear regression models with log-
transformed fatty acids as the outcome. For each fatty acid, cooking oil type and all foods for which estimates are presented are 
included in the model as predictors simultaneously. In addition, all estimates are adjusted for age (continuous), sex, and maternal 
education (continuous). Additionally, the model for long-chain n-6 is adjusted for height-for-age Z score (continuous), the model for 
ALA is adjusted for maternal age at child's birth (continuous), and the model for long-chain n-3 is adjusted for height-for-age Z score 
(continuous). Serving sizes: cream, dressing/mayonnaise, butter/margarine added to food: 1 tbs; chorizo, cooked eggs, fried/scrambled 
eggs, sausage, corn tortillas: 1 unit; sweet bread, white bread, canned tuna/sardines, fried chicken, hamburger, cake, fish, corn 
tacos/tostadas, hot dog: 1 portion; peanuts: 30g or 1 tbs; refried beans: 1/3 cup; viscera: ½ cup; avocado: ¼ unit; milk, 1 glass. N in 
each cooking oil category: soyabean, 63; sunflower, 17; corn, 20; palm, 24; canola, 15; mixed, 70; other, 3.
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Table 2.3. Mean (± SD) adipose tissue n-6 and n-3 polyunsaturated fatty acid weight percent 
concentrations by sociodemographic characteristics among adults from Mesoamerica 
Characteristics N 
LA 
18:2(n-6) 
Total  
long-chain n-6 
ALA  
18:3(n-3) 
Total  
long-chain n-3 
Overall 471 15.03 ± 4.89 1.16 ± 0.51 0.75 ± 0.34 0.24 ± 0.21 
              
Sex 
             
Female 245 15.26 ± 4.95 1.21 ± 0.50 0.75 ± 0.33 0.25 ± 0.17 
Male 226 14.78 ± 4.82 1.12 ± 0.50 0.75 ± 0.34 0.22 ± 0.25 
Pb 
 
0.06 0.03 0.78 0.18 
     
   
      
Age (years) 
             
<30 54 15.45 ± 4.87 1.08 ± 0.31 0.78 ± 0.32 0.22 ± 0.10 
30 - <35 100 15.66 ± 5.13 1.12 ± 0.48 0.83 ± 0.38 0.23 ± 0.23 
35 - <40 145 14.91 ± 4.56 1.16 ± 0.48 0.73 ± 0.30 0.24 ± 0.20 
40 - <45 97 14.99 ± 5.03 1.23 ± 0.64 0.73 ± 0.36 0.22 ± 0.15 
45 - <55 62 14.31 ± 5.02 1.23 ± 0.50 0.70 ± 0.33 0.25 ± 0.15 
55+ 12 12.88 ± 4.66 1.09 ± 0.54 0.68 ± 0.24 0.39 ± 0.70 
P, trenda 
 
0.07 0.21 0.08 0.34 
              
Height quartile (mothers/fathers medians, cm) 
          
Q1 (148.9/159.0) 115 14.77 ± 4.51 1.19 ± 0.47 0.69 ± 0.31 0.26 ± 0.30 
Q2 (153.1/164.9) 115 14.25 ± 4.99 1.13 ± 0.50 0.70 ± 0.34 0.22 ± 0.15 
Q3 (157.1/169.7) 127 15.16 ± 4.66 1.15 ± 0.59 0.77 ± 0.33 0.23 ± 0.16 
Q4 (162.8/176.4) 114 15.94 ± 5.30 1.18 ± 0.44 0.84 ± 0.35 0.23 ± 0.21 
P, trend 
 
0.44 0.72 0.002 0.50 
              
Body mass index (kg/m2) 
             
<25 118 15.95 ± 5.38 1.11 ± 0.51 0.78 ± 0.35 0.26 ± 0.28 
25-<30 190 14.91 ± 4.92 1.17 ± 0.48 0.74 ± 0.34 0.22 ± 0.20 
≥30 163 14.51 ± 4.40 1.20 ± 0.53 0.74 ± 0.33 0.23 ± 0.16 
P, trend 
 
0.09 0.11 0.21 0.37 
              
Education level 
             
Incomplete elementary 65 15.31 ± 5.72 1.14 ± 0.40 0.75 ± 0.37 0.22 ± 0.13 
Complete elementary 63 14.49 ± 3.73 1.22 ± 0.72 0.72 ± 0.28 0.23 ± 0.27 
Incomplete secondary 137 15.45 ± 4.89 1.16 ± 0.51 0.81 ± 0.35 0.22 ± 0.14 
Complete secondary 74 14.17 ± 4.98 1.09 ± 0.42 0.71 ± 0.35 0.24 ± 0.19 
Post secondary 122 15.28 ± 4.96 1.21 ± 0.48 0.74 ± 0.33 0.26 ± 0.28 
P, trend 
 
0.97 0.80 0.82 0.20 
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Table 2.3. Mean (± SD) adipose tissue n-6 and n-3 polyunsaturated fatty acid weight percent 
concentrations by sociodemographic characteristics among adults from Mesoamerica 
Characteristics N 
LA 
18:2(n-6) 
Total  
long-chain n-6 
ALA  
18:3(n-3) 
Total  
long-chain n-3 
Smoking status 
             
Never 301 15.81 ± 5.15 1.19 ± 0.50 0.78 ± 0.35 0.24 ± 0.18 
Past 129 13.92 ± 4.08 1.15 ± 0.54 0.71 ± 0.31 0.24 ± 0.29 
Current 39 12.38 ± 3.45 0.98 ± 0.36 0.70 ± 0.31 0.18 ± 0.13 
P 
 
0.0009 0.03 0.29 0.05 
              
Number of household assetsc 
             
0-4 84 14.90 ± 5.24 1.14 ± 0.46 0.76 ± 0.35 0.22 ± 0.12 
5-7 179 14.89 ± 5.06 1.08 ± 0.37 0.74 ± 0.34 0.22 ± 0.18 
8-9 93 15.58 ± 5.05 1.11 ± 0.44 0.78 ± 0.34 0.20 ± 0.12 
10-12 115 14.90 ± 4.21 1.36 ± 0.68 0.74 ± 0.32 0.31 ± 0.32 
P, trend 
 
0.83 0.004 0.78 0.008 
              
Food security 
             
No insecurity 147 15.19 ± 4.63 1.30 ± 0.61 0.75 ± 0.32 0.28 ± 0.29 
Mild insecurity 127 14.62 ± 4.98 1.10 ± 0.44 0.74 ± 0.34 0.22 ± 0.13 
Moderate insecurity 111 14.69 ± 5.04 1.10 ± 0.47 0.74 ± 0.35 0.21 ± 0.21 
Severe insecurity 84 15.80 ± 5.03 1.11 ± 0.40 0.79 ± 0.36 0.22 ± 0.13 
P, trend 
 
0.62 0.007 0.47 0.04 
              
Country of origin 
             
Guatemala 55 16.77 ± 2.74 1.23 ± 0.39 0.65 ± 0.15 0.30 ± 0.26 
El Salvador 59 11.41 ± 2.21 0.90 ± 0.41 0.44 ± 0.13 0.18 ± 0.15 
Dominican Republic 59 22.40 ± 4.93 1.22 ± 0.39 1.16 ± 0.36 0.24 ± 0.10 
Honduras 58 10.08 ± 2.61 0.97 ± 0.29 0.60 ± 0.32 0.16 ± 0.13 
Nicaragua 56 13.31 ± 2.92 1.02 ± 0.32 0.88 ± 0.29 0.15 ± 0.09 
Panama 46 15.72 ± 3.31 1.13 ± 0.34 0.69 ± 0.22 0.23 ± 0.16 
Costa Rica 43 17.60 ± 3.89 1.86 ± 0.92 0.86 ± 0.32 0.44 ± 0.46 
Mexico 40 15.05 ± 3.25 1.10 ± 0.23 0.82 ± 0.27 0.22 ± 0.07 
Belize 55 13.67 ± 3.33 1.21 ± 0.46 0.70 ± 0.29 0.24 ± 0.09 
P 
 
<0.0001 <0.0001 <0.0001 <0.0001 
aWald test from linear regression models with each fatty acid as the outcome and a variable representing 
ordinal categories of each characteristic introduced as a continuous predictor. An exchangeable 
covariance structure was specified in all models to account for clustering by family membership. 
bχ2 score statistic from linear regression models with each fatty acid as the outcome and indicator 
variables for each level of the characteristic as predictors. 
cFrom a list that included car, bicycle, refrigerator/freezer, gas stove, electric stove, blender, microwave, 
washing machine, color TV, sound set, computer, and internet. 
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Table 2.4. Adjusted percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by sociodemographic characteristics among adults from Mesoamerica 
Characteristics LA 18:2(n-6) 
Total 
long-chain n-6 
ALA 18:3(n-3) 
Total 
long-chain n-3 
Sex 
        
Female Reference Reference Reference Reference 
Male 0.5 (-4.3, 5.4) -9.5 (-14.7, -3.9) -0.8 (-7.9, 6.9) -17.5 (-25.4, -8.7) 
Pb 0.85 0.001 0.84 0.0002 
         
Age (years) 
        
Per 1 year -0.4 (-0.8, -0.1) 0.3 (-0.3, 0.8) -0.3 (-0.8, 0.2) 0.1 (-0.8, 0.9) 
Pb 0.02 0.33 0.18 0.87 
         
Height 
        
Per 1 cm -0.1 (-0.4, 0.3) 0.0 (-0.5, 0.4) 0.4 (-0.1, 1.0) -0.5 (-1.4, 0.5) 
Pb 0.72 0.88 0.15 0.33 
         BMI 
        
Per 1 kg/m2 -0.2 (-0.6, 0.1) 0.8 (0.2, 1.4) -0.7 (-1.2, -0.1) 0.0 (-0.9, 1.0) 
Pb 0.16 0.01 0.02 0.94 
         
Education level 
        
Per 1 year 0.0 (-0.5, 0.5) 0.5 (-0.2, 1.2) -0.2 (-0.9, 0.6) 1.0 (-0.1, 2.1) 
Pb 0.97 0.13 0.68 0.07 
         Smoking status 
        
Never Reference Reference Reference Reference 
Past -2.2 (-7.5, 3.5) 2.0 (-6.0, 10.7) -0.5 (-8.7, 8.5) 9.2 (-4.0, 24.4) 
Current -14.1 (-22.9, -4.2) -5.0 (-15.2, 6.4) -8.7 (-21.5, 6.2) 2.0 (-16.2, 24.2) 
Pc 0.04 0.49 0.49 0.43 
         
Country of origin 
        
Guatemala Reference Reference Reference Reference 
El Salvador -31.6 (-35.8, -27.0) -28.8 (-36.1, -20.6) -32.8 (-38.6, -26.5) -39.3 (-50.9, -25.0) 
Dominican Republic 29.4 (19.7, 39.9) -1.8 (-12.0, 9.7) 75.0 (57.2, 94.7) -13.9 (-28.2, 3.1) 
Honduras -40.6 (-45.5, -35.3) -22.6 (-30.9, -13.2) -13.9 (-24.6, -1.8) -44.6 (-54.4, -32.6) 
Nicaragua -20.7 (-27.0, -13.9) -17.1 (-26.6, -6.2) 29.9 (17.4, 43.9) -45.6 (-54.6, -34.9) 
Panama -7.9 (-14.7, -0.6) -8.9 (-19.2, 2.7) 4.0 (-7.3, 16.6) -23.7 (-39.0, -4.7) 
Costa Rica 3.3 (-5.2, 12.4) 38.6 (17.6, 63.2) 27.0 (7.7, 49.8) 18.5 (-8.1, 52.6) 
Mexico -12.4 (-20.5, -3.3) -8.2 (-16.3, 0.6) 22.0 (6.9, 39.3) -17.5 (-30.9, -1.4) 
Belize -21.4 (-27.9, -14.3) -6.0 (-18.0, 7.7) 1.8 (-12.5, 18.4) -11.2 (-25.1, 5.3) 
Pc <0.0001 <0.0001 <0.0001 <0.0001 
aFrom multivariable linear regression models of log-transformed fatty acids. Estimates are adjusted for age, sex, 
country of origin, and in the case of LA, smoking status. 
bWald test from multivariable linear regression models with a given fatty acid as the outcome. 
cType III F test of a categorical predictor from multivariable linear regression models with a given fatty acid as the 
outcome. 
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Figure 2.2. Adjusted percent differences (95% CI) in means of adipose tissue n-6 and n-3 polyunsaturated fatty acid concentrations by 
main oil type used at home for cooking and by food intake frequency (90th vs. 10th percentiles of servings/d) among adults from 
Mesoamerica.  
Estimates and confidence intervals are plotted on the log scale. Estimates are from multivariable linear regression models with log-
transformed fatty acids as the outcome. For each fatty acid, cooking oil type and all foods for which estimates are presented are 
included in the model as predictors simultaneously. In addition, all estimates are adjusted for age (continuous), sex, education 
(continuous), and for LA, smoking status (never, former, or current). Corn products include foods such as empanadas, pupusas, 
chorreadas, arepas, tamal asado, and others. Serving sizes: cream, dressing/mayonnaise, butter/margarine added to food: 1 tbs; corn 
products, chorizo, cooked eggs, fried/scrambled eggs, sausage, corn tortillas: 1 unit; fresh cheese, hard cheese, salami: 1 piece; sweet 
bread, white bread, canned tuna/sardines, fried chicken, hamburger, beef tortitas, cake, fish, beef/pork in soup or stew: 1 portion; 
peanuts, cashews: 30g or 1 tbs; viscera: ½ cup; avocado: ¼ unit; chocolate drink: 1 cup. N in each cooking oil category: soyabean, 
140; sunflower, 33; corn, 43; palm, 50; canola, 34; mixed, 148; other, 10.
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Supplemental Table 2.1. Means (±SD) of adipose tissue n-6 and n-3 polyunsaturated fatty acid 
weight percent concentrations by primary type of cooking oil among children from Mesoamerica 
Oil type N LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Soyabean 63 16.54 ± 6.02 0.97 ± 0.33 0.87 ± 0.42 0.23 ± 0.19 
Sunflower 17 13.96 ± 3.43 0.79 ± 0.28 0.70 ± 0.27 0.12 ± 0.11 
Corn 20 13.22 ± 5.23 0.87 ± 0.58 0.66 ± 0.39 0.12 ± 0.13 
Palm 24 10.63 ± 2.16 0.83 ± 0.62 0.57 ± 0.25 0.11 ± 0.15 
Canola 15 14.96 ± 2.79 1.24 ± 0.59 0.84 ± 0.27 0.22 ± 0.16 
Mixed oils 70 13.24 ± 3.89 0.95 ± 1.10 0.70 ± 0.31 0.18 ± 0.18 
Other 3 14.39 ± 2.89 0.86 ± 0.50 0.67 ± 0.26 0.24 ± 0.19 
Pa   <0.0001 0.17 0.007 0.01 
aχ2 score statistic from linear regression models with each fatty acid as the outcome and 
indicator variables for each oil type as predictors. 
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Supplemental Table 2.2. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
children from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Butter/margarine added to foodd 
        
Unadjusted 16.8 (9.0, 25.2) 8.9 (0.9, 17.5) 19.2 (6.9, 33.0) 9.9 (-7.5, 30.6) 
Adjusted, without countryb 16.0 (7.1, 25.6) 9.0 (0.5, 18.2) 20.8 (6.5, 36.9) 16.0 (-1.3, 36.3) 
Adjusted, with countryc 6.3 (0.2, 12.7) 0.4 (-7.5, 8.9) 14.3 (3.0, 26.9) 10.6 (-4.5, 28.2) 
         
Dressing/mayonnaised 
        
Unadjusted 12.9 (6.8, 19.4) 4.6 (-3.1, 12.9) 21.2 (12.9, 30.0) 20.1 (6.0, 36.1) 
Adjusted, without country 12.7 (6.5, 19.2) 3.7 (-3.3, 11.2) 22.0 (13.6, 30.9) 19.9 (5.9, 35.7) 
Adjusted, with country 4.4 (-0.4, 9.5) 0.3 (-5.5, 6.6) 9.6 (1.7, 18.0) 14.3 (1.3, 29.0) 
         
Avocadoe 
        
Unadjusted -1.5 (-8.2, 5.8) -2.2 (-10.0, 6.3) -5.3 (-13.6, 3.7) 1.9 (-12.0, 17.9) 
Adjusted, without country -3.3 (-11.7, 6.0) -5.6 (-14.6, 4.3) -7.4 (-17.4, 3.8) -4.4 (-20.6, 15.1) 
Adjusted, with country -5.5 (-10.6, -0.2) -12.5 (-20.6, -3.6) -9.9 (-17.2, -2.0) -4.1 (-17.7, 11.9) 
         
Peanutsf 
        
Unadjusted 3.7 (-7.9, 16.8) -9.8 (-21.6, 3.9) 0.3 (-19.6, 25.2) 1.2 (-15.5, 21.2) 
Adjusted, without country 3.1 (-8.6, 16.3) -10.8 (-22.5, 2.6) -1.6 (-21.7, 23.8) -0.4 (-15.6, 17.6) 
Adjusted, with country 2.1 (-3.2, 7.8) -7.8 (-15.6, 0.7) -9.7 (-26.3, 10.7) 1.1 (-10.5, 14.3) 
         
Cashewsf 
        
Unadjusted -2.3 (-6.0, 1.4) -2.8 (-8.9, 3.7) -2.9 (-7.6, 2.0) -1.7 (-9.3, 6.7) 
Adjusted, without country -2.9 (-6.1, 0.5) -3.1 (-9.5, 3.8) -3.3 (-8.1, 1.7) 0.2 (-7.9, 9.0) 
Adjusted, with country -0.4 (-3.9, 3.2) -0.5 (-6.5, 5.8) 0.1 (-4.5, 4.9) 2.7 (-6.0, 12.2) 
         
Refried beansg 
        
Unadjusted -9.8 (-15.0, -4.3) -7.5 (-15.3, 1.0) -9.7 (-16.9, -1.8) -18.7 (-28.8, -7.1) 
Adjusted, without country -8.2 (-13.7, -2.4) -7.2 (-14.5, 0.6) -10.0 (-17.2, -2.2) -21.6 (-31.6, -10.1) 
Adjusted, with country 3.1 (-2.4, 8.9) 2.9 (-5.9, 12.4) 1.7 (-6.1, 10.1) -16.5 (-29.4, -1.2) 
         
Corn tortillash 
        
Unadjusted -6.1 (-13.2, 1.7) 2.1 (-9.0, 14.6) -5.6 (-14.8, 4.6) -9.1 (-24.1, 8.8) 
Adjusted, without country -6.0 (-13.9, 2.6) 3.1 (-9.0, 16.9) -5.5 (-16.1, 6.5) -14.6 (-29.8, 4.0) 
Adjusted, with country 4.5 (-3.8, 13.6) 4.8 (-16.5, 31.4) 5.7 (-10.2, 24.3) -17.5 (-41.1, 15.6) 
         
Corn productsh,n 
        
Unadjusted -1.9 (-4.1, 0.4) -0.5 (-7.5, 7.1) -3.8 (-7.0, -0.4) -2.3 (-7.2, 2.7) 
Adjusted, without country -1.7 (-4.0, 0.7) -0.7 (-7.4, 6.6) -3.5 (-6.9, 0.1) -3.5 (-7.8, 1.0) 
Adjusted, with country 0.2 (-1.9, 2.3) -0.5 (-8.0, 7.6) -0.2 (-3.5, 3.2) -4.3 (-9.9, 1.6) 
         
Corn tostadas/tacosi 
        
Unadjusted 1.0 (-2.2, 4.3) 0.2 (-5.0, 5.8) 2.4 (-2.4, 7.4) 7.1 (-2.2, 17.3) 
Adjusted, without country 1.0 (-2.2, 4.4) -0.2 (-5.7, 5.6) 2.5 (-2.3, 7.7) 5.6 (-3.9, 16.0) 
Adjusted, with country 3.5 (-0.1, 7.2) 3.9 (-1.2, 9.4) 3.5 (-1.6, 8.8) 3.7 (-6.4, 14.8) 
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Supplemental Table 2.2. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
children from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
 
White breadi 
        
Unadjusted -3.8 (-15.1, 8.9) 6.1 (-17.3, 36.1) -23.6 (-39.3, -3.8) 4.5 (-23.6, 43.0) 
Adjusted, without country -4.8 (-16.0, 7.8) 4.0 (-19.2, 33.9) -23.1 (-40.0, -1.5) -2.0 (-28.1, 33.8) 
Adjusted, with country -6.7 (-17.3, 5.4) -13.9 (-34.1, 12.4) -13.4 (-34.7, 14.9) -5.0 (-38.8, 47.5) 
         
Sweet breadi 
        
Unadjusted -11.1 (-22.2, 1.6) 6.1 (-11.6, 27.3) -11.9 (-24.8, 3.2) -16.6 (-35.9, 8.6) 
Adjusted, without country -12.1 (-23.5, 1.1) 8.0 (-10.6, 30.4) -12.9 (-27.3, 4.2) -26.1 (-43.8, -2.9) 
Adjusted, with country -2.0 (-10.0, 6.8) 18.2 (-2.3, 43.0) 1.1 (-15.2, 20.4) -13.7 (-40.2, 24.6) 
         
Cakei 
        
Unadjusted 9.9 (3.6, 16.7) 5.2 (-1.4, 12.3) 14.4 (7.3, 21.9) 11.5 (-6.8, 33.4) 
Adjusted, without country 10.1 (3.9, 16.7) 5.9 (-1.0, 13.3) 13.2 (6.1, 20.8) 14.0 (-1.3, 31.6) 
Adjusted, with country 0.7 (-4.0, 5.6) 3.0 (-3.4, 9.8) 1.3 (-5.3, 8.3) 7.7 (-5.7, 23.0) 
         
Coated sandwich cookiesi 
        
Unadjusted 0.1 (-4.6, 5.0) 1.1 (-7.6, 10.7) -3.0 (-10.7, 5.3) -2.9 (-17.5, 14.2) 
Adjusted, without country 2.1 (-3.3, 7.8) 0.6 (-7.2, 9.1) -3.1 (-11.4, 6.1) -4.6 (-18.3, 11.3) 
Adjusted, with country 2.5 (-2.6, 8.0) -1.2 (-9.1, 7.4) 2.6 (-5.2, 11.0) -4.9 (-18.2, 10.4) 
         
Chocolate drinkj 
        
Unadjusted 13.5 (1.1, 27.5) 1.5 (-13.1, 18.5) 10.0 (-9.6, 33.9) 1.6 (-24.8, 37.1) 
Adjusted, without country 9.5 (-2.9, 23.6) -3.8 (-17.7, 12.4) 8.4 (-10.2, 30.9) -3.2 (-28.9, 31.8) 
Adjusted, with country 1.5 (-7.3, 11.2) -9.6 (-21.8, 4.5) -7.7 (-23.5, 11.3) -3.2 (-25.4, 25.6) 
         
Milkk 
        
Unadjusted 9.1 (-1.8, 21.3) -3.5 (-18.1, 13.7) 13.3 (-3.2, 32.7) -27.5 (-45.8, -3.0) 
Adjusted, without country 10.9 (-1.9, 25.4) 0.4 (-16.8, 21.1) 15.6 (-3.8, 38.9) -16.1 (-36.4, 10.5) 
Adjusted, with country 13.8 (2.8, 26.0) -3.9 (-19.7, 15.1) 28.6 (8.2, 52.9) -10.9 (-32.4, 17.4) 
         
Fresh cheesel 
        
Unadjusted -5.7 (-12.6, 1.8) 0.8 (-10.4, 13.3) 1.7 (-9.1, 13.7) 0.0 (-18.1, 22) 
Adjusted, without country -6.5 (-13.4, 1.0) 1.0 (-10.0, 13.3) 0.8 (-10.1, 13.1) 0.4 (-16.4, 20.5) 
Adjusted, with country 3.1 (-3.3, 9.9) 2.1 (-8.7, 14.3) 13.1 (1.0, 26.5) 20.9 (1.3, 44.4) 
         
Hard cheesel 
        
Unadjusted -11.6 (-23.9, 2.8) -3.4 (-19.4, 15.9) -4.9 (-22.1, 16.1) -16.3 (-29.9, 0.0) 
Adjusted, without country -11.4 (-23.1, 2.0) -2.7 (-18.8, 16.5) -6.0 (-22.4, 13.8) -14.6 (-28.5, 1.9) 
Adjusted, with country -2.7 (-7.8, 2.6) 3.5 (-14.9, 25.9) 1.9 (-13.1, 19.4) -3.8 (-29.9, 31.9) 
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Supplemental Table 2.2. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
children from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Cream cheesed 
        
Unadjusted -0.3 (-3.3, 2.8) -2.9 (-6.9, 1.3) -1.3 (-7.3, 5.0) -7.4 (-11.2, -3.4) 
Adjusted, without country -0.7 (-3.6, 2.3) -2.6 (-6.4, 1.3) -1.8 (-7.1, 3.9) -6.8 (-10.7, -2.7) 
Adjusted, with country 0.3 (-1.3, 1.9) -4.0 (-8.0, 0.2) 0.0 (-2.7, 2.7) -9.9 (-14.4, -5.2) 
         
Creamd 
        
Unadjusted -21.6 (-30.3, -11.9) 15.3 (-14.5, 55.6) -3.1 (-22, 20.4) -9.3 (-40.8, 39.0) 
Adjusted, without country -19.8 (-28.2, -10.4) 16.5 (-12.8, 55.6) -3.9 (-22, 18.4) -9.0 (-39.2, 36.3) 
Adjusted, with country 3.1 (-7.3, 14.6) 28.4 (-6.7, 76.7) 37.2 (8.1, 74.1) 41.5 (1.1, 97.9) 
         
Cooked eggsh 
        
Unadjusted 3.6 (-1.8, 9.4) -1.9 (-8.0, 4.6) 6.8 (-0.6, 14.8) 12.3 (-2.8, 29.8) 
Adjusted, without country 6.5 (-0.6, 14.3) 0.1 (-6.9, 7.6) 7.6 (-1.8, 17.9) 13.7 (-4.2, 34.9) 
Adjusted, with country -3.9 (-8.3, 0.8) -1.5 (-7.5, 4.9) -5.3 (-11.8, 1.7) 1.5 (-12.9, 18.3) 
         
Scrambled/fried eggsh 
        
Unadjusted 1.4 (-7.4, 10.9) 3.5 (-7.7, 16.1) 4.7 (-8.4, 19.8) -1.0 (-21.5, 24.9) 
Adjusted, without country -1.1 (-9.6, 8.2) 0.4 (-11.2, 13.4) 4.5 (-10.0, 21.4) -8.2 (-27.6, 16.4) 
Adjusted, with country 5.6 (-1.0, 12.6) -2.1 (-13.0, 10.3) 13.3 (-0.3, 28.8) 1.3 (-20.4, 28.9) 
         
Fishi 
        
Unadjusted -4.2 (-8.1, -0.2) -1.9 (-8.4, 5.1) -7.7 (-14.0, -1.0) 0.8 (-8.9, 11.4) 
Adjusted, without country -5.1 (-8.8, -1.2) -2.1 (-8.8, 5.0) -9.0 (-15.4, -2.2) 3.9 (-5.4, 14.1) 
Adjusted, with country -2.2 (-5.4, 1.2) -2.6 (-8.3, 3.5) -5.0 (-11.1, 1.6) 9.8 (0.4, 20.2) 
         
Canned tuna/sardinesi 
        
Unadjusted 11.8 (-0.2, 25.2) 0.8 (-15.2, 19.8) 5.5 (-7.2, 20.0) 6.0 (-19.9, 40.1) 
Adjusted, without country 9.4 (-1.0, 20.8) -3.6 (-19.0, 14.7) 1.0 (-10.4, 13.7) -0.5 (-24.9, 31.8) 
Adjusted, with country -0.6 (-8.0, 7.3) -9.0 (-22.0, 6.2) -6.5 (-17.3, 5.8) -8.8 (-28.1, 15.8) 
         
Fried chickeni 
        
Unadjusted 3.6 (-3.5, 11.2) -9.4 (-18.7, 1.0) 3.6 (-6.2, 14.4) -0.1 (-19.1, 23.2) 
Adjusted, without country 5.2 (-1.4, 12.2) -8.2 (-16.9, 1.4) 2.7 (-6.6, 12.9) 2.0 (-15.7, 23.3) 
Adjusted, with country -0.3 (-4.7, 4.3) -5.2 (-15.5, 6.4) -1.0 (-7.5, 6.0) -5.5 (-20.6, 12.3) 
         
Chicken (cooked/roasted)i 
        
Unadjusted 7.0 (0.2, 14.3) 0.3 (-7.9, 9.3) 6.8 (-2.5, 16.9) 12.1 (-4.0, 30.9) 
Adjusted, without country 5.1 (-1.8, 12.5) -0.4 (-9.1, 9.1) 5.6 (-4.0, 16.1) 11.4 (-3.7, 29.0) 
Adjusted, with country -1.1 (-6.2, 4.3) 3.6 (-4.8, 12.9) -1.2 (-9.0, 7.3) 4.0 (-10.0, 20.2) 
         
Beef/pork as main dishi 
        
Unadjusted -5.0 (-13.3, 4.0) -2.2 (-9.5, 5.7) -10.7 (-22.7, 3.2) 2.6 (-12.8, 20.7) 
Adjusted, without country -6.5 (-14.9, 2.7) -4.8 (-12.0, 3.0) -12.1 (-24.1, 1.8) -0.6 (-16.1, 17.8) 
Adjusted, with country -1.8 (-6.5, 3.1) -8.9 (-15.9, -1.4) -3.5 (-12.7, 6.6) 6.3 (-9.2, 24.5) 
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Supplemental Table 2.2. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
children from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
         
Beef/pork in soups, stews, etc.i 
        
Unadjusted 7.6 (-3.1, 19.5) 2.4 (-8.1, 14.1) 4.8 (-8.6, 20.1) 20.4 (-2.0, 48.0) 
Adjusted, without country 5.9 (-4.9, 18.0) -0.5 (-10.8, 10.9) 4.4 (-8.6, 19.3) 18.2 (-3.7, 45.2) 
Adjusted, with country -1.5 (-8.2, 5.7) -12.6 (-20.7, -3.7) 1.0 (-9.4, 12.6) 13.3 (-6.9, 37.9) 
         
Beef tortitasi 
        
Unadjusted -2.1 (-6.5, 2.4) 1.1 (-3.0, 5.4) -1.5 (-5.7, 2.8) 1.5 (-8.0, 11.9) 
Adjusted, without country -1.9 (-6.4, 2.8) 0.5 (-3.8, 5.0) -1.0 (-5.3, 3.5) 0.0 (-9.9, 11.0) 
Adjusted, with country 0.8 (-1.8, 3.5) 2.2 (-2.6, 7.3) 2.8 (-1.4, 7.2) 9.3 (-1.5, 21.3) 
         
Hamburgeri 
        
Unadjusted -5.6 (-10.2, -0.7) -8.4 (-14.6, -1.7) -9.6 (-15.6, -3.1) -8.4 (-20.8, 6.0) 
Adjusted, without country -6.4 (-11.0, -1.5) -8.6 (-14.9, -1.8) -10.8 (-16.9, -4.1) -7.4 (-21.2, 8.8) 
Adjusted, with country -4.4 (-8.4, -0.2) -6.5 (-12.7, 0.1) -7.6 (-13.3, -1.5) -7.3 (-19.9, 7.3) 
         
Hot dogi 
        
Unadjusted 3.7 (-1.0, 8.7) 1.3 (-3.0, 5.8) 3.2 (-2.2, 8.9) 12.0 (3.6, 21.1) 
Adjusted, without country 3.5 (-0.6, 7.8) 0.5 (-3.7, 4.8) 2.6 (-2.8, 8.3) 12.0 (3.7, 21.0) 
Adjusted, with country 0.4 (-2.6, 3.6) 3.7 (-0.2, 7.8) -0.5 (-5.1, 4.2) 8.5 (1.4, 16.1) 
         
Salamil 
        
Unadjusted 5.3 (1.8, 8.9) 3.3 (0.6, 6.2) 5.9 (0.3, 11.8) 8.8 (2.2, 15.8) 
Adjusted, without country 4.6 (0.9, 8.5) 2.7 (-0.5, 6.0) 5.3 (-0.4, 11.2) 9.0 (1.1, 17.6) 
Adjusted, with country -4.4 (-6.7, -2.1) 0.4 (-2.5, 3.4) -5.5 (-9.6, -1.2) 2.5 (-5.6, 11.4) 
         
Chorizoh 
        
Unadjusted 5.9 (-7.8, 21.7) -11.2 (-22.9, 2.2) 11.3 (-7.4, 33.7) 8.3 (-16.9, 41.1) 
Adjusted, without country 6.8 (-6.0, 21.4) -13.8 (-25.4, -0.5) 11.3 (-6.9, 33.1) 5.9 (-18.7, 37.8) 
Adjusted, with country -8.2 (-15.2, -0.7) -14.7 (-25.8, -2.0) -6.2 (-17.4, 6.4) -4.5 (-23.0, 18.4) 
         
Sausageh 
        
Unadjusted 0.8 (-8.3, 10.8) 4.3 (-8.1, 18.5) -2.3 (-14.0, 10.9) 16.5 (-6.9, 45.9) 
Adjusted, without country -0.9 (-10.2, 9.3) 5.9 (-7.3, 20.9) -3.8 (-16.4, 10.6) 23.7 (-0.5, 53.8) 
Adjusted, with country -1.8 (-10.0, 7.3) 12.0 (-1.6, 27.5) 2.7 (-9.8, 16.9) 22.3 (-1.9, 52.5) 
         
Visceram 
        
Unadjusted 6.4 (0.2, 13.0) -2.9 (-8.6, 3.1) 7.2 (0.0, 14.8) 8.7 (-2.9, 21.8) 
Adjusted, without country 5.4 (-1.3, 12.5) -3.6 (-9.2, 2.3) 6.6 (-1.2, 14.9) 9.7 (-2.1, 22.9) 
Adjusted, with country 0.6 (-3.6, 5.1) -4.7 (-9.4, 0.1) 1.5 (-2.6, 5.8) 3.1 (-6.9, 14.1) 
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Footnotes to Supplemental Table 2.2 
aFrom linear regression models with log-transformed fatty acid variables as outcomes and a continuous predictor 
representing intake frequency of a given food in servings per day. 
bAll models adjusted for age (continuous), sex, maternal education (continuous), and the following: long-chain n-6, 
height-for-age Z score (continuous); ALA, maternal age at child's birth (continuous); long-chain n-3, height-for-age 
Z score (continuous). 
cAdjusted for all of the above and country of origin. 
d1 tbs 
        
e1/4 unit 
        
f30g or 2 tbs 
        
g1/3 cup 
        
h1 unit 
        
i1 portion 
        
j1 cup 
        
k1 glass 
        
l1 piece 
        
m1/2 cup 
        
nEmpanadas, arepas, pupusas, etc. 
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Supplemental Table 2.3. Means (±SD) of adipose tissue n-6 and n-3 polyunsaturated fatty acid 
weight percent concentrations by primary type of cooking oil among adults from Mesoamerica 
Oil type N LA 18:2(n-6) Total long-chain n-6 ALA 18:3(n-3) Total long-chain n-3 
Soyabean 140 18.03 ± 5.62 1.26 ± 0.55 0.95 ± 0.36 0.26 ± 0.28 
Sunflower 33 14.39 ± 4.57 1.06 ± 0.32 0.70 ± 0.30 0.19 ± 0.10 
Corn 43 13.96 ± 4.21 1.11 ± 0.48 0.65 ± 0.26 0.19 ± 0.14 
Palm 50 10.50 ± 1.93 0.86 ± 0.26 0.51 ± 0.19 0.16 ± 0.13 
Canola 34 15.07 ± 3.80 1.32 ± 0.72 0.79 ± 0.27 0.29 ± 0.18 
Mixed oils 148 14.63 ± 3.68 1.18 ± 0.45 0.70 ± 0.31 0.25 ± 0.20 
Other 10 13.56 ± 3.05 1.22 ± 0.42 0.69 ± 0.33 0.18 ± 0.14 
Pa   <0.0001 0.0004 <0.0001 0.002 
aχ2 score statistic from linear regression models with each fatty acid as the outcome and indicator 
variables for each oil type as predictors. 
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Supplemental Table 2.4. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
adults from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Butter/margarine added to foodd 
        
Unadjusted 18.8 (8.8, 29.7) 10.3 (2.6, 18.6) 12.2 (-1.4, 27.8) 0.1 (-12.8, 14.9) 
Adjusted, without countryb 17.7 (8.3, 28.0) 8.8 (1.2, 17.0) 14.1 (0.4, 29.7) -1.3 (-14.1, 13.4) 
Adjusted, with countryc 2.2 (-2.0, 6.5) -0.1 (-6.6, 6.8) -3.0 (-9.8, 4.3) -13.7 (-25.6, 0.1) 
         
Dressing/mayonnaised 
        
Unadjusted 5.3 (0.4, 10.5) 1.9 (-1.6, 5.6) 4.1 (-2.4, 11.0) 3.9 (-2.9, 11.2) 
Adjusted, without country 4.9 (0.1, 9.8) 1.1 (-2.5, 4.8) 4.3 (-2.5, 11.5) 3.3 (-3.8, 10.9) 
Adjusted, with country 0.2 (-2.3, 2.9) -1.6 (-5.6, 2.6) -4.3 (-9.1, 0.7) -0.2 (-6.7, 6.7) 
         
Avocadoe 
        
Unadjusted 0.7 (-3.7, 5.3) -1.9 (-8.2, 4.9) 0.7 (-6.1, 8.0) 1.8 (-10.5, 15.8) 
Adjusted, without country -0.1 (-4.8, 4.9) -0.7 (-8.8, 8.3) -0.1 (-7.2, 7.6) 2.5 (-11.8, 19.1) 
Adjusted, with country -0.1 (-3.8, 3.7) -1.2 (-8.8, 6.9) -1.1 (-5.3, 3.3) 5.2 (-7.1, 19.0) 
         
Peanutsf 
        
Unadjusted 0.5 (-6.4, 8.0) -1.4 (-5.9, 3.4) 0.5 (-9.6, 11.7) -3.6 (-10.4, 3.6) 
Adjusted, without country 1.6 (-4.6, 8.2) -0.7 (-5.2, 4.0) 1.7 (-7.6, 12.0) -1.7 (-8.5, 5.5) 
Adjusted, with country 2.8 (-1.1, 6.8) 0.0 (-5.5, 5.8) 1.8 (-2.6, 6.5) -1.6 (-8.1, 5.4) 
         
Cashewsf 
        
Unadjusted 0.1 (-1.6, 1.9) 0.7 (-1.6, 3.0) -2.5 (-5.8, 1.0) 0.0 (-3.7, 3.8) 
Adjusted, without country 0.1 (-1.6, 1.8) 0.4 (-1.8, 2.5) -2.3 (-5.8, 1.3) -0.3 (-3.8, 3.4) 
Adjusted, with country 0.4 (-1.3, 2.1) 0.3 (-1.7, 2.3) -2.1 (-4.9, 0.8) -0.5 (-4.3, 3.5) 
         
Refried beansg 
        
Unadjusted -5.7 (-10.0, -1.1) -5.3 (-9.7, -0.6) -5.4 (-11.0, 0.5) -11.0 (-18.5, -2.9) 
Adjusted, without country -5.4 (-9.8, -0.7) -4.8 (-9.4, 0.0) -6.2 (-11.6, -0.5) -11.6 (-19.2, -3.4) 
Adjusted, with country -0.9 (-3.8, 2.0) -2.2 (-7.6, 3.6) -2.1 (-6.0, 2.0) -5.3 (-13.2, 3.3) 
         
Corn tortillash 
        
Unadjusted -13.0 (-20.4, -4.9) -13.4 (-22.0, -3.8) -34.0 (-41.1, -26.1) -0.6 (-16.2, 18.0) 
Adjusted, without country -12.3 (-19.8, -4.0) -12.0 (-21.5, -1.3) -36.2 (-43.4, -28.2) 4.7 (-12.6, 25.3) 
Adjusted, with country -4.1 (-15.2, 8.4) -2.7 (-17.2, 14.4) -8.2 (-23.2, 9.7) 12.3 (-17.5, 52.8) 
         
Corn productsh,n 
        
Unadjusted -4.7 (-8.2, -1.1) -4.8 (-9.0, -0.4) -12.0 (-16.1, -7.7) -8.9 (-14.2, -3.4) 
Adjusted, without country -5.2 (-8.7, -1.6) -4.6 (-8.8, -0.2) -11.8 (-16.1, -7.3) -8.3 (-13.5, -2.7) 
Adjusted, with country -1.9 (-4.7, 0.9) 0.6 (-4.3, 5.7) -3.5 (-7.0, 0.1) -6.1 (-11.2, -0.6) 
         
Corn tostadas/tacosi 
        
Unadjusted 0.3 (-3.3, 4.0) 2.1 (-2.1, 6.4) -2.4 (-7.5, 2.9) 2.8 (-3.5, 9.6) 
Adjusted, without country 0.0 (-3.6, 3.8) 2.9 (-1.7, 7.7) -0.2 (-5.5, 5.4) 3.6 (-3.4, 11.2) 
Adjusted, with country 2.0 (-1.0, 5.0) 2.2 (-2.2, 6.8) 0.5 (-4.9, 6.3) -1.5 (-8.3, 5.9) 
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Supplemental Table 2.4. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
adults from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
 
White breadi 
        
Unadjusted 0.1 (-4.4, 4.8) -5.1 (-10.8, 0.9) -8.1 (-12.9, -3.0) -1.2 (-10.9, 9.6) 
Adjusted, without country 1.7 (-3.1, 6.7) -4.2 (-10.3, 2.4) -7.5 (-12.8, -1.9) 0.9 (-9.3, 12.1) 
Adjusted, with country -0.9 (-4.4, 2.9) -2.0 (-8.0, 4.5) -0.3 (-5.0, 4.6) 0.6 (-10.2, 12.7) 
         
Sweet breadi 
        
Unadjusted -2.8 (-5.9, 0.4) -0.9 (-4.1, 2.5) -7.5 (-11.2, -3.7) 0.9 (-3.6, 5.6) 
Adjusted, without country -2.1 (-5.2, 1.1) -0.5 (-3.8, 3.0) -7.9 (-11.8, -3.8) 0.9 (-4.1, 6.1) 
Adjusted, with country -0.4 (-2.4, 1.6) 1.0 (-1.9, 3.9) -1.5 (-4.3, 1.3) -0.8 (-5.3, 4.0) 
         
Cakei 
        
Unadjusted 0.2 (-1.9, 2.4) -1.4 (-3.7, 1.0) 0.3 (-3.4, 4.1) -3.2 (-7.4, 1.3) 
Adjusted, without country 0.3 (-1.9, 2.5) -1.6 (-3.9, 0.6) 0.2 (-3.5, 4.0) -3.3 (-7.5, 1.1) 
Adjusted, with country 0.6 (-0.8, 2.0) -0.8 (-3.2, 1.7) 0.1 (-2.4, 2.6) -1.3 (-5.2, 2.9) 
         
Coated sandwich cookiesi 
        
Unadjusted 0.2 (-3.1, 3.5) -0.6 (-5.3, 4.3) 0.6 (-4.1, 5.6) -3.8 (-9.8, 2.7) 
Adjusted, without country 0.8 (-2.1, 3.7) -0.1 (-4.6, 4.6) 0.0 (-4.9, 5.2) -3.3 (-8.8, 2.7) 
Adjusted, with country 0.3 (-2.0, 2.7) -0.4 (-5.2, 4.7) 0.7 (-3.1, 4.7) -3.0 (-9.9, 4.6) 
         
Chocolate drinkj 
        
Unadjusted 5.3 (-3.5, 14.9) -1.3 (-9.4, 7.5) 7.2 (-4.2, 19.9) 13.0 (2.4, 24.7) 
Adjusted, without country 4.2 (-4.1, 13.2) -2.6 (-10.7, 6.2) 7.9 (-3.6, 20.9) 13.2 (1.8, 25.8) 
Adjusted, with country -6.0 (-10.3, -1.3) -5.8 (-14.2, 3.5) -8.2 (-14.9, -1.0) 8.7 (-4.2, 23.5) 
         
Milkk 
        
Unadjusted 4.4 (-0.9, 10.0) 7.0 (1.4, 12.8) 4.1 (-3.2, 11.9) 6.5 (-2.1, 15.9) 
Adjusted, without country 3.2 (-1.8, 8.4) 6.4 (0.6, 12.6) 4.4 (-3.0, 12.3) 5.0 (-3.9, 14.9) 
Adjusted, with country 0.0 (-4.1, 4.3) 2.2 (-3.1, 7.8) 1.1 (-5.3, 7.8) -1.3 (-9.4, 7.5) 
         
Fresh cheesel 
        
Unadjusted -5.6 (-8.9, -2.2) 1.3 (-7.0, 10.4) -3.5 (-9.0, 2.4) -0.2 (-7.6, 7.9) 
Adjusted, without country -5.6 (-8.8, -2.2) 1.4 (-7.3, 10.9) -3.1 (-8.6, 2.7) 0.3 (-7.4, 8.7) 
Adjusted, with country -0.7 (-4.1, 2.8) 3.7 (-4.6, 12.6) 3.9 (-1.0, 9.0) 5.0 (-2.6, 13.2) 
         
Hard cheesel 
        
Unadjusted -15.4 (-23.3, -6.7) -11.6 (-19.0, -3.6) -17.7 (-27.3, -6.7) -27.3 (-35.0, -18.7) 
Adjusted, without country -15.3 (-23.1, -6.7) -11.6 (-18.8, -3.7) -18.1 (-27.4, -7.6) -27.5 (-34.7, -19.4) 
Adjusted, with country -1.9 (-8.3, 4.9) 1.6 (-5.5, 9.2) -3.2 (-12.4, 7.0) -10.9 (-20.5, -0.2) 
         
Cream cheesed 
        
Unadjusted 0.0 (-4.7, 5.0) 4.6 (-3.4, 13.3) -3.8 (-11.1, 4.0) 5.6 (-3.2, 15.2) 
Adjusted, without country -0.5 (-5.4, 4.6) 3.3 (-5.2, 12.6) -5.2 (-11.9, 2.1) 2.9 (-6.3, 13.0) 
Adjusted, with country 0.7 (-2.8, 4.5) 2.0 (-4.4, 8.8) -2.3 (-8.0, 3.8) 1.0 (-7.1, 9.8) 
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Supplemental Table 2.4. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
adults from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
Creamd 
        
Unadjusted -23.2 (-30.8, -14.7) -20.1 (-27.4, -12.1) -22.7 (-30.9, -13.5) -17.7 (-27.0, -7.3) 
Adjusted, without country -22.3 (-29.8, -14.0) -20.3 (-27.7, -12.1) -24.1 (-32.1, -15.1) -18.8 (-28.2, -8.3) 
Adjusted, with country -7.5 (-15.9, 1.8) -12.6 (-21.7, -2.4) -4.8 (-12.4, 3.4) -2.5 (-13.0, 9.2) 
         
Cooked eggsh 
        
Unadjusted 0.0 (-2.6, 2.8) -0.2 (-2.5, 2.2) -0.9 (-3.9, 2.2) -6.4 (-10.3, -2.3) 
Adjusted, without country 0.4 (-2.5, 3.4) 0.1 (-2.2, 2.5) -0.4 (-4.0, 3.2) -6.1 (-10.3, -1.7) 
Adjusted, with country -0.4 (-2.4, 1.6) 0.9 (-1.1, 2.8) -0.3 (-3.0, 2.6) -5.6 (-8.9, -2.3) 
         
Scrambled/fried eggsh 
        
Unadjusted -2.6 (-6.7, 1.7) -2.8 (-9.4, 4.3) -4.2 (-11.0, 3.0) -2.0 (-10.4, 7.3) 
Adjusted, without country -0.1 (-4.0, 3.9) -1.0 (-8.0, 6.6) -2.9 (-9.5, 4.1) 1.8 (-7.4, 12.0) 
Adjusted, with country -0.6 (-3.7, 2.7) -0.8 (-5.9, 4.5) -1.4 (-5.8, 3.3) 3.1 (-5.1, 11.9) 
         
Fishi 
        
Unadjusted 0.8 (-5.5, 7.6) 1.2 (-9.2, 12.8) 1.1 (-10.6, 14.4) 7.4 (-9.2, 27.1) 
Adjusted, without country 0.3 (-6.2, 7.2) 0.5 (-10.0, 12.1) -0.7 (-11.6, 11.6) 7.0 (-10.0, 27.3) 
Adjusted, with country -1.4 (-6.8, 4.3) 1.4 (-7.0, 10.6) -4.5 (-12.5, 4.2) 13.9 (-2.4, 32.9) 
         
Canned tuna/sardinesi 
        
Unadjusted 20.1 (9.8, 31.4) 15.0 (2.7, 28.8) 19.9 (4.9, 37.0) 25.3 (7.4, 46.3) 
Adjusted, without country 20.4 (10.1, 31.8) 14.2 (2.0, 27.9) 17.8 (3.0, 34.8) 23.8 (6.1, 44.5) 
Adjusted, with country 6.5 (0.5, 12.9) 4.5 (-5.5, 15.5) -2.8 (-12.4, 7.7) 13.0 (-1.1, 29.0) 
         
Fried chickeni 
        
Unadjusted -0.6 (-5.7, 4.8) -5.5 (-10.1, -0.7) 6.0 (-2.3, 15.0) -9.7 (-17.7, -0.9) 
Adjusted, without country -0.3 (-5.0, 4.6) -4.1 (-8.8, 0.9) 4.3 (-3.8, 13.1) -9.2 (-17.0, -0.5) 
Adjusted, with country -2.3 (-5.7, 1.1) -2.4 (-6.8, 2.3) 0.7 (-4.6, 6.3) -6.8 (-13.7, 0.7) 
         
Chicken (cooked/roasted)i 
        
Unadjusted 2.6 (-0.5, 5.8) 3.3 (0.6, 6.0) 0.0 (-4.3, 4.4) 3.1 (-2.2, 8.6) 
Adjusted, without country 3.2 (0.4, 6.1) 3.1 (0.4, 6.0) 0.3 (-4.2, 4.9) 3.3 (-2.2, 9.1) 
Adjusted, with country 3.1 (0.8, 5.5) 4.2 (1.2, 7.2) 1.6 (-2.3, 5.6) 4.6 (-0.8, 10.2) 
         
Beef/pork as main dishi 
        
Unadjusted 0.0 (-4.1, 4.4) 2.9 (-1.6, 7.6) -6.9 (-12.6, -0.8) -3.0 (-14.9, 10.5) 
Adjusted, without country -0.1 (-4.1, 4.0) 2.8 (-1.5, 7.4) -7.4 (-13.1, -1.4) -3.5 (-15.3, 9.9) 
Adjusted, with country 0.6 (-2.7, 4.1) 2.9 (-2.1, 8.3) -1.9 (-6.2, 2.7) -2.4 (-13.5, 10.1) 
         
Beef/pork in soups, stews, etc.i 
        
Unadjusted 0.8 (-4.9, 6.8) 2.7 (-1.9, 7.6) 1.6 (-6.2, 10.0) -6.6 (-14.6, 2.2) 
Adjusted, without country 0.3 (-5.4, 6.3) 3.4 (-1.1, 8.1) 1.0 (-6.6, 9.1) -5.4 (-13.7, 3.7) 
Adjusted, with country -3.3 (-7.3, 0.8) 0.9 (-3.5, 5.5) -4.4 (-9.6, 1.1) -10.2 (-18.7, -0.9) 
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Supplemental Table 2.4. Percent differencesa (95% CI) in means of adipose tissue n-6 and n-3 
polyunsaturated fatty acids by food intake frequency (90th vs. 10th percentiles of servings/d) among 
adults from Mesoamerica 
Foods LA 18:2(n-6) 
Total  
long-chain n-6 
ALA 18:3(n-3) 
Total  
long-chain n-3 
 
Beef tortitasi 
        
Unadjusted -4.3 (-10.2, 2.0) -0.6 (-4.5, 3.4) -5.4 (-11.4, 0.9) -7.1 (-14.5, 0.9) 
Adjusted, without country -3.6 (-8.9, 2.1) -0.7 (-4.7, 3.4) -5.6 (-11.4, 0.6) -7.2 (-14.7, 0.8) 
Adjusted, with country -0.5 (-4.3, 3.5) 1.5 (-1.9, 4.9) -1.4 (-6.1, 3.6) -3.7 (-9.3, 2.1) 
         
Hamburgeri 
        
Unadjusted 1.5 (-2.2, 5.3) 4.4 (-1.2, 10.2) 4.7 (-2.4, 12.3) -1.4 (-11.4, 9.8) 
Adjusted, without country 2.4 (-1.4, 6.4) 5.5 (0.0, 11.2) 3.7 (-3.6, 11.6) -0.2 (-10.2, 11.0) 
Adjusted, with country 3.2 (-0.2, 6.6) 3.8 (-0.9, 8.8) 2.9 (-3.6, 9.7) -1.0 (-10.2, 9.1) 
         
Hot dogi 
        
Unadjusted -0.4 (-3.5, 2.8) -1.1 (-5.6, 3.5) 1.1 (-5.0, 7.7) 0.3 (-6.8, 7.8) 
Adjusted, without country -0.2 (-3.5, 3.2) -0.3 (-4.6, 4.3) 0.2 (-6.0, 6.7) 1.5 (-5.8, 9.4) 
Adjusted, with country -0.2 (-3.7, 3.5) 0.4 (-4.2, 5.2) -1.5 (-7.7, 5.1) 1.7 (-4.8, 8.7) 
         
Salamil 
        
Unadjusted 6.0 (2.6, 9.5) 0.4 (-2.4, 3.2) 11.6 (6.8, 16.5) -2.3 (-8.3, 4.1) 
Adjusted, without country 5.3 (2.2, 8.6) 0.5 (-2.2, 3.4) 11.0 (6.6, 15.7) -2.0 (-8.2, 4.7) 
Adjusted, with country 0.8 (-1.9, 3.6) -0.9 (-4.4, 2.8) 1.6 (-2.3, 5.5) -3.6 (-11.2, 4.8) 
         
Chorizoh 
        
Unadjusted -0.5 (-8.3, 8.0) -5.1 (-10.7, 0.9) -6.5 (-15.6, 3.6) -6.1 (-14.9, 3.6) 
Adjusted, without country -0.4 (-8.4, 8.3) -5.0 (-10.8, 1.3) -7.8 (-16.1, 1.4) -6.2 (-14.9, 3.5) 
Adjusted, with country -3.5 (-9.2, 2.4) -3.6 (-10.0, 3.4) -9.8 (-15.9, -3.3) -3.9 (-12.3, 5.3) 
         
Sausageh 
        
Unadjusted 0.1 (-3.3, 3.7) 1.3 (-2.0, 4.8) -6.0 (-10.5, -1.3) 0.2 (-6.6, 7.5) 
Adjusted, without country 0.2 (-3.4, 3.8) 1.3 (-2.1, 4.8) -6.3 (-10.6, -1.7) -0.1 (-6.9, 7.2) 
Adjusted, with country 0.1 (-2.7, 3.1) 1.9 (-1.8, 5.8) -3.0 (-7.1, 1.4) -0.8 (-6.3, 5.0) 
         
Visceram 
        
Unadjusted 5.0 (1.2, 8.9) 1.1 (-3.0, 5.4) 5.4 (-0.1, 11.2) -1.0 (-6.1, 4.5) 
Adjusted, without country 5.5 (1.8, 9.4) 1.5 (-2.5, 5.8) 5.6 (0.0, 11.5) -0.4 (-5.8, 5.4) 
Adjusted, with country 1.4 (-1.1, 4.1) 1.5 (-2.1, 5.3) 0.3 (-3.2, 4.0) -0.5 (-5.7, 4.9) 
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Footnotes to Supplemental Table 2.4. 
aFrom linear regression models with log-transformed fatty acid variables as outcomes and a continuous predictor 
representing intake frequency of a given food in servings per day. 
bAll models adjusted for age (continuous), sex, education (continuous), and the following: LA, smoking status 
(never, former, or current). 
cAdjusted for all of the above and country of origin. 
d1 tbs 
        
e1/4 unit 
        
f30g or 2 tbs 
        
g1/3 cup 
        
h1 unit 
        
i1 portion 
        
j1 cup 
        
k1 glass 
        
l1 piece 
        
m1/2 cup 
        
nEmpanadas, arepas, pupusas, etc. 
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Supplemental Table 2.5. Median (10th, 90th percentile) intake frequency of specific foods 
among adults and children from Mesoamerica 
Foods 
Adults median  
(10th, 90th percentile) 
intake frequency, 
servings/d 
Children median  
(10th, 90th percentile) 
intake frequency, 
servings/d 
Pa 
Butter/margarine added to foodd 0.07 (0.00, 1.00) 0.14 (0.00, 1.00) 0.46 
Dressing/mayonnaised 0.03 (0.00, 0.43) 0.07 (0.00, 0.43) 0.29 
Avocadoe 0.14 (0.00, 1.00) 0.14 (0.00, 0.79) <0.0001 
Peanutsf 0.00 (0.00, 0.43) 0.00 (0.00, 0.43) 0.41 
Cashewsf 0.00 (0.00, 0.07) 0.00 (0.00, 0.07) 0.18 
Refried beansg 0.14 (0.00, 1.00) 0.14 (0.00, 1.00) 0.34 
Corn tortillash 1.00 (0.00, 6.00) 1.00 (0.00, 2.50) <0.0001 
Corn productsh,n 0.07 (0.00, 0.43) 0.07 (0.00, 0.43) 0.08 
Corn tacos/tostadasi 0.00 (0.00, 0.14) 0.00 (0.00, 0.14) 0.75 
White breadi 0.79 (0.07, 2.50) 1.00 (0.07, 4.50) 0.0004 
Sweet breadi 0.14 (0.00, 1.00) 0.43 (0.00, 2.50) 0.02 
Cakei 0.00 (0.00, 0.14) 0.07 (0.00, 0.43) 0.002 
Coated sandwich cookiesi 0.00 (0.00, 0.43) 0.14 (0.00, 1.00) <0.0001 
Chocolate drinkj 0.00 (0.00, 0.43) 0.07 (0.00, 0.79) <0.0001 
Milkk 0.14 (0.00, 1.00) 0.43 (0.07, 2.50) <0.0001 
Fresh cheesel 0.14 (0.00, 0.43) 0.07 (0.00, 0.43) 0.006 
Hard cheesel 0.10 (0.00, 1.00) 0.07 (0.00, 1.00) 0.14 
Cream cheesed 0.00 (0.00, 0.43) 0.00 (0.00, 0.43) 0.69 
Creamd 0.07 (0.00, 1.00) 0.10 (0.00, 1.00) 0.21 
Cooked eggsh 0.14 (0.00, 0.43) 0.14 (0.00, 0.43) 0.58 
Scrambled/fried eggsh 0.43 (0.07, 1.00) 0.43 (0.07, 1.00) 0.62 
Fishi 0.07 (0.00, 0.43) 0.07 (0.00, 0.14) 0.24 
Canned tuna/sardinesi 0.07 (0.00, 0.43) 0.07 (0.00, 0.43) 0.40 
Fried chickeni 0.14 (0.00, 0.43) 0.14 (0.00, 0.43) 0.58 
Chicken (cooked/roasted)i 0.43 (0.07, 0.43) 0.43 (0.07, 0.43) 0.28 
Beef/pork as main dishi 0.14 (0.00, 0.43) 0.14 (0.00, 0.43) 0.87 
Beef/pork in soups, stews, etc.i 0.14 (0.00, 0.43) 0.14 (0.00, 0.43) 0.58 
Beef tortitasi 0.07 (0.00, 0.14) 0.07 (0.00, 0.14) 0.08 
Hamburgeri 0.00 (0.00, 0.14) 0.07 (0.00, 0.14) 0.02 
Hot dogi 0.00 (0.00, 0.14) 0.00 (0.00, 0.14) 0.01 
Salamil 0.00 (0.00, 0.43) 0.07 (0.00, 0.43) 0.03 
Chorizoh 0.07 (0.00, 0.43) 0.07 (0.00, 0.43) 0.10 
Sausageh 0.14 (0.00, 0.43) 0.14 (0.00, 0.43) 0.17 
Visceram 0.00 (0.00, 0.14) 0.00 (0.00, 0.14) 0.006 
aFrom a Wilcoxon signed rank test. 
d1 tbs 
e1/4 unit 
f30g or 2 tbs 
g1/3 cup 
h1 unit 
i1 portion 
j1 cup 
k1 glass 
l1 piece 
m1/2 cup 
nEmpanadas, arepas, pupusas, etc. 
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Supplemental Figure 2.1. Country-specific proportions of primary cooking oil usage among 
Mesoamerican households. The figure includes all households for which information was available 
on primary cooking oil type. 
N for each country: Dominican Republic, 30; Costa Rica, 25; Nicaragua, 31; Panama, 25; 
Mexico, 21; Belize, 29; Honduras, 26; El Salvador, 28; Guatemala, 29. 
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Chapter 3. Adipose tissue polyunsaturated fatty acids and metabolic syndrome among 
adult parents and their children in Mesoamerica 
 
Kerry S. Flannagan, Manuel Ramirez-Zea, Ana Victoria Roman,  
Arun K. Das, Eduardo Villamor  
 
Abstract 
Objective: The aim of the study was to examine the associations of adipose tissue n-3 and n-6 
polyunsaturated fatty acid (PUFA) biomarkers with metabolic syndrome (MetS) among adult 
parents and their school-age children in 9 Mesoamerican countries. 
Design: In this cross-sectional study, we measured concentrations of n-3 and n-6 PUFA in 
gluteal adipose tissue by gas chromatography. In adults, MetS was defined according to the 
National Cholesterol Education Program's Adult Treatment Panel III definition (three or more of 
the following: abdominal obesity, high fasting glucose, hypertension, low serum high-density 
lipoprotein (HDL) cholesterol, and high triglycerides). In children, we created an age- and sex-
standardized metabolic risk score using abdominal circumference, the homeostasis model of 
insulin resistance, blood pressure, serum HDL cholesterol, and triglycerides. We estimated 
prevalence ratios of MetS in adults and mean differences in metabolic score in children across 
quartiles of PUFA using multivariable-adjusted Poisson and linear regression models, 
respectively. 
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Setting: Capitals of Guatemala, El Salvador, the Dominican Republic, Honduras, Nicaragua, 
Panama, Costa Rica, and Belize, and Tuxtla Gutiérrez in Mexico. 
Subjects: 468 parents and 201 children aged 7-12 y. 
Results: Among adults, MetS was associated with low alpha-linolenic acid (ALA; P=0.004), 
high eicosapentaenoic acid (EPA; P=0.04), and low gamma-linolenic acid (GLA; P=0.01) in 
adipose tissue. It was linearly, positively associated with dihomogamma-linolenic acid (DGLA; 
P=0.0004) concentrations and with a Δ6-desaturase activity index (P=0.04). There was a 
significant interaction between ALA and linoleic acid (LA; P=0.03); the lowest MetS prevalence 
was among adults with high ALA and low LA. Among children, the metabolic score was 
positively associated with docosapentaenoic acid (DPA; P, trend=0.01); no n-6 PUFA were 
significantly associated with the metabolic score after adjustment. 
Conclusions: Among Mesoamerican adults, MetS prevalence is inversely associated with 
adipose tissue ALA and GLA, and positively associated with EPA, DGLA, and the Δ6-
desaturase index. Among children, metabolic risk score is positively associated with DPA. 
Keywords: polyunsaturated fatty acids; metabolic syndrome; children; Mesoamerica 
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Introduction 
The metabolic syndrome (MetS) is a clustering of risk factors for chronic disease 
including abdominal obesity, high fasting glucose, hypertension, low HDL cholesterol, and high 
serum triglycerides (1). It involves the development of insulin resistance following abdominal 
obesity (2) and is associated with increased risk of cardiovascular disease, diabetes, and 
mortality (3). MetS component risk factors can track from childhood into adulthood (4,5), and 
adverse metabolic profiles in childhood predict the development of cardiometabolic outcomes in 
adulthood, including type II diabetes and atherosclerosis (4,6). Therefore, the identification of 
modifiable exposures leading to metabolic disregulation in early life is crucial in order to prevent 
the development of chronic disease. 
Polyunsaturated fatty acids (PUFA) are nutritional factors that could play a role in the 
development of MetS. The main classes of PUFA are the n-3 and n-6 families. Each consists of 
one essential fatty acid (alpha-linolenic acid [18:3 n-3; ALA] and linoleic acid [18:2 n-6; LA], 
respectively) that can only be obtained from diet, and several long-chain PUFA that can be 
produced through endogenous elongation and desaturation of the essential fatty acids. Intake of 
long-chain n-3 PUFA including eicosapentaenoic acid (20:5 n-3; EPA) and docosahexaenoic 
acid (22:6 n-3; DHA) has been inversely related to metabolic characteristics including visceral 
adiposity and serum triglycerides, and positively associated with high-density lipoprotein (HDL) 
cholesterol in adults (7). A recent meta-analysis of cross-sectional and case-control studies of 
adults and children found that circulating biomarkers of EPA, DHA, and docosapentaenoic acid 
(22:5 n-3; DPA), another n-3 PUFA, were all inversely associated with MetS (8). However, 
studies using adipose tissue concentrations, which best reflect long-term intake (9), have found 
positive associations between these PUFA and MetS or its insulin resistance component in adults 
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(10,11). In addition, other meta-analyses have not found protective associations between long-
chain n-3 PUFA and type 2 diabetes (12) or cardiovascular disease (13). Evidence concerning 
other PUFA is more limited. Some (10,14–17) but not all (8,18) studies have found that ALA 
and LA biomarkers and intake are inversely associated with MetS or its components, whereas 
each has been inversely associated with risk of type 2 diabetes (12,19). 
The relation between PUFA status and cardiometabolic health in childhood is uncertain. 
Supplementation trials and observational studies with circulating biomarkers in pregnancy, 
infancy, or early childhood have found inconsistent associations of PUFA with measures of 
blood pressure, insulin resistance, and blood lipids throughout childhood and adolescence (20). 
Long-chain n-3 PUFA supplementation during middle childhood and adolescence has resulted in 
decreases in blood pressure, insulin resistance, and serum triglycerides in some (21–24) but not 
all (25) trials. Associations of blood biomarkers of ALA, LA, or long-chain n-6 PUFA with 
MetS components in middle childhood and adolescence are inconsistent (26–29). 
The majority of observational studies of the relation between PUFA and MetS have relied 
on dietary assessment or blood biomarkers for ascertainment of exposure status. Dietary 
assessment is subject to measurement error and blood concentrations of PUFA may not reflect 
long-term intake. Furthermore, evidence in children is scant, especially in low- and middle-
income countries. We conducted a cross-sectional study among families from nine countries in 
Mesoamerica, a region experiencing a large and growing burden of MetS and cardiometabolic 
disease (30,31). We ascertained PUFA status using adipose tissue concentrations, which are the 
gold standard biomarkers of long-term fatty acid intake (9). The aim of the study was to examine 
associations of these biomarkers with MetS in adult parents and their school-aged children. 
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Methods 
Study design and population 
This study was conducted in the context of the Nine Mesoamerican Countries Metabolic 
Syndrome (NiMeCoMeS) Study, a cross-sectional investigation of school-aged children and 
their parents. Details of the study have been described previously (30). Briefly, participants were 
recruited between July 2011 and November 2013 from the capital cities of Guatemala, El 
Salvador, the Dominican Republic, Honduras, Nicaragua, Panama, Costa Rica, and Belize, and 
the city of Tuxtla Gutiérrez in Chiapas, Mexico. Using enrollment lists from public primary 
schools in each city, study personnel randomly selected potentially eligible students who were 7-
12 years of age. Researchers visited the schools to assess additional eligibility criteria, including 
that the child lived with both biological parents, neither the child nor the mother was pregnant, 
and that the child did not have any siblings already invited to participate. If children met all 
criteria, their parents received an explanation of the study and its procedures, and were invited to 
enroll. The final sample consisted of 267 families (Guatemala, 31; El Salvador, 30; the 
Dominican Republic, 30; Honduras, 30; Nicaragua, 31; Panama, 26; Costa Rica, 27; Belize, 31; 
and Mexico, 31).  
All study procedures were approved by the Institutional Review Boards (IRB) of 
collaborating institutions in each of the nine countries and by the University of Michigan Health 
and Behavioral Sciences IRB. All adults provided written informed consent to participate. 
Parents provided written informed consent for their children. Assent to participate was confirmed 
from the children before enrollment. 
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Data collection 
Data collection took place at home or at a family visit to a health center. All participants 
were asked to fast for at least 6 hours before the appointment. At the visit, participants completed 
questionnaires that inquired on sociodemographic characteristics, including their age, education 
level, smoking status, and socioeconomic status (SES) indicators. 
Trained study personnel obtained anthropometric measurements on each participant using 
standardized procedures and calibrated instruments. Height was measured without shoes to the 
nearest millimeter with the use of portable Seca stadiometers (Seca, Hamburg, Germany). 
Weight was measured in light clothing to the nearest 100 g with use of Tanita scales (Tanita, 
Tokyo, Japan). Waist circumference was measured to the nearest millimeter at the end of an 
unforced exhalation using an inelastic measuring tape. In adults, it was measured at the midpoint 
of the lower end of the ribcage and the iliac crest; in children, it was measured above the 
uppermost lateral border of the right ilium. All anthropometric measures were obtained in 
triplicate. Blood pressure was measured using Omron HEM-712C digital blood pressure 
monitors (Omron Healthcare, Inc., Lake Forest, IL, USA) while the participant was seated. It 
was measured in triplicate with at least one minute between each reading, and the final blood 
pressure value was calculated as the average of the second and third readings. 
Finally, researchers obtained biological samples from all participants. A fasting blood 
sample was obtained by venipuncture of the antecubital vein. A gluteal adipose tissue sample 
was obtained by numbing the upper area of the left gluteus with an anesthetic spray and an ice 
pack, inserting a 16-gauge needle at a 45˚ angle, and aspirating tissue into the syringe (32). All 
samples were transported on ice to laboratories in the country in which they were collected. 
There, plasma and serum were separated and stored at -20˚C, and adipose tissue samples were 
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stored in a 3:2 hexane:isopropanol solution in amber vials at -70˚C. Samples were then 
transported frozen to the Institute of Nutrition of Central America and Panama (INCAP) in 
Guatemala City, Guatemala, where biochemical analysis of plasma and serum took place. 
Adipose tissue samples were subsequently transported to the University of Michigan for fatty 
acids analysis. 
Laboratory methods 
Serum insulin was measured by chemiluminescent immunoassay on an Immulite 1000 
system (Siemens Healthcare Diagnostics Products, Tarrytown, NY, USA). Plasma glucose 
concentrations were measured using the Cobas c111 automated chemistry analyzer system 
(Roche Diagnostics, Manneheim, Germany), and serum lipid profiles were assessed by 
enzymatic colorimetric assays on the same system. 
Adipose tissue fatty acid analysis was conducted at the University of Michigan Regional 
Comprehensive Metabolomics Resource Core. Using the Bligh and Dyer method (33), total 
lipids were extracted from 20-25 mg of adipose tissue with 10 μL of 4 mM nonadecanoic acid 
(C19:0) added as an internal standard. The fatty acid portions of the total lipids were derivatized 
into methyl esters using boron trifluoride-methanol as previously described (34). These were 
then extracted using a 2:1 hexane-water mixture and centrifugation. The hexane layer containing 
the methyl esters was separated from the aqueous layer and dried, and the esters were re-
dissolved in 100-200 μL hexane, depending on the original sample volume. Fatty acids were 
analyzed by gas chromatography (GC). Using an autosampler, 1-2 μL of sample was injected 
onto an Agilent 680N GC (Agilent, Santa Clara, CA, USA) equipped with a flame ionization 
detector, a 100 m x 0.25 mm x 0.2 μm SP-2560 column (Sigma-Aldrich, Bellefonte, PA, USA), 
and Chemstation software for data analysis. A calibration curve was created from known 
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amounts of C19:0 (the internal standard) and other authentic methyl esters in order to quantify 
fatty acids. The authentic methyl ester mixture was also used to identify fatty acids in samples 
based on retention times. The coefficient of variation for GC analyses was between 2.5-3.6%. 
Definition of outcomes 
In adults, the primary outcome was the presence of MetS defined according to the 
National Cholesterol Education Program's Adult Treatment Panel III (ATP III) as having three or 
more of the following five conditions: abdominal obesity, high fasting glucose, high blood 
pressure, low serum HDL cholesterol, and high serum triglycerides (1). Abdominal obesity was 
defined as waist circumference >102 cm in men and >88 cm in women; high fasting glucose as 
plasma glucose ≥100 mg/dL; high blood pressure as either systolic blood pressure ≥130 mm Hg, 
diastolic blood pressure ≥85 mm Hg, or treatment with antihypertensive medication; low HDL 
cholesterol as serum HDL <40 mg/dL in men or <50 mg/dL in women, or treatment for low 
HDL cholesterol levels; and high serum triglycerides as concentrations ≥150 mg/dL or treatment 
with medication for high triglyceride levels. 
There is not a conventional definition of MetS in children under 10 years of age. For this 
reason, the primary outcome in children was a continuous metabolic score, as has been 
previously suggested (35). This score was based on the same five components as MetS in adults, 
including waist circumference, insulin resistance measured using the homeostasis model of 
insulin resistance (HOMA-IR) (36), mean arterial pressure, serum HDL cholesterol, and serum 
triglycerides. Sex- and age-standardized component scores were created by regressing each log-
transformed component on sex and log-transformed age using linear regression, and obtaining 
standardized residuals. After multiplying the HDL cholesterol score by -1, we calculated the 
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mean of the five component scores in order to create a single overall metabolic score. Higher 
values of this score represent poorer metabolic health. 
In supplemental analyses, we also considered as outcomes the five MetS or metabolic 
score components in adults and children, respectively. 
Definition of exposures 
In both adults and children, the primary exposures were adipose tissue biomarkers of n-3 
and n-6 PUFA, expressed as mass percentages of total fatty acids measured in a sample. N-3 
PUFA included ALA, EPA, DPA, and DHA. Among n-6 PUFA, we examined LA, gamma-
linolenic acid (18:3 n-6; GLA), dihomo-gamma-linolenic acid (20:3 n-6; DGLA), and 
arachidonic acid (20:4 n-6; AA). We also considered as exposures the DGLA/LA and 
AA/DGLA ratios, as measures of Δ6-desaturase (D6D) and Δ5-desaturase (D5D) enzymatic 
activity, respectively. 
Exposures were categorized into quartiles to allow for non-linear associations with the 
outcomes. Since EPA and GLA concentrations in adipose tissue are typically low and many 
samples had no detectable amount, we categorized EPA into tertiles for adults and children, and 
categorized GLA into tertiles for children. 
Covariates 
 We considered as covariates known independent predictors of MetS (30), including 
sociodemographic and anthropometric characteristics as well as other adipose tissue fatty acid 
biomarkers. In adults, education level was defined as the number of completed years of school 
and categorized as incomplete elementary (1-5), complete elementary (6), incomplete secondary 
(7-11), complete secondary (12), or post-secondary (≥13). For anthropometric measures, we used 
the median of the three replicates in all analyses (37). Body mass index (BMI) was calculated as 
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kg/m2. In children, we calculated sex- and age-standardized Z scores for height and BMI using 
the World Health Organization Growth Reference for children ages 5-19 y (38). 
Data analysis 
The final analytic sample consisted of 468 parents and 201 children in whom an adipose 
tissue sample and assessment of MetS components were both available. 
Adults 
In bivariate analysis, we estimated prevalences of MetS and its components by quartiles 
of fatty acid concentrations. We performed tests for linear trends using Poisson regression 
models with MetS or a component as the dichotomous outcome and a variable representing 
medians of each fatty acid quartile introduced as a continuous predictor. In multivariable 
analysis, we estimated adjusted prevalence ratios and 95% confidence intervals (CI) using 
Poisson regression models. All models were adjusted for known independent predictors of MetS 
(30) including sex, age, height, education level, country of origin, total adipose tissue trans fatty 
acids, and adipose tissue palmitoleic acid (16:1), a product of de novo lipogenesis that is 
associated with carbohydrate intake (39). Further adjustment for total energy intake as measured 
through a food frequency questionnaire, previously described in detail (40), did not affect the 
results; thus, it was excluded from the final models. Models for each PUFA were adjusted for 
other PUFA that could confound the association with the main exposure, but that would not be 
intermediates on the possible causal pathway from the main PUFA exposure to MetS. ALA and 
LA were adjusted for each other; long-chain n-3 PUFA were adjusted for LA, total long-chain n-
6 PUFA, and their precursor n-3 PUFA; and long-chain n-6 PUFA were adjusted for ALA, total 
long-chain n-3 PUFA, and their precursor n-6 PUFA. For long-chain n-3 PUFA, we also fitted 
models that included the D6D index. To control for potential residual confounding arising from 
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non-linearity of the fatty acid-MetS associations, covariate fatty acids were entered into the 
model as linear and non-linear terms obtained from restricted cubic spline models (41) with 
knots placed at the 5th, 50th, and 95th percentiles of their respective distributions. 
Supplemental analyses of MetS components followed an analogous approach. Models 
with high fasting glucose, high blood pressure, low HDL cholesterol, or low serum triglycerides 
as outcomes were additionally adjusted for BMI. To assess whether associations between PUFA 
and MetS differed by underlying health status, we fitted additional models of MetS components 
other than high fasting glucose only among adults without high fasting glucose/diabetes 
diagnosis. We were unable to examine associations among those with high fasting 
glucose/diabetes diagnosis because of the small sample size (N=54). 
Finally, we assessed the presence of interaction between the precursor fatty acids of each 
path, ALA and LA. We cross-classified participants according to whether their adipose tissue 
concentrations of these fatty acids were low or high. Low concentrations were defined as being 
below the median of all adults in the study (ALA: 0.71%, LA: 15.9%), and high concentrations 
were defined as being at or above the median. We calculated the prevalence of MetS in each of 
the four categories of this cross-classification, and tested for interaction using a multivariable-
adjusted Poisson regression model with indicator variables for high concentrations of ALA and 
LA, and a term for their cross-product as predictors. 
 All models were fitted using generalized estimating equations and empirical standard 
errors, which are robust to heteroskedasticity and non-normality (42). An exchangeable 
correlation structure was specified to account for clustering by family membership. 
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Children 
In bivariate analysis, we compared the distribution of the overall and component-specific 
metabolic scores across quartiles of each fatty acid exposure using means ± SD. We performed 
tests for linear trends using linear regression models with the metabolic score as the outcome and 
a variable representing medians of each fatty acid quartile introduced as a continuous predictor. 
In multivariable analysis, we estimated adjusted mean differences in the overall or 
component-specific metabolic scores and 95% CI using linear regression models. These models 
were adjusted for previously reported predictors of the metabolic score (30) including the child's 
height-for-age Z score, maternal height, the number of parents with MetS, country of origin, total 
adipose tissue trans fatty acids, and adipose tissue palmitoleic acid. Models with HOMA-IR, 
mean arterial pressure, serum HDL cholesterol, or serum triglyceride scores as outcomes were 
adjusted for BMI-for-age Z scores. In addition, models for each PUFA were adjusted for other 
PUFA as described for adults. Because the prevalence of insulin resistance (HOMA-IR ≥3.2) 
among children in our study was only 2%, we were unable to examine interactions between 
insulin resistance and PUFA on the score components. 
We assessed interaction between ALA and LA by cross-classifying children according to 
whether they had high or low concentrations of these PUFA. Low and high levels were defined 
as being below or at or above the median values among children (ALA: 0.69%, LA: 13.59%), 
respectively. We tested for interaction using a linear regression model with indicator variables 
for high ALA and high LA, and a term for their cross-product. All models were fitted using 
generalized estimating equations and robust standard errors. 
All analyses were conducted using Statistical Analysis Software version 9.4 (SAS 
Institute, Cary, NC, USA).  
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Results 
Adults. Mean (±SD) age among adult participants was 38.3 ± 7.3 y; 51.9% were women. 
The overall prevalence of MetS was 36.8%.  
N-3 PUFA. In bivariate analysis, the prevalence of MetS was not associated with any n-3 
PUFA (Table 1). In multivariable analysis, low ALA and high EPA concentrations were each 
positively associated with MetS in non-linear manners. The prevalence among participants in the 
lowest quartile of ALA was 68% higher than that among adults in quartiles 2, 3, or 4 (95% CI: 
18%, 138%; P=0.004). Participants in the highest tertile of EPA had a 38% higher prevalence 
than did those in the lowest two tertiles (95% CI: 1%, 88%; P=0.04). Adjustment for the D6D 
activity index did not change this association. 
ALA was inversely related to fasting glucose and serum triglycerides. Adjusted 
prevalences of high fasting glucose and high serum triglycerides among people in the lowest 
quartile of ALA were 158% higher (95% CI: 8%, 515%; P=0.03) and 34% higher (95% CI: 7%, 
69%; P=0.01), respectively, than were those among participants in the highest three quartiles 
(Supplemental Table 1). EPA was positively associated with high blood pressure. Associations 
between n-3 PUFA and MetS components other than high fasting glucose were similar among 
the entire sample and among adults without high fasting glucose/diabetes diagnosis 
(Supplemental Table 3). 
N-6 PUFA. In unadjusted analysis, DGLA, AA, and the D6D activity index were 
positively associated with prevalence of MetS, while the D5D activity index was inversely 
associated with this outcome (Table 2). After adjustment, high GLA was inversely related to 
MetS in a non-linear fashion. The prevalence in the highest quartile was 38% lower than the 
prevalence in quartiles 1, 2, or 3 (95% CI: -58%, -11%; P=0.01). DGLA remained positively 
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related to MetS; every 1 SD (0.16%) difference in adipose tissue DGLA was associated with a 
28% greater prevalence of MetS (95% CI: 12%, 46%; P=0.0002). In addition, every 1 SD (0.01) 
difference in the D6D activity index was associated with an 18% greater prevalence (95% CI: 
1%, 38%; P=0.04). AA and the D5D activity index were not related to MetS after adjustment. 
GLA was inversely associated with fasting glucose (Supplemental Table 2). DGLA and 
the D6D activity index were both positively associated with all components of MetS, most 
strongly with high fasting glucose. Every 1 SD difference in DGLA and the D6D activity index 
was associated with an 86% (95% CI: 16%, 198%; P=0.01) and a 42% (95% CI: 8%, 86%; 
P=0.01) higher prevalence of high fasting glucose, respectively. The D5D activity index was 
inversely related to fasting glucose. Associations between n-6 PUFA and MetS components 
other than high fasting glucose were similar in the subset of adults without high fasting 
glucose/diabetes diagnosis (Supplemental Table 4). 
Interaction between ALA and LA. The prevalence of MetS was highest among adults with 
low ALA/low LA (38.8% of 183) or high ALA/high LA (38.8% of 183), intermediate among 
adults with low ALA/high LA (29.4% of 51), and lowest among those with high ALA/low LA 
(25.5% of 51) (P, test for interaction=0.04). After adjustment, prevalence ratios comparing each 
group to those with low ALA/low LA were: for high ALA/high LA, 0.85 (95% CI: 0.62, 1.15; 
P=0.29); for low ALA/high LA, 0.66 (95% CI: 0.39, 1.11; P=0.12); and for high ALA/low LA, 
0.56 (95% CI: 0.34, 0.94; P=0.03) (P, test for interaction=0.03). 
Children. Mean age of children was 10.0 ± 1.5 y; 54.2% were girls. 
N-3 PUFA. In bivariate analysis, DPA and DHA were each positively associated with the 
metabolic score (Table 3). After adjustment, children in the highest quartile of DPA had a mean 
metabolic score 0.09 units higher than did children in the lowest quartile (95% CI: 0.02, 0.17; 
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P=0.02); adjustment for the D6D activity index did not change the association. After adjustment, 
the association with DHA was attenuated and became non-statistically significant. 
DPA was positively associated with HOMA-IR and with the serum triglyceride score in a 
non-linear manner (Supplemental Table 3). Children in the lowest quartile of DPA had a mean 
serum triglyceride score 0.17 units lower than did children in quartiles 2, 3, or 4 (95% CI: -0.31, 
-0.03; P=0.02). DHA was inversely associated with serum HDL cholesterol. 
N-6 PUFA. In bivariate analysis, LA, DGLA, AA, and the D6D activity index were each 
positively associated with the metabolic score (Table 4). After adjustment, these positive 
associations remained but were attenuated and became non-statistically significant. 
LA and DGLA were each positively associated with waist circumference after adjustment 
(Supplemental Table 4). AA was positively associated with waist circumference and inversely 
associated with serum triglycerides. The D6D and D5D activity indices were each positively 
related to waist circumference. 
Interaction between ALA and LA. Children with low ALA/low LA (N=76), low ALA/ 
high LA (N=24), and high ALA/high LA (N=77) had similar mean metabolic scores (-0.01 ± 
0.23, 0.03 ± 0.20, and 0.04 ± 0.21, respectively). Children with high ALA/low LA (N=24) had 
the lowest mean score (-0.11 ± 0.26). However, the interaction was not statistically significant 
(P=0.19).  
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Discussion 
In this cross-sectional study of Mesoamerican families we found that, among adults, 
MetS prevalence was inversely associated with adipose tissue ALA but positively related to 
EPA. In addition, MetS was inversely related to GLA but positively to DGLA and the D6D 
activity index. In children, DPA was positively associated with an overall metabolic risk score. 
The inverse association between ALA and MetS among Mesoamerican adults is in line 
with results from previous studies that suggested a protective association (14,43). In particular, 
of three cross-sectional investigations of adipose tissue ALA and MetS or its components, two 
found inverse associations with insulin resistance (11,15) and one found inverse relations with 
MetS, high waist circumference, and fasting glucose (10). By contrast, a meta-analysis of cross-
sectional and case-control studies of blood biomarkers or intake of ALA found no significant 
association with MetS (8). Some of the studies included in the meta-analysis were conducted 
among children and several did not adjust for any confounders, which may explain the 
discrepancy with our results in adults. In addition, blood biomarkers may not reflect long-term 
intake as adipose tissue does. A protective effect of ALA could be explained through its 
incorporation into cell membranes (44) and the resulting enhancement of membrane fluidity and 
glucose transport, which is also consistent with the inverse association we found between ALA 
and high fasting glucose. Although ALA can be endogenously metabolized into EPA, DPA, and 
DHA, and some of these long chain PUFA have been related to cardiometabolic health (7), our 
results do not support the view that a potential protective effect of ALA may operate through 
these PUFA because EPA was related to MetS in the opposite direction as ALA; in addition, 
conversion is generally inefficient (45). 
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We did not find an association between LA and MetS in adults. Research on LA and 
MetS is limited, but available evidence generally suggests a potential protective role. Some 
(16,17) but not all (18) studies have found inverse associations between LA concentrations in 
blood and incident MetS. Circulating LA is also associated with lower serum triglycerides and 
higher HDL cholesterol (46), and inversely associated with insulin resistance (47) and risk of 
type 2 diabetes (19). Our results may not be consistent because of differences in the level of LA 
intake in our study population as compared to others, the use of adipose tissue biomarkers to 
ascertain exposure status, or unmeasured confounding by other aspects of diet. 
MetS prevalence was lowest among adults with high adipose tissue concentrations of 
ALA and low concentrations of LA. Two studies of PUFA intake did not find evidence for an 
interaction between ALA and LA with respect to MetS or coronary heart disease incidence 
(48,49). Our use of adipose tissue biomarkers may explain this discrepancy. A commonly 
proposed mechanism by which ALA and LA might interact is through competition for desaturase 
and elongase enzymes, which means that endogenous production of long chain n-3 PUFA from 
ALA could depend on intake levels of LA (46). However, our results do not support this 
explanation since long chain n-3 PUFA were not associated with improved metabolic health. 
Instead, the possible protective effects of ALA may be influenced by LA. For example, ALA 
incorporation into cell membranes may be reduced in the presence of high dietary LA. The 
interaction may also be spurious.  
Unexpectedly, we found that EPA, a long chain n-3 PUFA, was positively associated 
with MetS among adults. This is consistent with a cross-sectional study of MetS and adipose 
tissue PUFA that was conducted in Costa Rica (10) but in contrast with other evidence (7,8). 
Two additional cross-sectional studies found no association between adipose tissue EPA (11) or 
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EPA+DHA (15) and insulin resistance in elderly Swedish men and adults from North America, 
respectively. It is possible that adipose tissue concentrations of EPA may not reflect levels in 
plasma membranes, which could have a direct influence on metabolic outcomes (50). 
Alternatively, our results might be specific to Mesoamerican populations, which are 
underrepresented in existing literature. In support of this possibility, the association between 
intake or circulating biomarkers of EPA and type 2 diabetes differs by region (12). In addition, 
variation in the genes encoding for desaturase enzymes modify the association between dietary 
PUFA and MetS components (51). Finally, although adjustment for the D6D activity index did 
not change any of the associations between these PUFA and MetS or its components, residual 
confounding by D6D activity could remain (51). 
Among adults, DGLA and the D6D activity index were strongly positively associated 
with MetS and all its components. DGLA accumulation in adipose tissue could be a result of 
higher D6D activity, but independent effects of DGLA and D6D on MetS cannot be ruled out. 
The positive association of DGLA with MetS is consistent with many (17,18,52,53) but not all 
(16,54) previous studies. Although DGLA is a precursor for anti-inflammatory eicosanoids (55), 
in one study plasma DGLA was positively associated with C-reactive protein (56), a marker of 
inflammation. Higher D6D activity has been associated with MetS, insulin resistance, and risk of 
diabetes (57). Furthermore, variations in the FADS2 gene that encodes D6D are associated with 
MetS and its components in adults (51). D6D is the rate-limiting step in production of long chain 
n-6 PUFA from LA, so the adverse metabolic consequences of D6D activity could be related to 
increased production of pro-inflammatory and vasoconstrictive eicosanoids from long-chain n-6 
PUFA. 
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Among children, ALA was not associated with the metabolic score. This is consistent 
with the few cross-sectional studies that have previously addressed this question (26–28). The 
fact that there was an inverse association in adults but not among children could reflect 
differences in the effect of ALA by age. Alternatively, the effects of ALA may be cumulative 
from childhood and only apparent in adult life. Also, ALA may only have an effect on extreme 
metabolic dysregulation which may not be apparent when comparing the continuous 
distributions of a metabolic score. Because there were fewer children than adults in our study, we 
may have also lacked statistical power to detect an association. 
We found no association between LA and the metabolic score in children, consistent with 
results from two previous investigations of blood biomarkers of LA and MetS (27) or blood 
pressure (29). Two other studies found and inverse association between LA in blood and MetS 
(26,28). These studies used varying definitions of MetS, rather than a continuous score as we 
did. Discrepancies may also be related to the use of adipose tissue biomarkers to measure PUFA 
status in our study, which had not been performed before in pediatric MetS research. 
We found that DPA was positively associated with metabolic score among children, 
while DHA and EPA were not significantly related to this outcome in multivariable analysis. The 
only previous study that examined this question in children found a positive but non-statistically 
significant association between plasma DPA and MetS (27). Another study found that a pattern 
of high plasma EPA, DPA, and DHA in pregnancy was associated with higher HDL cholesterol 
and lower serum triglycerides at 6 years (58). Studies of EPA and DHA supplementation in 
pregnancy, infancy, and early childhood have produced inconsistent results related to MetS 
components (20). In middle childhood and adolescence, supplementation has been protective in 
some (21–24) but not all (25) trials. Observational studies of EPA and DHA among children are 
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also inconsistent (26–28,59,60). Overall, our results and those of previous studies do not 
consistently support a protective effect of long-chain n-3 PUFA on MetS in school-age children.  
We did not find an association between D6D activity and metabolic score in children, in 
contrast with previous studies of blood PUFA or FADS gene variants (28,61–63). The specific 
gene variants in FADS2 present in this population may not be associated with lipid and glucose 
metabolism in childhood, or we may have lacked sufficient statistical power to detect these 
association. LA, DGLA, AA, and the D6D and D5D activity indices were each positively 
associated with waist circumference, which may reflect upregulation of adipogenesis by n-6 
PUFA (64). Because abdominal adiposity is central to the etiology of MetS (2), these 
associations may suggest that children with high n-6 PUFA status might develop MetS in the 
future. 
The primary limitation of this study is its cross-sectional design, which prevents making 
causal inference. For example, reverse causation could explain the findings with long chain 
PUFA and enzyme activity indices if metabolic dysregulation alters desaturase activity. Because 
biomarkers can reflect both dietary intake and endogenous metabolism of long chain PUFA, it is 
unclear to what extent our results are related to each of these factors. Finally, the relatively small 
number of children may have limited statistical power. The main strength of the study is the use 
of adipose tissue biomarkers of PUFA, which is the gold standard for assessing long-term fatty 
acid intake (9). Adipose tissue biomarkers have rarely been employed among children. Another 
strength is that the study provides information on the associations between fatty acid status and 
MetS in very under-studied populations. The family design allowed us to examine associations 
among both children and adults. We were also able to adjust for a number of important 
confounders in the analyses.  
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In conclusion, MetS prevalence is inversely associated with adipose tissue ALA and 
GLA, and positively associated with EPA, DGLA, and the D6D activity index among adults. 
Among children, metabolic risk score is positively associated with DPA in adipose tissue. Future 
studies should assess these associations using longitudinal designs. A potential protective effect 
of ALA against MetS warrants further investigation, since ALA status can be easily enhanced 
through relatively simple dietary interventions (65).  
 92 
Acknowledgements 
Participants in the Nine Mesoamerican Countries Metabolic Syndrome Study (NiMeCoMeS) 
Group: 
Mexico: Erika Lopez, Liz Peña, Alejandra Maldonado, Aldeni Vasquez, Aldrin Lopez 
Belize: Lilly Mahung, Diomar Salazar 
Guatemala: Fernanda Kroker, Maria Alejandra Cordova, Regina Garcia, Lilian Navas 
El Salvador: Josefina Sibrian, Mauricio Flores, Noel Avalos 
Honduras:  Astarte Alegria, Jorge A. Sierra, Hector Murillo 
Nicaragua: Ana María Gutierrez, Carmen María Flores, Mario Romero 
Costa Rica: Emilce Ulate, Natalia Valverde, Andrea Fiatt, Juan Manuel Valverde 
Panama: Flavia Fontes, Raisa Rodriguez, Emerita Pons, Lino Chue, Elka Gonzalez 
Dominican Republic: Rafael Montero, Francisco Torres, Amarilis Then, Melvi Perez 
 
Financial support: The study was funded by the United States National Heart, Lung, and Blood 
Institute, contract BAA-NHLBI-HV-09-12. Fatty acids were quantified using Core Services 
supported by grant DK097153 from the National Institutes of Health to the University of 
Michigan. 
 
  
 93 
 
Table 3.1. Prevalence and adjusted prevalence ratios of metabolic syndromea by 
adipose tissue biomarkers of n-3 polyunsaturated fatty acid intake among adults from 
Mesoamerica 
Fatty acidb category  
(median, weight % of total FA) 
N 
Unadjusted 
prevalence (%) 
Adjusted PR  
(95% CI)c 
Overall 468 36.3 
  
     
ALA 18:3(n-3) 
    
Q1 (0.40) 117 40.2 1.00 
Q2 (0.62) 117 33.3 0.61 (0.42, 0.89) 
Q3 (0.80) 117 35.0 0.57 (0.37, 0.86) 
Q4 (1.15) 117 36.8 0.62 (0.37, 1.02) 
P, trendd 
 
0.71 0.15 
     
EPA 20:5(n-3) 
    
Q1 (0.00) 320 35.6 1.00 
Q2 (0.03) 74 32.4 0.88 (0.61, 1.27) 
Q3 (0.07) 74 43.2 1.35 (0.98, 1.85) 
P, trend 
 
0.31 0.14 
     
DPA 22:5(n-3) 
    
Q1 (0.00) 117 31.6 1.00 
Q2 (0.06) 117 40.2 1.36 (0.96, 1.93) 
Q3 (0.10) 117 40.2 1.15 (0.78, 1.69) 
Q4 (0.17) 117 33.3 1.08 (0.72, 1.62) 
P, trend 
 
0.68 0.78 
     
DHA 22:6(n-3) 
    
Q1 (0.00) 117 32.5 1.00 
Q2 (0.08) 117 46.2 1.35 (0.94, 1.93) 
Q3 (0.12) 117 30.8 0.78 (0.50, 1.20) 
Q4 (0.18) 117 35.9 0.99 (0.64, 1.54) 
P, trend 
 
0.81 0.59 
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Footnotes to Table 3.1. 
aDefined according to the National Cholesterol Education Program's Adult Treatment Panel III 
as having three or more of the following components: abdominal obesity, high fasting glucose, 
high blood pressure, low serum HDL cholesterol, and high serum triglycerides. 
bALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid. 
cFrom Poisson regression models. All models are adjusted for sex, age, height, education level, 
country of origin, total trans fatty acids, and palmitoleic acid. Additionally, estimates for ALA 
are adjusted for LA. Estimates for specific long-chain n-3 PUFA are adjusted for LA, total long-
chain n-6 PUFA, and their precursor PUFA. All covariate fatty acids were entered into the model 
as restricted cubic splines with knots placed at the 5th, 50th, and 95th percentiles of observed 
values. 
dWald test from Poisson regression models with a metabolic syndrome as the outcome and a 
variable representing medians of ordinal categories of the predictor introduced as continuous. 
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Table 3.2. Prevalence and adjusted prevalence ratios of metabolic syndromea by 
adipose tissue biomarkers of n-6 polyunsaturated fatty acid intake among adults 
from Mesoamerica 
Fatty acidb category (median, 
weight % of total FA) 
N 
Unadjusted 
prevalence (%) 
Adjusted PR  
(95% CI)c 
LA 18:2(n-6) 
    
Q1 (9.84) 117 35.0 1.00 
Q2 (12.67) 117 36.8 1.06 (0.70, 1.59) 
Q3 (16.17) 117 39.3 1.15 (0.74, 1.81) 
Q4 (20.58) 117 34.2 1.26 (0.71, 2.25) 
P, trendd 
 
0.93 0.40 
     
GLA 18:3(n-6) 
    
Q1 (0.00) 153 37.9 1.00 
Q2 (0.05) 105 39.0 1.01 (0.74, 1.40) 
Q3 (0.08) 105 40.0 0.96 (0.70, 1.32) 
Q4 (0.15) 105 27.6 0.61 (0.41, 0.91) 
P, trend 
 
0.06 0.02 
     
DGLA 20:3(n-6) 
    
Q1 (0.15) 117 23.9 1.00 
Q2 (0.21) 117 29.9 1.37 (0.89, 2.11) 
Q3 (0.29) 117 41.9 1.94 (1.34, 2.80) 
Q4 (0.41) 117 49.6 2.39 (1.62, 3.54) 
P, trend 
 
<0.0001 <0.0001 
     
AA 20:4(n-6) 
    
Q1 (0.25) 117 26.5 1.00 
Q2 (0.34) 117 33.3 1.18 (0.78, 1.78) 
Q3 (0.46) 117 41.9 1.25 (0.81, 1.92) 
Q4 (0.65) 117 43.6 1.22 (0.74, 2.02) 
P, trend 
 
0.003 0.51 
     
Δ6-Desaturase index (DGLA/LA) 
  
Q1 (0.011) 117 24.8 1.00 
Q2 (0.015) 117 27.4 1.22 (0.80, 1.84) 
Q3 (0.020) 117 41.9 1.79 (1.21, 2.64) 
Q4 (0.028) 117 51.3 2.57 (1.71, 3.88) 
P, trend 
 
<0.0001 <0.0001 
     
Δ5-Desaturase index (AA/DGLA) 
  
Q1 (1.13) 117 44.4 1.00 
Q2 (1.46) 117 39.3 0.96 (0.69, 1.32) 
Q3 (1.77) 117 31.6 0.80 (0.57, 1.13) 
Q4 (2.41) 117 29.9 0.96 (0.64, 1.44) 
P, trend 
 
0.02 0.74 
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Footnotes to Table 3.2. 
aDefined according to the National Cholesterol Education Program's Adult Treatment Panel III 
as having three or more of the following components: abdominal obesity, high fasting glucose, 
high blood pressure, low serum HDL cholesterol, and high serum triglycerides. 
bLA, linoleic acid; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; AA, 
arachidonic acid. 
cFrom Poisson regression models. All models are adjusted for sex, age, height, education level, 
country of origin, total trans fatty acids, and palmitoleic acid. Additionally, estimates for LA are 
adjusted for ALA. Estimates for specific long-chain n-6 PUFA are adjusted for ALA, total long-
chain n-3 PUFA, and their precursor PUFA. The Δ6-desaturase index is adjusted for ALA, total 
long-chain n-3 PUFA, and GLA. The Δ5-desaturase index is adjusted for ALA, total long-chain 
n-3 PUFA, and DGLA. All covariate fatty acids were entered into the model as restricted cubic 
splines with knots placed at the 5th, 50th, and 95th percentiles of observed values. 
dWald test from Poisson regression models with a metabolic syndrome as the outcome and a 
variable representing medians of ordinal categories of the predictor introduced as continuous. 
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Table 3.3. Means and adjusted mean differences in metabolic syndrome scorea by 
adipose tissue biomarkers of n-3 polyunsaturated fatty acid intake among children 
from Mesoamerica 
Fatty acidb category (median, 
weight % of total FA) 
N 
Mean Z score 
(±SD) 
Adjusted mean 
difference (95% CI)c 
ALA 18:3(n-3) 
    
  
Q1 (0.40) 50 -0.04 ± 0.22 Reference 
Q2 (0.61) 50 0.03 ± 0.22 0.01 (-0.07, 0.09) 
Q3 (0.76) 51 -0.01 ± 0.23 0.02 (-0.06, 0.11) 
Q4 (1.09) 50 0.02 ± 0.22 0.01 (-0.08, 0.11) 
P, trendd 
 
0.38 0.81 
       
EPA 20:5(n-3) 
      
Q1 (0.00) 170 0.00 ± 0.23 Reference 
Q2 (0.04) 15 0.03 ± 0.17 -0.08 (-0.17, 0.02) 
Q3 (0.10) 16 0.03 ± 0.19 0.01 (-0.07, 0.10) 
P, trend 
 
0.39 0.90 
       
DPA 22:5(n-3) 
      
Q1 (0.00) 73 -0.05 ± 0.22 Reference 
Q2 (0.05) 42 -0.01 ± 0.19 0.01 (-0.06, 0.09) 
Q3 (0.08) 43 0.06 ± 0.22 0.09 (0.00, 0.17) 
Q4 (0.15) 43 0.05 ± 0.25 0.09 (0.02, 0.17) 
P, trend 
 
0.01 0.01 
       
DHA 22:6(n-3) 
      
Q1 (0.00) 51 -0.07 ± 0.23 Reference 
Q2 (0.06) 50 -0.02 ± 0.18 -0.04 (-0.12, 0.03) 
Q3 (0.10) 50 0.06 ± 0.23 0.00 (-0.08, 0.08) 
Q4 (0.18) 50 0.03 ± 0.25 0.06 (-0.02, 0.15) 
P, trend 
 
0.01 0.06 
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Footnotes to Table 3.3. 
aComponent scores (waist circumference, HOMA-IR, mean arterial pressure, serum HDL 
cholesterol, and serum triglycerides) were created by regressing each log-transformed 
component on sex and log-transformed age in linear regression models and obtaining 
standardized residuals. The overall score was calculated as the average of the five component 
scores, after the HDL cholesterol score was multplied by -1. 
bALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid. 
cFrom linear regression models. All models are adjusted for the child's height-for-age Z score, 
maternal height, country of origin, total trans fatty acids, and palmitoleic acid. In addition, 
estimates for ALA are adjusted for LA. Estimates for specific long-chain n-3 PUFA are adjusted 
for LA, total long-chain n-6 PUFA, and their precursor PUFA. All covariate fatty acids were 
entered into the model as restricted cubic splines with knots placed at the 5th, 50th, and 95th 
percentiles of observed values. 
dWald test from linear regression models with metabolic score as the outcome and a variable 
representing medians of ordinal categories of the predictor introduced as continuous. 
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Table 3.4. Means and adjusted mean differences in metabolic syndrome scorea by 
adipose tissue biomarkers of n-6 polyunsaturated fatty acid intake among children 
from Mesoamerica 
Fatty acidb category (median, 
weight % of total FA) 
N 
Mean Z score 
(±SD) 
Adjusted mean difference 
(95% CI)c 
LA 18:2(n-6) 
 
     Q1 (9.20) 50 -0.04 ± 0.23 Reference 
Q2 (12.04) 50 -0.03 ± 0.25 0.00 (-0.08, 0.08) 
Q3 (14.85) 51 0.03 ± 0.19 0.05 (-0.04, 0.14) 
Q4 (19.82) 50 0.05 ± 0.22 0.05 (-0.06, 0.17) 
P, trendd 
 
0.02 0.37 
  
  
   
GLA 18:3(n-6) 
    
  
Q1 (0.00) 87 -0.02 ± 0.23 Reference 
Q2 (0.06) 57 0.03 ± 0.20 -0.01 (-0.08, 0.06) 
Q3 (0.15) 57 0.00 ± 0.25 -0.01 (-0.10, 0.08) 
P, trend 
 
0.59 0.77 
 
    
  
DGLA 20:3(n-6) 
      Q1 (0.09) 50 -0.07 ± 0.18 Reference 
Q2 (0.14) 50 -0.02 ± 0.21 -0.01 (-0.08, 0.06) 
Q3 (0.19) 51 0.01 ± 0.25 0.02 (-0.06, 0.09) 
Q4 (0.29) 50 0.08 ± 0.24 0.05 (-0.04, 0.13) 
P, trend 
 
0.0002 0.23 
 
      AA 20:4(n-6) 
      Q1 (0.17) 50 -0.07 ± 0.20 Reference 
Q2 (0.28) 50 -0.01 ± 0.20 0.00 (-0.07, 0.07) 
Q3 (0.36) 51 0.04 ± 0.25 0.01 (-0.06, 0.09) 
Q4 (0.55) 50 0.05 ± 0.23 0.01 (-0.07, 0.09) 
P, trend 
 
0.004 0.77 
 
      Δ6-Desaturase index (DGLA/LA) 
  Q1 (0.007) 50 -0.07 ± 0.17 Reference 
Q2 (0.011) 50 0.00 ± 0.19 -0.03 (-0.10, 0.03) 
Q3 (0.014) 51 -0.02 ± 0.23 -0.03 (-0.10, 0.05) 
Q4 (0.019) 50 0.09 ± 0.28 0.07 (-0.01, 0.14) 
P, trend 
 
0.002 0.06 
       
Δ5-Desaturase index (AA/DGLA) 
  
Q1 (1.27) 50 0.00 ± 0.24 Reference 
Q2 (1.68) 50 0.04 ± 0.23 0.05 (-0.02, 0.12) 
Q3 (1.97) 51 0.00 ± 0.23 0.01 (-0.06, 0.07) 
Q4 (3.16) 50 -0.03 ± 0.20 0.03 (-0.05, 0.11) 
P, trend 
 
0.25 0.63 
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Footnotes to Table 3.4. 
aComponent scores (waist circumference, HOMA-IR, mean arterial pressure, serum HDL 
cholesterol, and serum triglycerides) were created by regressing each log-transformed 
component on sex and log-transformed age in linear regression models and obtaining 
standardized residuals. The overall score was calculated as the average of the five component 
scores, after the HDL cholesterol score was multplied by -1. 
bLA, linoleic acid; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; AA, 
arachidonic acid. 
cFrom linear regression models. All models are adjusted for the child's height-for-age Z score, 
maternal height, country of origin, total trans fatty acids, and palmitoleic acid. Additionally, 
estimates for LA are adjusted for ALA. Estimates for specific long-chain n-6 PUFA are adjusted 
for ALA, total long-chain n-3 PUFA, and their precursor PUFA. The Δ6-desaturase index is 
adjusted for ALA, total long-chain n-3 PUFA, and GLA. The Δ5-desaturase index is adjusted for 
ALA, total long-chain n-3 PUFA, and DGLA. All covariate fatty acids were entered into the 
model as restricted cubic splines with knots placed at the 5th, 50th, and 95th percentiles of 
observed values. 
dWald test from linear regression models with metabolic score as the outcome and a variable 
representing medians of ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.1. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of 
n-3 polyunsaturated fatty acid intake among adults from Mesoamerica 
 
Abdominal obesitya High fasting glucoseb High blood pressurec Low serum HDL cholesterold High serum triglyceridese 
Fatty acid category 
(median, weight % of 
total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR (95% 
CI)f 
Unadjusted 
prevalence 
(%) 
Adjusted PR  
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Overall 47.6 
  
8.8 
  
21.6 
  
81.8 
  
51.5 
  
                
ALA 18:3(n-3) 
               Q1 (0.40) 49.6 1.00 16.2 1.00 14.5 1.00 77.8 1.00 63.2 1.00 
Q2 (0.62) 46.2 0.84 (0.62, 1.14) 9.4 0.54 (0.24, 1.19) 22.4 1.02 (0.56, 1.88) 78.6 0.91 (0.79, 1.05) 50.4 0.77 (0.61, 0.99) 
Q3 (0.80) 53.8 0.91 (0.65, 1.28) 3.4 0.15 (0.05, 0.45) 23.9 1.19 (0.60, 2.37) 81.2 0.85 (0.73, 1.00) 46.2 0.70 (0.52, 0.93) 
Q4 (1.15) 41.0 0.80 (0.51, 1.26) 6.0 0.41 (0.13, 1.30) 25.6 0.98 (0.39, 2.42) 89.7 0.93 (0.78, 1.11) 46.2 0.76 (0.54, 1.08) 
P, trend 0.24 0.44 0.02 0.13 0.04 0.91 0.005 0.56 0.005 0.16 
                
EPA 20:5(n-3) 
               
Q1 (0.00) 46.6 1.00 9.4 1.00 19.7 1.00 82.8 1.00 53.1 1.00 
Q2 (0.03) 48.6 0.89 (0.70, 1.14) 5.4 0.77 (0.29, 2.07) 23.0 1.46 (0.89, 2.40) 79.7 0.94 (0.84, 1.06) 41.9 0.82 (0.62, 1.08) 
Q3 (0.07) 51.4 1.08 (0.84, 1.37) 9.5 1.12 (0.49, 2.56) 28.4 1.46 (0.95, 2.25) 79.7 1.03 (0.90, 1.17) 54.1 1.13 (0.88, 1.43) 
P, trend 0.45 0.74 0.83 0.91 0.09 0.05 0.48 0.88 0.7 0.65 
                
DPA 22:5(n-3) 
               
Q1 (0.00) 38.5 1.00 8.5 1.00 20.5 1.00 74.4 1.00 53.0 1.00 
Q2 (0.06) 45.3 0.96 (0.74, 1.25) 8.5 1.49 (0.60, 3.69) 21.4 1.28 (0.76, 2.15) 86.3 1.14 (1.00, 1.28) 55.6 1.22 (0.98, 1.53) 
Q3 (0.10) 60.7 0.99 (0.75, 1.29) 11.1 1.41 (0.53, 3.74) 20.5 0.99 (0.59, 1.66) 81.2 0.99 (0.86, 1.14) 47.9 1.05 (0.81, 1.37) 
Q4 (0.17) 46.2 0.90 (0.66, 1.21) 6.8 0.76 (0.26, 2.16) 24.1 1.04 (0.59, 1.82) 85.5 1.06 (0.92, 1.22) 49.6 1.02 (0.78, 1.33) 
P, trend 0.30 0.51 0.70 0.64 0.53 0.92 0.06 0.64 0.42 0.93 
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Supplemental Table 3.1. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of 
n-3 polyunsaturated fatty acid intake among adults from Mesoamerica 
 
Abdominal obesitya High fasting glucoseb High blood pressurec Low serum HDL cholesterold High serum triglyceridese 
Fatty acid category 
(median, weight % of 
total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR (95% 
CI)f 
Unadjusted 
prevalence 
(%) 
Adjusted PR  
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
DHA 22:6(n-3) 
               
Q1 (0.00) 40.2 1.00 7.7 1.00 20.5 1.00 76.9 1.00 53.8 1.00 
Q2 (0.08) 54.7 1.11 (0.84, 1.46) 10.3 1.47 (0.53, 4.03) 27.4 1.86 (1.08, 3.21) 83.8 0.99 (0.87, 1.14) 52.1 1.12 (0.87, 1.44) 
Q3 (0.12) 59.0 1.05 (0.79, 1.41) 6.8 0.81 (0.22, 3.00) 14.5 1.06 (0.53, 2.11) 83.8 0.92 (0.79, 1.07) 46.2 0.94 (0.72, 1.22) 
Q4 (0.18) 36.8 0.80 (0.57, 1.11) 10.3 1.56 (0.46, 5.23) 24.1 1.44 (0.73, 2.84) 82.9 0.95 (0.81, 1.11) 53.8 1.04 (0.79, 1.37) 
P, trend 0.63 0.15 0.62 0.59 0.82 0.44 0.22 0.40 0.82 0.96 
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Footnotes to Supplemental Table 3.1. 
aWaist circumference >102 cm in men and >88 cm in women. 
b≥100 mg/dL  
cSystolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or receiving antihypertensive medication. 
d<40 mg/dL in men and <50 mg/dL in women or receiving treatment for low HDL cholesterol. 
e≥150 mg/dL or receiving treatment for hyperlipidemia. 
fFrom Poisson regression models. All models are adjusted for sex, age, height, education level, country of origin, total trans fatty 
acids, and palmitoleic acid. Models for all risk factors other than waist circumference are adjusted for BMI. Additionally, estimates for 
ALA are adjusted for LA. Estimates for specific long-chain n-3 PUFA are adjusted for LA, total long-chain n-6 PUFA, and their 
precursor PUFA. All covariate fatty acids were entered into the model as restricted cubic splines with knots placed at the 5th, 50th, 
and 95th percentiles of observed values. 
gWald test from Poisson regression models with each metabolic characteristic as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.2. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of n-
6 polyunsaturated fatty acid intake among adults from Mesoamerica 
 
Abdominal obesitya High fasting glucoseb High blood pressurec Low serum HDL cholesterold High serum triglyceridese 
Fatty acid category  
(median, weight %  
of total FA) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI)f 
Unadjusted  
prevalence (%) 
Adjusted PR 
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
LA 18:2(n-6) 
              
 Q1 (9.84) 46.2 1.00 12.0 1.00 17.1 1.00 74.4 1.00 54.7 1.00 
Q2 (12.67) 54.7 1.05 (0.82, 1.34) 11.1 0.81 (0.37, 1.77) 14.7 0.84 (0.43, 1.67) 80.3 1.10 (0.95, 1.28) 55.6 1.20 (0.91, 1.58) 
Q3 (16.17) 43.6 0.91 (0.67, 1.24) 6.0 0.45 (0.14, 1.47) 27.4 1.62 (0.82, 3.21) 88.0 1.22 (1.05, 1.42) 54.7 1.29 (0.93, 1.81) 
Q4 (20.58) 46.2 1.11 (0.72, 1.73) 6.0 0.75 (0.17, 3.22) 27.4 1.80 (0.76, 4.26) 84.6 1.18 (0.97, 1.45) 41.0 1.17 (0.77, 1.76) 
P, trendg 0.45 0.78 0.06 0.59 0.008 0.07 0.02 0.10 0.02 0.52 
 
               GLA 18:3(n-6) 
               Q1 (0.00) 44.4 1.00 13.1 1.00 21.7 1.00 77.8 1.00 54.9 1.00 
Q2 (0.05) 51.4 0.94 (0.73, 1.21) 9.5 0.80 (0.38, 1.70) 21.0 1.29 (0.76, 2.18) 82.9 1.12 (0.99, 1.27) 53.3 1.09 (0.85, 1.39) 
Q3 (0.08) 55.2 0.92 (0.73, 1.15) 7.6 0.68 (0.30, 1.53) 21.0 1.01 (0.59, 1.74) 83.8 1.13 (1.00, 1.27) 56.2 1.23 (0.95, 1.59) 
Q4 (0.15) 41.0 0.94 (0.67, 1.33) 2.9 0.24 (0.07, 0.87) 22.9 0.76 (0.47, 1.24) 84.8 1.02 (0.90, 1.16) 40.0 0.91 (0.68, 1.21) 
P, trend 0.85 0.62 0.003 0.01 0.83 0.32 0.14 0.57 0.03 0.83 
 
               DGLA 20:3(n-6) 
               Q1 (0.15) 36.8 1.00 3.4 1.00 17.1 1.00 73.5 1.00 46.2 1.00 
Q2 (0.21) 35.9 0.89 (0.64, 1.23) 6.8 2.36 (0.72, 7.82) 17.9 1.02 (0.57, 1.82) 80.3 1.04 (0.91, 1.19) 50.4 1.31 (1.01, 1.70) 
Q3 (0.29) 59.0 1.26 (0.98, 1.63) 13.7 4.12 (1.34, 12.67) 23.1 1.57 (0.89, 2.77) 82.9 1.09 (0.96, 1.25) 50.4 1.43 (1.11, 1.85) 
Q4 (0.41) 59.0 1.31 (1.00, 1.73) 11.1 4.90 (1.52, 15.81) 28.4 1.68 (0.95, 2.94) 90.6 1.22 (1.07, 1.39) 59.0 1.73 (1.32, 2.28) 
P, trend 0.0001 0.007 0.01 0.002 0.01 0.04 0.0003 0.001 0.04 0.0001 
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Supplemental Table 3.2. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of n-
6 polyunsaturated fatty acid intake among adults from Mesoamerica 
 
Abdominal obesitya High fasting glucoseb High blood pressurec Low serum HDL cholesterold High serum triglyceridese 
Fatty acid category  
(median, weight %  
of total FA) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI)f 
Unadjusted  
prevalence (%) 
Adjusted PR 
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
Unadjusted  
prevalence (%) 
Adjusted PR  
(95% CI) 
AA 20:4(n-6) 
 
  
 
  
 
  
 
  
 
  Q1 (0.25) 35.9 1.00 6.0 1.00 16.2 1.00 77.8 1.00 50.4 1.00 
Q2 (0.34) 46.2 1.21 (0.90, 1.61) 6.8 0.92 (0.35, 2.41) 19.7 1.08 (0.62, 1.88) 82.9 1.00 (0.88, 1.14) 52.1 1.05 (0.80, 1.37) 
Q3 (0.46) 52.1 1.27 (0.95, 1.71) 12.0 1.31 (0.49, 3.48) 25.0 1.20 (0.67, 2.15) 80.3 0.91 (0.79, 1.05) 48.7 0.87 (0.65, 1.18) 
Q4 (0.65) 56.4 1.41 (1.01, 1.96) 10.3 0.71 (0.26, 1.95) 25.6 0.97 (0.55, 1.71) 86.3 0.96 (0.83, 1.11) 54.7 0.94 (0.68, 1.31) 
P, trend 0.006 0.06 0.15 0.42 0.05 0.82 0.13 0.49 0.61 0.55 
  
              Δ6-Desaturase index (DGLA/LA) 
              Q1 (0.011) 28.2 1.00 2.6 1.00 20.5 1.00 78.6 1.00 39.3 1.00 
Q2 (0.015) 49.6 1.47 (1.08, 1.99) 4.3 1.50 (0.38, 5.97) 17.1 1.02 (0.61, 1.70) 77.8 1.03 (0.91, 1.16) 45.3 1.12 (0.83, 1.49) 
Q3 (0.020) 55.6 1.56 (1.12, 2.15) 9.4 2.48 (0.69, 8.96) 24.8 1.52 (0.89, 2.60) 82.9 1.09 (0.96, 1.24) 57.3 1.36 (1.03, 1.80) 
Q4 (0.028) 57.3 1.62 (1.16, 2.27) 18.8 6.69 (1.73, 25.88) 24.1 1.77 (1.03, 3.04) 88.0 1.20 (1.04, 1.38) 64.1 1.73 (1.29, 2.33) 
P, trend <0.0001 0.01 <0.0001 0.0001 0.27 0.02 0.02 0.006 <0.0001 <0.0001 
                
Δ5-Desaturase index (AA/DGLA) 
              
Q1 (1.13) 53.0 1.00 12.0 1.00 21.6 1.00 85.5 1.00 60.7 1.00 
Q2 (1.46) 52.1 1.05 (0.85, 1.31) 10.3 1.24 (0.64, 2.41) 23.1 1.03 (0.61, 1.71) 86.3 0.94 (0.85, 1.05) 52.1 0.89 (0.70, 1.13) 
Q3 (1.77) 46.2 1.11 (0.86, 1.42) 12.0 1.27 (0.60, 2.70) 17.9 0.82 (0.45, 1.49) 77.8 0.86 (0.76, 0.98) 45.3 0.76 (0.59, 0.98) 
Q4 (2.41) 39.3 1.14 (0.84, 1.53) 0.9 0.15 (0.02, 1.18) 23.9 1.13 (0.64, 1.97) 77.8 0.90 (0.78, 1.03) 47.9 0.82 (0.63, 1.08) 
P, trend 0.03 0.39 0.0001 0.05 0.76 0.67 0.06 0.12 0.04 0.15 
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Footnotes to Supplemental Table 3.2. 
aWaist circumference >102 cm in men and >88 cm in women. 
b≥100 mg/dL  
cSystolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or receiving antihypertensive medication. 
d<40 mg/dL in men and <50 mg/dL in women or receiving treatment for low HDL cholesterol. 
e≥150 mg/dL or receiving treatment for hyperlipidemia. 
fFrom Poisson regression models. All models are adjusted for sex, age, height, education level, country of origin, total trans fatty 
acids, and palmitoleic acid. Models of all risk factors other than waist circumference are adjusted for BMI. Additionally, estimates for 
LA are adjusted for ALA. Estimates for specific long-chain n-6 PUFA are adjusted for ALA, total long-chain n-3 PUFA, and their 
precursor PUFA. The Δ6-desaturase index is adjusted for ALA, total long-chain n-3 PUFA, and GLA. The Δ5-desaturase index is 
adjusted for ALA, total long-chain n-3 PUFA, and DGLA. All covariate fatty acids were entered into the model as restricted cubic 
splines with knots placed at the 5th, 50th, and 95th percentiles of observed values. 
gWald test from Poisson regression models with each metabolic characteristic as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.3. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of 
n-3 polyunsaturated fatty acid intake among adults from Mesoamerica without high fasting glucose or diagnosed diabetes 
 
Abdominal obesitya High blood pressureb Low serum HDL cholesterolc High serum triglyceridesd 
Fatty acid category 
(median, weight % of 
total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR  
(95% CI)e 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
 (95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Overall 45.4 
  
21.7 
  
81.4 
  
49.0 
  
             
ALA 18:3(n-3) 
            Q1 (0.40) 47.3 1.00 17.2 1.00 77.4 1.00 58.1 1.00 
Q2 (0.62) 42.7 0.83 (0.58, 1.17) 20.4 0.78 (0.41, 1.50) 78.6 0.88 (0.75, 1.04) 48.5 0.82 (0.61, 1.09) 
Q3 (0.80) 52.7 0.93 (0.63, 1.38) 22.3 1.04 (0.52, 2.07) 80.4 0.81 (0.68, 0.96) 46.4 0.80 (0.58, 1.11) 
Q4 (1.15) 38.7 0.83 (0.50, 1.37) 26.4 0.99 (0.40, 2.43) 88.7 0.88 (0.73, 1.07) 44.3 0.84 (0.56, 1.25) 
P, trendf 0.30 0.62 0.11 0.88 0.01 0.35 0.04 0.48 
             
EPA 20:5(n-3) 
            
Q1 (0.00) 43.4 1.00 19.6 1.00 82.6 1.00 50.9 1.00 
Q2 (0.03) 50.0 0.92 (0.71, 1.18) 23.5 1.68 (1.01, 2.81) 77.9 0.91 (0.80, 1.03) 38.2 0.79 (0.57, 1.08) 
Q3 (0.07) 49.2 1.03 (0.78, 1.36) 29.2 1.46 (0.92, 2.31) 80.0 1.03 (0.89, 1.18) 52.3 1.10 (0.84, 1.44) 
P, trend 0.31 0.96 0.07 0.05 0.50 >0.99 0.78 0.84 
             
DPA 22:5(n-3) 
            
Q1 (0.00) 37.7 1.00 20.8 1.00 72.6 1.00 51.9 1.00 
Q2 (0.06) 42.7 0.90 (0.67, 1.20) 23.3 1.37 (0.79, 2.36) 86.4 1.16 (1.01, 1.32) 53.4 1.17 (0.91, 1.50) 
Q3 (0.10) 58.0 0.98 (0.73, 1.32) 20.0 0.96 (0.54, 1.70) 82.0 1.05 (0.90, 1.22) 43.0 0.97 (0.73, 1.30) 
Q4 (0.17) 43.8 0.85 (0.59, 1.22) 22.9 1.07 (0.59, 1.95) 84.8 1.08 (0.92, 1.27) 47.6 1.01 (0.75, 1.38) 
P, trend 0.33 0.43 0.81 0.89 0.05 0.42 0.38 0.98 
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Supplemental Table 3.3. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers of 
n-3 polyunsaturated fatty acid intake among adults from Mesoamerica without high fasting glucose or diagnosed diabetes 
 
Abdominal obesitya High blood pressureb Low serum HDL cholesterolc High serum triglyceridesd 
Fatty acid category 
(median, weight % of 
total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR  
(95% CI)e 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
 (95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
DHA 22:6(n-3) 
            
Q1 (0.00) 38.1 1.00 21.9 1.00 75.2 1.00 53.3 1.00 
Q2 (0.08) 51.9 1.11 (0.82, 1.51) 28.8 1.82 (1.03, 3.22) 84.6 1.00 (0.87, 1.15) 50.0 1.05 (0.80, 1.39) 
Q3 (0.12) 54.8 1.03 (0.73, 1.44) 13.5 0.87 (0.41, 1.83) 84.6 0.94 (0.80, 1.10) 43.3 0.88 (0.65, 1.19) 
Q4 (0.18) 36.6 0.82 (0.56, 1.20) 22.8 1.31 (0.63, 2.74) 81.2 0.93 (0.79, 1.11) 49.5 0.95 (0.69, 1.30) 
P, trend 0.94 0.25 0.71 0.64 0.23 0.36 0.42 0.62 
  
 109 
Footnotes to Supplemental Table 3.3. 
aWaist circumference >102 cm in men and >88 cm in women. 
bSystolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or receiving antihypertensive medication. 
c<40 mg/dL in men and <50 mg/dL in women or receiving treatment for low HDL cholesterol. 
d≥150 mg/dL or receiving treatment for hyperlipidemia. 
eFrom Poisson regression models. All models are adjusted for sex, age, height, education level, country of origin, total trans fatty 
acids, and palmitoleic acid. Models for all risk factors other than waist circumference are adjusted for BMI. Additionally, estimates for 
ALA are adjusted for LA. Estimates for specific long-chain n-3 PUFA are adjusted for LA, total long-chain n-6 PUFA, and their 
precursor PUFA. All covariate fatty acids were entered into the model as restricted cubic splines with knots placed at the 5th, 50th, 
and 95th percentiles of observed values. 
fWald test from Poisson regression models with each metabolic characteristic as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.4. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers 
of n-6 polyunsaturated fatty acid intake among adults from Mesoamerica without high fasting glucose or diagnosed diabetes 
 
Abdominal obesitya High blood pressureb Low serum HDL cholesterolc High serum triglyceridesd 
Fatty acid category 
(median, weight % 
of total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI)e 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
LA 18:2(n-6) 
           
 Q1 (9.84) 43.4 1.00 19.2 1.00 75.8 1.00 51.5 1.00 
Q2 (12.67) 51.5 1.04 (0.78, 1.38) 14.6 0.72 (0.34, 1.56) 77.7 1.07 (0.92, 1.24) 51.5 1.22 (0.88, 1.71) 
Q3 (16.17) 41.0 0.87 (0.62, 1.23) 26.7 1.54 (0.73, 3.25) 87.6 1.22 (1.05, 1.41) 53.3 1.41 (0.96, 2.08) 
Q4 (20.58) 45.8 1.05 (0.65, 1.71) 26.2 1.55 (0.60, 3.98) 84.1 1.19 (0.98, 1.46) 40.2 1.28 (0.80, 2.06) 
P, trendf 0.78 0.99 0.06 0.14 0.05 0.06 0.10 0.32 
 
            GLA 18:3(n-6) 
            Q1 (0.00) 39.7 1.00 20.6 1.00 76.3 1.00 51.1 1.00 
Q2 (0.05) 51.1 0.94 (0.71, 1.24) 21.7 1.44 (0.82, 2.53) 82.6 1.10 (0.97, 1.25) 51.1 1.09 (0.83, 1.43) 
Q3 (0.08) 53.8 0.92 (0.71, 1.19) 22.6 1.16 (0.66, 2.02) 84.9 1.13 (0.99, 1.29) 54.8 1.22 (0.91, 1.63) 
Q4 (0.15) 39.8 0.94 (0.65, 1.36) 22.4 0.80 (0.49, 1.30) 83.7 1.01 (0.88, 1.16) 38.8 0.89 (0.64, 1.24) 
P, trend 0.82 0.66 0.72 0.46 0.15 0.65 0.10 0.77 
 
            DGLA 20:3(n-6) 
            Q1 (0.15) 36.0 1.00 18.0 1.00 73.9 1.00 45.9 1.00 
Q2 (0.21) 32.4 0.82 (0.57, 1.17) 19.0 1.15 (0.65, 2.04) 80.0 1.06 (0.92, 1.21) 49.5 1.29 (0.97, 1.70) 
Q3 (0.29) 57.7 1.26 (0.96, 1.65) 21.6 1.52 (0.84, 2.75) 83.5 1.11 (0.96, 1.27) 44.3 1.33 (0.99, 1.79) 
Q4 (0.41) 57.4 1.33 (0.99, 1.78) 28.7 1.63 (0.92, 2.89) 89.1 1.21 (1.05, 1.38) 56.4 1.72 (1.26, 2.35) 
P, trend 0.0001 0.006 0.04 0.08 0.002 0.004 0.13 0.0009 
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Supplemental Table 3.4. Prevalence and adjusted prevalence ratios of metabolic syndrome components by adipose tissue biomarkers 
of n-6 polyunsaturated fatty acid intake among adults from Mesoamerica without high fasting glucose or diagnosed diabetes 
 
Abdominal obesitya High blood pressureb Low serum HDL cholesterolc High serum triglyceridesd 
Fatty acid category 
(median, weight % 
of total FA) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI)e 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
Unadjusted 
prevalence 
(%) 
Adjusted PR 
(95% CI) 
AA 20:4(n-6) 
 
  
 
  
 
  
 
  Q1 (0.25) 35.8 1.00 17.4 1.00 78.0 1.00 49.5 1.00 
Q2 (0.34) 44.2 1.19 (0.87, 1.64) 20.2 1.06 (0.59, 1.88) 82.7 0.98 (0.86, 1.11) 49.0 1.03 (0.76, 1.40) 
Q3 (0.46) 49.0 1.32 (0.95, 1.84) 23.5 1.14 (0.61, 2.12) 79.6 0.90 (0.78, 1.04) 43.9 0.87 (0.63, 1.20) 
Q4 (0.65) 53.4 1.41 (0.98, 2.02) 26.2 0.99 (0.55, 1.81) 85.4 0.94 (0.80, 1.10) 53.4 1.01 (0.70, 1.46) 
P, trend 0.02 0.08 0.09 0.94 0.22 0.37 0.63 0.90 
  
           Δ6-Desaturase 
index (DGLA/LA) 
            Q1 (0.011) 26.8 1.00 20.5 1.00 77.7 1.00 39.3 1.00 
Q2 (0.015) 50.0 1.53 (1.11, 2.10) 17.6 1.04 (0.61, 1.79) 79.6 1.07 (0.95, 1.21) 45.4 1.17 (0.88, 1.57) 
Q3 (0.020) 52.4 1.52 (1.07, 2.17) 24.3 1.52 (0.88, 2.62) 81.6 1.08 (0.95, 1.24) 53.4 1.33 (0.99, 1.79) 
Q4 (0.028) 54.9 1.74 (1.22, 2.47) 25.3 1.64 (0.92, 2.94) 87.9 1.20 (1.03, 1.39) 60.4 1.72 (1.23, 2.40) 
P, trend 0.0002 0.006 0.23 0.05 0.05 0.02 0.0006 0.0005 
             
Δ5-Desaturase 
index (AA/DGLA)             
Q1 (1.13) 53.5 1.00 20.8 1.00 84.2 1.00 56.4 1.00 
Q2 (1.46) 48.0 0.98 (0.76, 1.26) 23.5 1.03 (0.58, 1.82) 86.7 0.97 (0.86, 1.10) 48.0 0.82 (0.61, 1.10) 
Q3 (1.77) 42.6 1.09 (0.82, 1.45) 18.8 0.95 (0.50, 1.77) 78.2 0.89 (0.77, 1.02) 43.6 0.81 (0.60, 1.08) 
Q4 (2.41) 38.6 1.11 (0.80, 1.53) 23.7 1.12 (0.64, 1.97) 77.2 0.90 (0.78, 1.03) 48.2 0.86 (0.65, 1.14) 
P, trend 0.04 0.47 0.71 0.65 0.09 0.13 0.21 0.43 
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Footnotes to Supplemental Table 3.4. 
aWaist circumference >102 cm in men and >88 cm in women. 
bSystolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or receiving antihypertensive medication. 
c<40 mg/dL in men and <50 mg/dL in women or receiving treatment for low HDL cholesterol. 
d≥150 mg/dL or receiving treatment for hyperlipidemia. 
eFrom Poisson regression models. All models are adjusted for sex, age, height, education level, country of origin, total trans fatty 
acids, and palmitoleic acid. Models of all risk factors other than waist circumference are adjusted for BMI. Additionally, estimates for 
LA are adjusted for ALA. Estimates for specific long-chain n-6 PUFA are adjusted for ALA, total long-chain n-3 PUFA, and their 
precursor PUFA. The Δ6-desaturase index is adjusted for ALA, total long-chain n-3 PUFA, and GLA. The Δ5-desaturase index is 
adjusted for ALA, total long-chain n-3 PUFA, and DGLA. All covariate fatty acids were entered into the model as restricted cubic 
splines with knots placed at the 5th, 50th, and 95th percentiles of observed values. 
fWald test from Poisson regression models with each metabolic characteristic as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.5. Means and adjusted mean differences in metabolic syndrome component scoresa by adipose tissue biomarkers of 
n-3 polyunsaturated fatty acid intake among children from Mesoamerica 
 
Waist circumference HOMA-IR Mean arterial pressure Serum HDL cholesterol Serum triglycerides 
Fatty acid category 
(median, weight % 
of total FA) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI)b 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
ALA 18:3(n-3) 
                         Q1 (0.40) -0.02 ± 0.16 Reference -0.08 ± 0.57 Reference -0.04 ± 0.13 Reference 0.03 ± 0.23 Reference -0.02 ± 0.45 Reference 
Q2 (0.61) 0.02 ± 0.13 -0.02 (-0.06, 0.03) 0.07 ± 0.58 0.08 (-0.14, 0.31) 0.00 ± 0.12 0.00 (-0.05, 0.04) 0.04 ± 0.27 0.05 (-0.06, 0.15) 0.11 ± 0.47 0.07 (-0.12, 0.26) 
Q3 (0.76) 0.00 ± 0.16 0.00 (-0.04, 0.05) 0.04 ± 0.56 0.17 (-0.07, 0.40) 0.00 ± 0.15 -0.01 (-0.07, 0.05) 0.05 ± 0.28 0.05 (-0.05, 0.16) -0.02 ± 0.45 -0.03 (-0.24, 0.18) 
Q4 (1.09) 0.02 ± 0.17 -0.01 (-0.06, 0.04) -0.07 ± 0.65 0.11 (-0.19, 0.41) 0.01 ± 0.13 -0.02 (-0.08, 0.04) -0.17 ± 0.34 0.00 (-0.14, 0.13) -0.06 ± 0.35 -0.01 (-0.24, 0.21) 
P, trend 0.39 0.77 0.90 0.54 0.05 0.53 0.0002 0.81 0.29 0.72 
                          
EPA 20:5(n-3) 
                         
Q1 (0.00) 0.00 ± 0.15 Reference -0.02 ± 0.60 Reference -0.01 ± 0.13 Reference -0.01 ± 0.30 Reference 0.00 ± 0.45 Reference 
Q2 (0.04) 0.07 ± 0.18 -0.05 (-0.11, 0.01) 0.00 ± 0.46 -0.10 (-0.38, 0.18) 0.03 ± 0.14 0.01 (-0.06, 0.08) 0.00 ± 0.38 0.11 (-0.03, 0.25) 0.05 ± 0.32 0.03 (-0.16, 0.22) 
Q3 (0.10) 0.01 ± 0.18 -0.01 (-0.07, 0.06) 0.14 ± 0.61 0.12 (-0.13, 0.37) 0.00 ± 0.12 0.01 (-0.05, 0.07) -0.02 ± 0.19 -0.01 (-0.11, 0.10) -0.02 ± 0.44 -0.02 (-0.24, 0.20) 
P, trend 0.47 0.60 0.30 0.53 0.53 0.70 0.97 0.69 0.99 0.92 
                          
DPA 22:5(n-3) 
                         
Q1 (0.00) -0.04 ± 0.12 Reference -0.10 ± 0.57 Reference -0.02 ± 0.14 Reference 0.06 ± 0.25 Reference -0.04 ± 0.45 Reference 
Q2 (0.05) 0.01 ± 0.15 0.00 (-0.05, 0.04) -0.02 ± 0.53 0.09 (-0.13, 0.31) -0.04 ± 0.14 -0.04 (-0.09, 0.01) 0.03 ± 0.29 -0.02 (-0.12, 0.08) 0.04 ± 0.41 0.15 (-0.03, 0.33) 
Q3 (0.08) 0.06 ± 0.17 0.03 (-0.02, 0.08) 0.06 ± 0.64 0.14 (-0.05, 0.34) 0.05 ± 0.10 0.04 (-0.02, 0.09) -0.09 ± 0.31 -0.02 (-0.11, 0.08) 0.02 ± 0.46 0.20 (0.02, 0.37) 
Q4 (0.15) 0.02 ± 0.17 0.01 (-0.03, 0.06) 0.08 ± 0.63 0.20 (0.01, 0.38) 0.01 ± 0.13 0.01 (-0.03, 0.06) -0.09 ± 0.32 -0.06 (-0.15, 0.03) 0.03 ± 0.41 0.17 (0.01, 0.32) 
P, trend 0.01 0.40 0.09 0.04 0.07 0.36 0.002 0.18 0.37 0.04 
                          
DHA 22:6(n-3) 
                         
Q1 (0.00) -0.05 ± 0.12 Reference -0.13 ± 0.60 Reference -0.01 ± 0.15 Reference 0.08 ± 0.25 Reference -0.08 ± 0.42 Reference 
Q2 (0.06) 0.02 ± 0.15 -0.05 (-0.09, 0.00) -0.01 ± 0.55 0.12 (-0.12, 0.36) -0.02 ± 0.13 -0.04 (-0.10, 0.01) 0.08 ± 0.23 0.03 (-0.08, 0.13) 0.01 ± 0.29 0.08 (-0.10, 0.26) 
Q3 (0.10) 0.04 ± 0.18 -0.04 (-0.08, 0.01) 0.13 ± 0.64 0.15 (-0.07, 0.36) 0.03 ± 0.11 -0.01 (-0.06, 0.05) -0.08 ± 0.30 -0.06 (-0.18, 0.06) 0.01 ± 0.52 0.07 (-0.14, 0.28) 
Q4 (0.18) 0.01 ± 0.15 0.01 (-0.04, 0.05) -0.02 ± 0.56 0.15 (-0.04, 0.34) -0.03 ± 0.14 -0.04 (-0.09, 0.02) -0.14 ± 0.33 -0.14 (-0.24, -0.04) 0.08 ± 0.48 0.19 (-0.02, 0.41) 
P, trend 0.05 0.43 0.24 0.16 0.66 0.30 <0.0001 0.001 0.10 0.08 
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Footnotes to Supplemental Table 3.5. 
aScores for metabolic syndrome components (waist circumference, HOMA-IR, mean arterial pressure, serum HDL cholesterol, and 
serum triglycerides) were created by regressing each log-transformed component on sex and log-transformed age in linear regression 
models and obtaining standardized residuals. 
bFrom linear regression models. All models are adjusted for the child's height-for-age Z score, maternal height, country of origin, total 
trans fatty acids, and palmitoleic acid. Models for all risk factors except waist circumference are adjusted for BMI-for-age Z score. In 
addition, estimates for ALA are adjusted for LA. Estimates for specific long-chain n-3 PUFA are adjusted for LA, total long-chain n-6 
PUFA, and their precursor PUFA. All covariate fatty acids were entered into the model as restricted cubic splines with knots placed at 
the 5th, 50th, and 95th percentiles of observed values. 
cWald test from linear regression models with each metabolic score component as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous. 
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Supplemental Table 3.6. Means and adjusted mean differences in metabolic syndrome component scoresa by adipose tissue biomarkers of 
n-6 polyunsaturated fatty acid intake among children from Mesoamerica 
 
Waist circumference HOMA-IR Mean arterial pressure Serum HDL cholesterol Serum triglycerides 
Fatty acid category 
(median, weight % of 
total FA) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI)b 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
LA 18:2(n-6) 
                         
Q1 (9.20) -0.03 ± 0.14 Reference -0.10 ± 0.61 Reference -0.05 ± 0.11 Reference 0.06 ± 0.24 Reference 0.01 ± 0.44 Reference 
Q2 (12.04) -0.01 ± 0.16 0.01 (-0.03, 0.04) -0.07 ± 0.64 -0.02 (-0.21, 0.17) 0.00 ± 0.14 0.03 (-0.02, 0.07) 0.07 ± 0.25 0.01 (-0.08, 0.11) 0.00 ± 0.48 -0.05 (-0.24, 0.13) 
Q3 (14.85) 0.00 ± 0.14 0.03 (-0.01, 0.08) 0.16 ± 0.54 0.20 (-0.05, 0.45) 0.00 ± 0.14 -0.02 (-0.08, 0.05) 0.04 ± 0.24 0.03 (-0.09, 0.16) 0.00 ± 0.38 -0.15 (-0.38, 0.07) 
Q4 (19.82) 0.05 ± 0.16 0.09 (0.03, 0.15) -0.02 ± 0.54 -0.08 (-0.44, 0.28) 0.02 ± 0.14 -0.02 (-0.09, 0.05) -0.21 ± 0.35 -0.03 (-0.20, 0.13) -0.01 ± 0.45 -0.23 (-0.51, 0.05) 
P, trendc 0.008 0.002 0.32 0.54 0.02 0.48 <0.0001 0.59 0.83 0.10 
 
                         GLA 18:3(n-6) 
                         Q1 (0.00) -0.02 ± 0.14 Reference -0.02 ± 0.60 Reference -0.01 ± 0.13 Reference 0.03 ± 0.23 Reference -0.02 ± 0.43 Reference 
Q2 (0.06) 0.04 ± 0.16 -0.01 (-0.05, 0.03) 0.10 ± 0.48 0.00 (-0.17, 0.18) 0.01 ± 0.14 0.02 (-0.02, 0.06) 0.04 ± 0.30 0.11 (0.03, 0.19) 0.06 ± 0.45 0.05 (-0.10, 0.20) 
Q3 (0.15) 0.00 ± 0.16 -0.02 (-0.07, 0.02) -0.10 ± 0.66 0.00 (-0.23, 0.22) -0.01 ± 0.14 0.01 (-0.05, 0.06) -0.12 ± 0.34 -0.01 (-0.12, 0.10) -0.02 ± 0.44 0.03 (-0.16, 0.22) 
P, trend 0.41 0.33 0.51 0.99 0.85 0.73 0.004 0.83 0.93 0.72 
 
                         DGLA 20:3(n-6) 
                         Q1 (0.09) -0.06 ± 0.14 Reference -0.17 ± 0.49 Reference -0.04 ± 0.13 Reference 0.08 ± 0.24 Reference -0.01 ± 0.42 Reference 
Q2 (0.14) -0.02 ± 0.13 0.00 (-0.05, 0.04) -0.08 ± 0.57 -0.06 (-0.27, 0.16) 0.00 ± 0.13 0.04 (-0.01, 0.09) 0.00 ± 0.28 -0.04 (-0.14, 0.06) -0.02 ± 0.46 -0.11 (-0.28, 0.07) 
Q3 (0.19) 0.02 ± 0.14 0.03 (-0.02, 0.07) 0.06 ± 0.66 -0.01 (-0.24, 0.22) -0.01 ± 0.13 0.02 (-0.03, 0.08) -0.02 ± 0.29 0.00 (-0.11, 0.11) -0.01 ± 0.43 -0.16 (-0.35, 0.03) 
Q4 (0.29) 0.08 ± 0.17 0.06 (0.01, 0.11) 0.16 ± 0.60 0.02 (-0.22, 0.26) 0.02 ± 0.14 0.01 (-0.04, 0.06) -0.11 ± 0.34 0.01 (-0.11, 0.14) 0.05 ± 0.44 -0.15 (-0.34, 0.04) 
P, trend <0.0001 0.005 0.001 0.71 0.03 0.98 0.001 0.61 0.50 0.16 
 
                         AA 20:4(n-6) 
   
  
   
  
   
  
   
  
   
  Q1 (0.17) -0.07 ± 0.15 Reference -0.14 ± 0.58 Reference -0.05 ± 0.11 Reference 0.09 ± 0.22 Reference -0.03 ± 0.40 Reference 
Q2 (0.28) -0.03 ± 0.13 0.02 (-0.03, 0.06) -0.06 ± 0.57 -0.10 (-0.29, 0.10) -0.02 ± 0.13 -0.02 (-0.06, 0.03) -0.04 ± 0.29 -0.06 (-0.15, 0.03) 0.01 ± 0.46 -0.05 (-0.21, 0.11) 
Q3 (0.36) 0.04 ± 0.15 0.05 (0.00, 0.10) 0.03 ± 0.63 -0.14 (-0.34, 0.07) 0.02 ± 0.15 0.01 (-0.04, 0.06) -0.07 ± 0.34 0.01 (-0.08, 0.10) 0.03 ± 0.48 -0.13 (-0.29, 0.03) 
Q4 (0.55) 0.08 ± 0.16 0.06 (0.01, 0.11) 0.13 ± 0.57 -0.08 (-0.30, 0.14) 0.02 ± 0.14 -0.03 (-0.08, 0.03) -0.02 ± 0.31 0.08 (-0.03, 0.19) 0.01 ± 0.41 -0.18 (-0.35, -0.02) 
P, trend <0.0001 0.02 0.01 0.57 0.005 0.35 0.09 0.08 0.66 0.03 
    
                      Δ6-Desaturase index (DGLA/LA) 
                     Q1 (0.007) -0.06 ± 0.13 Reference -0.21 ± 0.53 Reference -0.02 ± 0.12 Reference -0.02 ± 0.32 Reference -0.06 ± 0.39 Reference 
Q2 (0.011) -0.01 ± 0.13 -0.01 (-0.05, 0.04) 0.00 ± 0.50 -0.12 (-0.32, 0.07) -0.01 ± 0.12 -0.01 (-0.06, 0.03) -0.01 ± 0.32 0.02 (-0.07, 0.12) 0.03 ± 0.42 -0.09 (-0.26, 0.07) 
Q3 (0.014) 0.03 ± 0.14 0.03 (-0.02, 0.07) -0.02 ± 0.57 -0.14 (-0.36, 0.07) -0.01 ± 0.14 -0.01 (-0.06, 0.05) 0.01 ± 0.25 0.00 (-0.09, 0.10) -0.07 ± 0.48 -0.18 (-0.35, -0.01) 
Q4 (0.019) 0.06 ± 0.18 0.06 (0.02, 0.11) 0.20 ± 0.69 0.01 (-0.19, 0.22) 0.03 ± 0.15 0.01 (-0.03, 0.06) -0.03 ± 0.30 -0.01 (-0.11, 0.09) 0.10 ± 0.44 -0.05 (-0.22, 0.12) 
P, trend <0.0001 0.002 0.001 0.76 0.06 0.49 0.84 0.80 0.10 0.57 
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Supplemental Table 3.6. Means and adjusted mean differences in metabolic syndrome component scoresa by adipose tissue biomarkers of 
n-6 polyunsaturated fatty acid intake among children from Mesoamerica 
 
Waist circumference HOMA-IR Mean arterial pressure Serum HDL cholesterol Serum triglycerides 
Fatty acid category 
(median, weight % of 
total FA) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI)b 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Mean Z score 
(±SD) 
Adjusted mean 
difference 
(95% CI) 
Δ5-Desaturase index (AA/DGLA) 
  
                   Q1 (1.27) -0.01 ± 0.19 Reference -0.02 ± 0.67 Reference -0.03 ± 0.12 Reference -0.03 ± 0.29 Reference 0.03 ± 0.42 Reference 
Q2 (1.68) 0.01 ± 0.14 0.02 (-0.02, 0.06) 0.07 ± 0.53 0.04 (-0.15, 0.24) 0.00 ± 0.13 0.02 (-0.02, 0.07) -0.05 ± 0.33 0.03 (-0.07, 0.12) 0.07 ± 0.48 0.03 (-0.13, 0.19) 
Q3 (1.97) 0.04 ± 0.14 0.05 (0.01, 0.09) -0.01 ± 0.63 -0.13 (-0.32, 0.07) 0.02 ± 0.16 0.02 (-0.03, 0.07) 0.03 ± 0.28 0.08 (-0.01, 0.17) -0.03 ± 0.41 -0.09 (-0.25, 0.06) 
Q4 (3.16) -0.01 ± 0.14 0.05 (0.01, 0.10) -0.07 ± 0.53 -0.05 (-0.26, 0.16) -0.01 ± 0.13 0.02 (-0.03, 0.06) 0.01 ± 0.27 0.06 (-0.03, 0.16) -0.06 ± 0.44 -0.14 (-0.33, 0.05) 
P, trend 0.78 0.01 0.45 0.52 0.67 0.68 0.39 0.22 0.19 0.10 
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Footnotes to Supplemental Table 3.6. 
aScores for metabolic syndrome components (waist circumference, HOMA-IR, mean arterial pressure, serum HDL cholesterol, and 
serum triglycerides) were created by regressing each log-transformed component on sex and log-transformed age in linear regression 
models and obtaining standardized residuals. 
bFrom linear regression models. All models are adjusted for the child's height-for-age Z score, maternal height, country of origin, total 
trans fatty acids, and palmitoleic acid. Models for all risk factors except waist circumference are adjusted for BMI-for-age Z score. 
Additionally, estimates for LA are adjusted for ALA. Estimates for specific long-chain n-6 PUFA are adjusted for ALA, total long-
chain n-3 PUFA, and their precursor PUFA. The Δ6-desaturase index is adjusted for ALA, total long-chain n-3 PUFA, and GLA. The 
Δ5-desaturase index is adjusted for ALA, total long-chain n-3 PUFA, and DGLA. All covariate fatty acids were entered into the model 
as restricted cubic splines with knots placed at the 5th, 50th, and 95th percentiles of observed values. 
cWald test from linear regression models with each metabolic score component as the outcome and a variable representing medians of 
ordinal categories of the predictor introduced as continuous.
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Chapter 4. Serum polyunsaturated fatty acids in middle childhood and body mass index 
change through adolescence 
 
Kerry S. Flannagan, Sheila Gahagan, Arun K. Das, Betsy Lozoff, Eduardo Villamor 
 
Abstract 
Objective: The aim of this study was to assess associations of serum biomarkers of n-3 and n-6 
polyunsaturated fatty acids (PUFA) at 5 and 10 y of age with change in body mass index (BMI)-
for-age Z scores (BAZ) through age 16 y. 
Design: In this longitudinal study, we quantified serum PUFA by gas chromatography in 
samples collected at 5 y and 10 y of age. BMI was measured at 5, 10, and 16 y. We compared the 
change in BAZ through 16 y of age between PUFA quartiles at 5 or 10 y and between quartiles 
of PUFA change from 5 to 10 y by fitting growth curves from multivariable linear mixed models 
with restricted cubic splines. 
Setting: Santiago, Chile. 
Population: 418 children. 
Results: At 5 y of age, serum docosahexaenoic acid (DHA) was inversely associated with BAZ 
change from ages 5 to 16 y. Among children in the highest quartile of DHA, mean BAZ change 
was 0.51 Z scores lower (95% CI: -0.88, -0.13; P=0.008) than among children in the lowest 
quartile. At 10 y of age, arachidonic acid (AA) was positively related to BAZ change from ages 
10 to 16 y. Children in the lowest quartile of AA had a mean change in BAZ 0.17 Z scores lower 
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(95% CI: -0.34, -0.01; P=0.04) compared with children in the highest three quartiles. Change in 
eicosapentaenoic acid (EPA) between ages 5 and 10 y was inversely associated with change in 
BAZ from ages 10 to 16 y (P, trend=0.04). Change in AA (P, trend=0.03) and the Δ5-desaturase 
(D5D) activity index (P, trend=0.003) were each positively associated with BAZ change. 
Conclusions: Serum concentrations of some long-chain n-3 PUFA in middle childhood are 
associated with less weight gain through adolescence whereas the n-6 PUFA AA and D5D 
activity are related to increased weight gain. 
Keywords: polyunsaturated fatty acids, children, BMI, Chile, growth  
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Introduction 
Childhood obesity is perhaps the strongest and most prevalent early life risk factor for the 
development of chronic diseases, including type 2 diabetes, hypertension, and coronary heart 
disease (1). Childhood obesity has increased globally throughout recent decades (2) and 
represents a significant public health concern. The identification of potentially modifiable 
exposures that influence the development of adiposity in early life is crucial in order to address 
this epidemic. Nutrition in childhood can affect long-term cardiometabolic health (3), and is 
potentially amenable to cost-effective interventions; thus, it represents a promising means of 
preventing or reducing childhood obesity. 
Polyunsaturated fatty acids (PUFA), the basic constituents of dietary fat, are potentially 
relevant nutritional factors in the etiology of chronic disease. These are fatty acids with more 
than one double bond in their carbon chain, classified primarily into the n-3 and n-6 families. 
Alpha-linolenic acid (ALA; 18:3 n-3) and linoleic acid (LA; 18:2 n-6) are the essential fatty 
acids in each of these families and can only be obtained from diet. Through a series of enzymatic 
desaturation and elongation reactions, ALA and LA are converted endogenously into long-chain 
PUFA, which have a wide range of physiological roles in child development and in the 
regulation of cardiovascular function and inflammation (4). 
In vitro and animal studies suggest that PUFA can influence body composition. The long-
chain n-3 PUFA eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaneoic acid (DHA; 22:6 
n-3) reduce adiposity and inhibit weight gain (5), while n-6 PUFA promote adipogenesis (6). 
However, results from studies in humans are mixed (7), and most investigations have been 
conducted in adults. Because PUFA are necessary for fetal development and are present in breast 
milk, a number of studies have focused on maternal PUFA intake during pregnancy or lactation, 
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or PUFA intake in infancy (8). These studies have found positive, inverse, and null associations 
between specific PUFA and adiposity throughout childhood and adolescence in both intervention 
and observational studies. Fewer studies have focused on PUFA in middle childhood. Of these, 
most are cross-sectional (9–18), and have produced inconclusive results regarding specific PUFA 
and measures of adiposity. One longitudinal study of 77 Japanese children found that changes in 
plasma DHA and dihomo-gamma-linolenic acid (DGLA; 20:3 n-6), a long-chain n-6 PUFA, 
from ages 10 to 13 y were positively associated with concomitant changes in height-standardized 
weight, while change in LA was inversely associated with weight change (19). In another study 
of Colombian children who were 5-12 y at baseline, serum ALA was inversely associated with 
estimated change in BMI-for-age Z scores between 6 and 14 y (20). 
Middle childhood comprises a number of important developmental changes in body 
composition and adiposity (21,22), and this period is also the time during which the number of 
adipocytes in the body is determined (23). Therefore, middle childhood represents a potentially 
sensitive period during which diet quality might influence the development of obesity. Few 
studies have been conducted in low- and middle-income countries where childhood obesity is 
increasing rapidly (2), and the PUFA supply in diet is limited (24). Findings from higher-income 
settings may not be generalizable to these populations. In Latin America in particular, the public 
health burden of childhood obesity and chronic disease is high (25,26). 
 We conducted a longitudinal study of serum PUFA biomarkers and BMI change in a 
cohort of children from Santiago, Chile, who were recruited during the beginning of the 
country's nutrition transition. The aim of the study was to investigate associations between 
PUFA status at 5 and 10 y of age and change in BMI-for-age Z scores through adolescence. 
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Methods 
Study design and population 
This longitudinal investigation was conducted in a cohort of Chilean children who were 
followed from infancy through adolescence as participants of studies on the effects of iron status 
on neurodevelopment. Details of the original studies have been described previously (27,28). 
Briefly, participants were infants from low- and middle-income families living in Santiago, 
Chile, who were recruited between 1991 and 1996 when they were 4 to 6 months old. Eligible 
infants were singleton, born at term weighing at least 3 kg through uncomplicated, vaginal births, 
and did not have major health complications. Infants without iron deficiency anemia at 
recruitment were enrolled in a supplementation trial; they were randomly assigned to receive 
high or low- dose iron supplementation (either through drops or infant formula) or usual nutrition 
until they were 12 months old. Infants who were anemic at recruitment were treated with iron 
and enrolled in an observational neurodevelopment study, along with the next non-anemic infant. 
Of the 1798 infants originally enrolled, 1657 participants completed the trial and 135 completed 
the neurodevelopment study. Follow up continued during childhood; 888 children were assessed 
at age 5 y and 1127 children were examined at 10 y of age. A subset of 679 participants were 
assessed at 16 y of age as part of a study of obesity and cardiovascular risk. This group did not 
differ from the original cohort with respect to sociodemographic and nutritional characteristics 
including socioeconomic status, birth weight, or breastfeeding. Data used in the current 
investigation are from participants in the study at 16 y of age who had available serum samples 
at one or both of the 5 and 10 y time points. 
Study procedures were approved by institutional review boards at the University of Chile 
Institute of Nutrition and Food Technology (INTA), the University of Michigan, and the 
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University of California, San Diego. Parents provided written informed consent to participate for 
their children and written assent was obtained from children beginning at age 10 y. 
Data collection 
Birth weight in g, birth length in cm, and gestational age in weeks were obtained from 
hospital records. Gestational age was estimated from the date of the mother's last menstrual 
period. At enrollment, study nutritionists collected information from parents on household 
socioeconomic indicators. Information on the date of the first bottle feeding and last 
breastfeeding was collected prospectively from mothers at weekly study visits between 
enrollment and 12 months of age. When infants had already been bottle fed at enrollment, 
mothers were asked to recall the date of the first bottle. Because feeding breast milk by bottle 
was rare in this population, bottle feeding was equivalent to providing infant formula or cow's 
milk. 
Anthropometric measurements were collected at INTA at all time points by trained study 
personnel using standardized techniques. At 5, 10, and 16 y of age weight was measured to the 
nearest 100 g using a Seca scale (Seca, Hamburg, Germany) and height was measured to the 
nearest millimeter using a Holtain stadiometer (Holtain, Crymych, UK). Measures were obtained 
in duplicate and a third measurement was obtained if the first two differed by more than 0.3 kg 
or 0.5 cm. 
Researchers obtained a blood sample by venipuncture at the 5 and 10 y assessments. 
Blood components were separated and serum samples were transported to the University of 
Michigan where they were cryostored at -80˚C. 
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Fatty acid analysis 
Serum fatty acids were quantified at the University of Michigan Regional Comprehensive 
Metabolomics Resource Core. Total lipids were extracted from 200 l of serum using the 
method described by Bligh and Dyer (29). 10 μL of 4 mM nonadecanoic acid (C19:0) was added 
as an internal standard. Boron trifluoride-methanol was used to derivatize the fatty acid portion 
of the total lipids into their methyl esters as previously described (30). To extract the methyl 
esters, a 2:1 hexane-water mixture was added and the sample was centrifuged. The hexane layer 
containing the methyl esters was removed from the aqueous layer and dried, and the methyl 
esters were re-suspended in 100-200 μL of hexane, depending on the volume of the original 
sample. Fatty acids were analyzed using gas chromatography (GC). 1-2 μL of sample was 
injected by autosampler onto an Agilent 680N GC (Agilent, Santa Clara, CA, USA) equipped 
with a flame ionization detector, a 100 m x 0.25 mm x 0.2 μm SP-2560 column (Sigma-Aldrich, 
Bellefonte, PA, USA), and Chemstation software for data analysis. To quantify fatty acids, 
known amounts of C19:0 and other authentic methyl esters were used to create a calibration 
curve. The authentic methyl esters were also used to identify fatty acids in samples based on 
their retention times. The coefficient of variation for GC analyses of specific fatty acids ranged 
between 2.5-3.6%. 
Definition of exposures 
The main exposures were serum biomarkers of n-3 and n-6 PUFA expressed as weight 
percentages of total fatty acids. We examined serum PUFA concentrations measured at the 5 y 
and 10 y assessments, and change in serum PUFA concentrations between the two time points. 
Among n-3 PUFA, we considered ALA, EPA, docosapentaenoic acid (22:5 n-3; DPA), and 
DHA. The n-6 PUFA were LA, gamma-linolenic acid (18:3 n-3; GLA), DGLA, and arachidonic 
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acid (20:4 n-6; AA). We also considered the GLA/LA and DGLA/AA ratios, as activity indices 
of the Δ6-desaturase (D6D) and Δ5-desaturase (D5D) enzymes, respectively. We categorized all 
exposures into quartiles to allow for non-linear associations with the outcomes. 
Definition of outcomes 
The primary outcomes were changes in body mass index (BMI), expressed as age- and 
sex-standardized Z scores (BAZ). We calculated BMI as kg/m2, and converted it to BAZ using 
the World Health Organization Growth Reference for children ages 5-19 y (31). Using the 5 y 
PUFA biomarkers as exposures, we considered BAZ change from 5 to 16 y as the outcome. In 
the analyses of 10 y PUFA and 5-10 y change in PUFA concentrations, the outcome was change 
in BAZ between 10 and 16 y. 
Covariates 
Covariates were sociodemographic and anthropometric characteristics measured in 
infancy, and other serum fatty acids measured at 5 and 10 y. Birth length and birth weight were 
categorized as average or large for gestational age using the INTERGROWTH 21st standards for 
newborn size (32). We defined large for gestational age as being ≥90th percentile. Because birth 
weight ≥3 kg was one of the inclusion criteria into the study, there were no children ≤10th 
percentile of weight for gestational age and thus we did not consider a category of small for 
gestational age. Seven children who were ≤10th percentile for length were included in the 
average for gestational age category. Breastfeeding was categorized as <6 months (last 
breastfeeding before 180 days old), ≥6 months mixed breastfeeding (last breastfeeding on or 
after 180 days old and first bottle feeding on or before 180 days old), and ≥6 months exclusive 
breastfeeding (last breastfeeding on or after 180 days old and first bottle feeding after 180 days 
old or never). Iron supplementation from the original study was categorized as any vs. none by 
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combining the high and low dose supplement groups. Socioeconomic status (SES) in infancy 
was measured using a modified Graffar index (33). This index comprises 13 items related to 
family structure; education and employment of the head of household; crowding and physical 
condition of the home; and ownership of the home, car, and household appliances. Each item is 
scored from 0 to 5 for a possible score of 0 to 65 on the total index, with higher values indicating 
lower SES. We divided the index into quintiles. We also considered as covariates serum total 
trans fatty acids which have been related to weight gain among adults (34) and serum 
palmitoleic acid (16:1 n-7), which is associated with carbohydrate intake (35). 
Statistical analysis 
The final analytic samples consisted of children with serum PUFA and BAZ measured at 
5 y and at least one subsequent BAZ measurement at 10 or 16 y of age (N=239), and children 
with PUFA measured at 10 y and BAZ measured at 10 and 16 y (N=418). The analysis of change 
in PUFA concentrations from 5 to 10 y of age in relation to change in BAZ from ages 10 to 16 y 
included 141 children with PUFA measurements at both 5 and 10 y and BAZ at 10 and 16 y of 
age. 
Predictors of PUFA at 5 and 10 y of age 
We first examined the distribution of PUFA biomarkers at ages 5 and 10 y by categories 
of covariates using means ± SD, to identify potential confounders of the PUFA-BAZ change 
associations. For dichotomous covariates we tested the statistical significance of the associations 
with use of Wald tests from linear regression models with each PUFA as the outcome and an 
indicator for the characteristic as a predictor. For categorical variables, we used a 2 score 
statistic. For ordinal covariates, we conducted tests for linear trend by introducing into the model 
a variable representing category-specific medians into the model as a continuous predictor. 
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PUFA at 5 y of age and BAZ change from ages 5 to 16 y 
In bivariate analysis, we estimated mean ± SE BAZ at ages 5 and 16 y and BAZ change 
from 5 to 16 y of age by quartiles of PUFA biomarkers measured at age 5 y. These estimates 
were from growth curves calculated separately among children in each PUFA quartile with the 
use of mixed effects linear regression models as previously described (36). The outcome in the 
models was BAZ, and age was represented as a predictor using restricted cubic splines (37). 
These spline functions consist of piecewise cubic polynomials that are smoothly joined at the 
knots and constrained to be linear in the tails. They allow for flexible, smoothed modeling of 
non-linear changes in BAZ through childhood. We fitted these models using data from the 5, 10, 
and 16 y of age assessments, and placed the three knots at the median ages of children at each 
assessment. Predictors included indicators for each PUFA quartile, linear and spline terms for 
age, and interaction terms between the quartiles and age terms. The models also included random 
intercepts and age slopes for each child to account for within-child correlation of the BAZ 
measurements over time. Because these models do not require an equal number of observations 
per child, we included all available measurements in the model using the exact age of the 
children at each visit, in decimal years. From these models, we estimated the mean BAZ ± SE at 
5 and 16 y, and the mean ± SE BAZ change between 5 and 16 y among children in each PUFA 
quartile. 
In multivariable analysis, we obtained adjusted mean differences and 95% confidence 
intervals (CI) in BAZ change from ages 5 to 16 y between PUFA quartiles using adjusted mixed 
effects regression models. We included as adjustment variables the covariates that were 
associated with PUFA biomarkers in bivariate analysis or that are known predictors of BAZ 
change. The final models included sex, birth weight, breastfeeding, Graffar index, total serum 
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trans fatty acids, and palmitoleic acid measured at 5 y. In addition, we adjusted each PUFA for 
its measured concentration in infancy, and for other PUFA measured at 5 y that could confound 
the association with BAZ change but would not be intermediates on the causal pathway. All n-3 
PUFA were adjusted for LA and total long-chain n-6 PUFA, while all n-6 PUFA were adjusted 
for ALA and total long-chain n-3 PUFA. Long chain PUFA were also adjusted for their 
immediate precursor. All covariate fatty acids were represented using restricted cubic splines 
with knots placed at the 5th, 50th, and 95th percentiles of their distribution in order to account for 
possible non-linearity of their associations with the outcome. All models were fitted using 
empirical variance estimates, which are robust to heteroskedasticity and deviations from 
normality (38). 
In supplemental analyses, we determined whether associations between PUFA and BAZ 
change differed by baseline weight status by stratifying the analyses between normal-weight 
participants (BAZ ≤1) and children with overweight/obesity (BAZ >1) at the age 5 y assessment. 
We tested the statistical significance of interaction terms between baseline weight status and 
PUFA predictors with the use of three-way cross-product terms between PUFA, age terms, and 
weight status. 
PUFA at 10 y of age and BAZ change from ages 10 to 16  y 
In bivariate analysis, we estimated mean ± SE BAZ at ages 10 and 16 y and BAZ 
changes from 10 to 16 y of age by quartiles of PUFA biomarkers measured at the age 10 y 
assessment. These estimates were from mixed effects linear regression models fitted using data 
from the ages 10 and 16 y assessments. The outcome was BAZ and predictors included indicator 
variables for PUFA quartiles, a linear term for age, and interaction terms between each quartile 
and age. Models also included random intercepts for each child. 
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In multivariable analysis, we obtained adjusted mean differences with 95% CI in BAZ 
change from 10 to 16 y of age between PUFA quartiles using the first quartile as reference. 
Models were adjusted for sex, birth weight, breastfeeding, Graffar index, the main exposure 
PUFA measured in infancy, and serum trans fatty acids and palmitoleic acid measured at 10 y of 
age. Additionally, we included other PUFA biomarkers assessed at age 10 y as described for the 
models with age 5 y PUFA as the main exposures. We did not adjust for any PUFA measured at 
5 y because 277 children lacked this information. We conducted supplemental analyses stratified 
by weight status at 10 y by including an indicator variable for overweight/obesity and interaction 
terms between this variable and PUFA exposures in the models. 
Change in PUFA concentrations from ages 5 to 10 y and change in BAZ from ages 10 to 16 y 
In the subset of children with data on serum PUFA at both 5 and 10 y of age (N=141), we 
calculated the change in serum concentrations of each PUFA by subtracting the measurements at 
the 5 y assessment from those at the 10 y assessment. Next, we estimated mean ± SE BAZ at 
ages 10 and 16 y and BAZ change from ages 10 to 16 y by quartiles of change in PUFA 
following an analogous approach to that described for age 10 y PUFA as main exposures. In 
addition to baseline characteristics, mean differences in BAZ change were further adjusted for 
change in total trans fatty acids, palmitoleic acid, and other PUFA between ages 5 and 10 y. 
We conducted all analyses using Statistical Analysis Software version 9.4 (SAS Institute, 
Cary, NC, USA). 
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Results 
PUFA at 5 y of age. Among children included in the analysis of 5 y serum PUFA 
(N=239), 11, 33, and 195 had measurements at ages 10 y only, 16 y only, and both 10 and 16 y, 
respectively. Fifty-three percent were boys. Mean ± SD BAZ at 5, 10, and 16 y of age were, 
respectively, 0.94 ± 1.17, 1.00 ± 1.14, and 0.67 ± 1.18. Forty-four percent had overweight or 
obesity at 5 y of age. 
Predictors of PUFA at 5 y of age. Serum ALA concentrations were higher among 
children who had been breastfed <6 months compared with those who had been breastfed ≥6 
months (Table 1). Socioeconomic status in infancy was positively associated with EPA and 
DGLA; whereas iron supplementation was related to higher DGLA. Serum AA was higher 
among children born tall for gestational age. 
BAZ change from ages 5 to 16 y. In bivariate analysis, DPA and DHA at age 5 y were 
each inversely associated with BAZ change (Table 2). After adjustment, the association with 
DPA was not statistically significant; however, DHA remained inversely associated with BAZ 
change (P, trend=0.03). Compared with children in the lowest quartile of serum DHA, BAZ 
change among those in the highest quartile was 0.51 Z scores lower (95% CI: -0.88, -0.13; 
P=0.008). This association did not differ significantly between normal weight children and 
children with overweight or obesity (P, interaction=0.07) (Supplemental Table 1). None of the 
n-6 PUFA were associated with BAZ change.  
 LA was inversely associated with BAZ change among children with overweight or 
obesity only (P, trend=0.02) (P, interaction=0.004) (Supplemental Table 1). 
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PUFA at 10 y of age. Among children included in the analysis of 10 y PUFA (N=418), 
53% were boys. Mean ± SD BAZ at 10 and 16 y of age were 1.03 ± 1.15 and 0.70 ± 1.12; 55% 
had overweight or obesity at 10 y of age. 
Predictors of PUFA at 10 y of age. At 10 y, ALA was lower among boys compared with 
girls (Table 3). EPA was inversely associated with birth weight, whereas DPA was positively 
associated with iron supplementation. LA was lower among boys than girls. GLA and the D6D 
activity index were each positively associated with birth length and weight. 
BAZ change from ages 10 to 16 y. None of the n-3 PUFA were significantly associated 
with change in BAZ (Table 4). In bivariate analysis, AA was positively associated with BAZ 
change (P, trend=0.02), as was the D5D activity index (P, trend=0.03). After adjustment, 
children in the lowest quartile of AA had a mean change in BAZ 0.17 Z scores lower (95% CI: -
0.34, -0.01; P=0.04) than did children in the highest three quartiles. The association with D5D 
was attenuated and became non-statistically significant. None of the associations differed by 10 y 
weight status at age 10 y (Supplemental Table 2). 
Change in PUFA concentrations between 5 and 10 y of age. In bivariate analysis, no 
changes in n-3 PUFA were significantly associated with BAZ change from 10 to 16 y of age 
(Table 5). After adjustment, change in EPA was inversely associated with change in BAZ. 
Children in the highest quartile of EPA change had a 0.32 Z score lower change in BAZ (95% 
CI: -0.64, 0.00; P, trend=0.04).  
In bivariate analysis of n-6 PUFA, change in the D5D activity index was positively 
associated with 10-16 y BAZ change. After adjustment, children in the highest quartile of D5D 
activity change had a mean change in BAZ 0.64 Z scores higher than children in the lowest 
quartile (95% CI: 0.27, 1.02; P=0.001). Change in AA was also positively associated with 
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change in BAZ after adjustment. Mean BAZ change among children in the highest quartile was 
0.51 Z scores higher than among those in the lowest quartile (95% CI: 0.11, 0.90; P=0.01).  
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Discussion 
In this longitudinal study of Chilean children, serum DPA and DHA at 5 y of age were 
inversely associated with BAZ change between 5 and 16 y of age, while serum AA at 10 y of age 
or change in AA from 5 to 10 y were positively associated with BAZ from 10 to 16 y. Increased 
EPA from 5 to 10 y was related to less change in BAZ between 10 and 16 y, while increased 
D5D activity was associated with higher BAZ change. 
BAZ in this population was generally high, likely as a result of the ongoing nutrition 
transition in Chile at the time of measurement (39). Nearly half and over half of children had 
overweight or obesity at 5 and 10 y of age, respectively, according to World Health Organization 
cut points (40). At high percentiles, BMI in childhood is strongly correlated with fat mass (41), 
and the World Health Organization BAZ cut points have a high specificity for diagnosing 
overweight (42). Thus, in the context of this study, BAZ likely mainly reflects adiposity rather 
than fat-free mass, and greater changes in BAZ represent increases in adiposity above levels that 
are already associated with adverse health outcomes such as high serum triglycerides and insulin 
resistance (43).  
We found that when children were 5 y old, DPA and DHA were inversely associated with 
change in BAZ through 16 y of age. Most previous studies of these PUFA and BMI in middle 
childhood are cross-sectional in design. Of these, three (10–12) found an inverse association 
between plasma or serum DHA and either BMI or obesity, one found a positive association 
between DHA in adipose tissue and overweight or obesity (15), and seven others (9,13,14,16–
19) found no association between DHA in plasma, erythrocytes, or whole blood and BMI or 
obesity. In one study of 77 Japanese children, a 3-year change in plasma DHA was positively 
associated with concomitant change in height-standardized weight among boys only (19). In a 
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longitudinal study of 668 Colombian children, serum DHA at baseline (when the children were 
5-12 y old) was not associated with change in BAZ estimated between 6 and 14 y of age (20). 
Finally, two small randomized trials of supplementation with either EPA+DHA for 1 month (44) 
or DHA alone for 6 months (45) found no effect on BMI. The relation of DPA in plasma or 
erythrocytes and BMI among children was studied mostly in a few cross-sectional studies. Of 
these, all three (13,14,17) found no association. There are several potential explanations for 
discrepancies between our results and those of previous investigations. Many of the cross-
sectional studies are small and in some the authors did not adjust for potential confounders in 
their analyses. Moreover, the findings from these studies could be biased by reverse causation, 
since adiposity itself could influence PUFA levels through effects on the activity of desaturase 
enzymes (46). The age ranges of children in these studies were either entirely older than 5 y or 
included 5-y-old children only as the very youngest participants, so discrepancies may reflect 
true differences in the associations at different points of middle childhood. Consistent with this 
notion, we found no association between DHA at 10 y of age and BAZ change. A difference in 
participants' ages may explain the discrepancy between our findings and those of the study in 
Colombia, since most of the participating children were older than 5 y at baseline when serum 
PUFA concentrations were measured. Finally, the two randomized interventions may have not 
had effects because the intervention periods were too short to effect changes in BMI.  
There are several mechanisms that could explain a protective effect of DHA against the 
development of adiposity. Long-chain n-3 fatty acids may reduce total caloric intake by 
increasing feelings of satiety (47). They may also regulate lipid metabolism by promoting 
lipolysis and -oxidation and inhibiting lipogenesis, thus reducing fat deposition in adipose 
tissue (48). Our finding that DHA was associated with BAZ change when measured at 5 y of age 
 141 
but not at 10 y may reflect a greater influence of this PUFA in earlier childhood on long-term 
body composition. The adiposity rebound, an inflexion point in growth when BMI begins to 
increase, starts at 5 y of age, on average, and is followed approximately 2 years later by an 
increase in fat mass (21). The timing of the adiposity rebound is related to risk of adult obesity 
(49); thus, a reduction in adiposity by DHA at this developmental stage may be particularly 
influential on adiposity trajectories. However, we cannot rule out selection bias as a possible 
explanation for the findings, since 277 children with information on PUFA at 10 y of age lacked 
measurements at 5 y of age. 
We found an inverse association between change in EPA from 5 to 10 y of age and BAZ 
change from 10 to 16 y. Most previous investigations have found no association (10,11,14–
16,18,20) or a positive (9,19) relation between EPA and BMI or obesity in children. Results from 
our study are consistent with the proposed mechanism of inhibition of adipose tissue deposition 
by long-chain n-3 PUFA, but it is unclear why the associations of PUFA at age 5 y and PUFA 
change between 5 and 10 y of age are inconsistent. It is possible that EPA and DHA are 
associated with BAZ change through different mechanisms that operate during different periods 
of development. The association with EPA may also be spurious. 
Serum AA at 10 y of age and change in AA between ages 5 and 10 y were each 
positively associated with BAZ change between 10 and 16 y. AA may promote adiposity through 
production of the eicosanoid prostacyclin, which promotes differentiation of preadipocytes into 
adipocytes (50). Adipose tissue AA was positively associated with obesity among 10- to 12-y-
old children in one previous study (15). However, plasma, serum, or erythrocyte AA was not 
associated with BMI or obesity in most previous cross-sectional studies (9–11,13,14,18,19,51), 
or with change in standardized weight among Japanese children (19) or BAZ change in the 
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longitudinal study of Colombian children (20). Some of the discrepancies between our results 
and previous studies may be related to the fact that some did not adjust for potential confounders, 
or because of differences in the range of AA levels present in different study populations. Mean 
serum AA weight percentages ranged from 6.0 among the Colombian children to 8.3-9.1 in the 
Japanese compared with 3.2 among the Chilean children at 10 y of age. This may reflect 
differences in intake or endogenous metabolism of AA that also affect the association with BAZ 
change. 
Change in the D5D activity index between 5 and 10 y of age was positively associated 
with BAZ change from 10 to 16 y. Few previous studies have assessed this relation in children, 
and the results have been inconclusive (12,14,18,19,51,52). In two longitudinal studies, change 
in D5D activity over 3 y was inversely associated with simultaneous change in height-
standardized weight among Japanese children (19), and baseline D5D activity was inversely 
associated with BMI 2 y later in a European cohort (52). Moreover, higher D5D activity in adults 
is inversely associated with a number of other cardiovascular risk factors including triglyceride 
levels and insulin resistance, and with incident diabetes and cardiovascular disease (53). We 
noted that change in the D5D activity index was inversely associated with BAZ at 10 y of age, 
but independent of BAZ at age 16 y. It is possible that D5D activity is inversely related to BAZ 
but only in the short term. 
We did not find overall associations between ALA or LA and BAZ changes, although LA 
at 5 y of age was inversely associated with BAZ change among overweight and obese children. 
In previous cross-sectional studies, biomarkers of ALA have been either positively associated 
(9,13,14,17,18) or not associated (10,11,15,19) with measures of adiposity, while associations 
with LA have been either inverse (9,13,18) or null (10,11,14,15,19). Three year change in 
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plasma ALA was not associated with concomitant change in weight among Japanese children, 
while there was an inverse association between LA and weight changes (19). Mean ALA and LA 
concentrations among the Japanese children were much lower than those in our study population, 
which may explain the discrepancy. The Japanese children may also have been generally heavier 
than children in our study, which would be consistent with our finding that LA was only 
inversely associated with BAZ change among overweight/obese children. However, because the 
authors did not report BMI or BAZ in the Japanese study but rather a different measure of 
standardized weight, it is difficult to compare the relative levels of adiposity in the two 
populations. This study also assessed simultaneous changes in PUFA and weight, which may 
reflect reverse causation or short-term effects of ALA and LA that differ from associations with 
longer-term adiposity. Among Colombian children, serum ALA was inversely associated with 6-
14 y BAZ change (20). Levels of these PUFA present in the Colombian population were 
comparable to those among children in the present study, and we did not find that associations 
between ALA and BAZ change differed by baseline BAZ. There may be other aspects of dietary 
context that differ between the two populations and modify or confound the ALA-BAZ change. 
One of the limitations of this study is that most covariates were only measured in infancy, 
rather than concurrently with the exposures, so there may be residual confounding by 
sociodemographic characteristics or diet in childhood. Some of our results may be driven in part 
by associations between PUFA and BAZ at baseline, which could be the result of reverse 
causation; thus the true associations with BAZ change may be attenuated compared with those 
we report. Nevertheless, we chose not to adjust for baseline BAZ in our primary analyses of 
BAZ change, since this adjustment itself can induce bias (54). For this reason, the results of our 
analyses stratified by baseline weight status should be interpreted with caution. 
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One of the primary strengths of this study is the prospective design, which greatly limits 
the possibility of reverse causation compared to previous cross-sectional studies. Compared with 
dietary measures, the use of PUFA biomarkers is not subject to recall bias or systematic errors 
from the use of food composition tables. Our study provides information on a topic of great 
public health importance that has not been frequently studied, especially in populations 
undergoing the nutrition transition. Finally, the availability of multiple exposure and outcome 
measurements during follow up allowed us to assess these associations separately during 
different developmental periods. 
In conclusion, serum concentrations of some long-chain n-3 PUFA in middle childhood 
are associated with less weight gain through adolescence whereas the n-6 PUFA AA and D5D 
activity are related to increased weight gain. Future studies should examine whether the observed 
associations between PUFA in childhood and BAZ change through adolescence persist and 
predict health outcomes in adulthood. The effect of dietary interventions involving long-chain n-
3 PUFA in childhood on the development of adiposity requires investigation in randomized 
trials.  
  
 145 
Acknowledgements 
 This study was funded by grants HL117860, HD033487, and HL088530 from the 
National Institutes of Health. 
 146 
Table 4.1. Serum biomarkers of polyunsaturated fatty acidsa at 5 y by categories of sociodemographic characteristics in infancy and other 
fatty acids at 5 y among children from Santiago, Chile 
  
N-3 N-6 
Characteristics N 
ALA 
18:3(n-3) 
EPA 
20:5(n-3) 
DPA 
22:5(n-3) 
DHA 
22:6(n-3) 
LA 
18:2(n-6) 
GLA 
18:3(n-6) 
DGLA 
20:3(n-6) 
AA 
20:4(n-6) 
∆6-desaturase 
activity index 
(GLA/LA) 
∆5-desaturase 
activity index 
(AA/DGLA) 
Overall 239 0.30 ± 0.16 0.27 ± 0.12 0.17 ± 0.09 0.62 ± 0.54 27.14 ± 4.44 0.21 ± 0.18 0.77 ± 0.36 1.78 ± 0.50 0.008 ± 0.008 4.23 ± 6.80 
                                
Infancy sociodemographic characteristics 
                             
Sex 
                               
Female 113 0.30 ± 0.15 0.27 ± 0.13 0.17 ± 0.09 0.63 ± 0.74 27.51 ± 4.05 0.20 ± 0.16 0.74 ± 0.31 1.74 ± 0.49 0.007 ± 0.006 4.09 ± 5.82 
Male 126 0.30 ± 0.17 0.27 ± 0.12 0.17 ± 0.08 0.61 ± 0.25 26.81 ± 4.75 0.23 ± 0.20 0.80 ± 0.39 1.81 ± 0.50 0.009 ± 0.010 4.36 ± 7.59 
Pb 
 
0.89 0.69 0.80 0.80 0.22 0.24 0.17 0.30 0.07 0.76 
                                
Birth length 
                               
Average for gestational agec 157 0.30 ± 0.16 0.27 ± 0.12 0.17 ± 0.08 0.62 ± 0.64 26.98 ± 4.57 0.22 ± 0.18 0.78 ± 0.37 1.73 ± 0.48 0.008 ± 0.008 3.79 ± 5.98 
Large for gestational age 82 0.29 ± 0.15 0.27 ± 0.13 0.18 ± 0.10 0.63 ± 0.26 27.45 ± 4.19 0.21 ± 0.18 0.75 ± 0.32 1.87 ± 0.52 0.008 ± 0.008 5.07 ± 8.12 
Pb 
 
0.77 0.75 0.19 0.86 0.42 0.73 0.64 0.04 0.90 0.21 
                                
Birth weight 
                               
Average for gestational age 168 0.30 ± 0.15 0.27 ± 0.12 0.17 ± 0.07 0.62 ± 0.62 27.08 ± 4.48 0.22 ± 0.18 0.77 ± 0.37 1.75 ± 0.47 0.008 ± 0.008 4.05 ± 6.65 
Large for gestational age 71 0.28 ± 0.19 0.27 ± 0.14 0.18 ± 0.11 0.61 ± 0.24 27.29 ± 4.37 0.21 ± 0.18 0.76 ± 0.32 1.84 ± 0.56 0.008 ± 0.008 4.65 ± 7.18 
Pb 
 
0.48 0.98 0.22 0.79 0.73 0.88 0.72 0.22 0.81 0.55 
                                
Breastfeeding 
                               
Breastfeeding <6 mo 57 0.35 ± 0.19 0.26 ± 0.12 0.17 ± 0.10 0.74 ± 1.01 26.86 ± 4.34 0.22 ± 0.16 0.80 ± 0.50 1.78 ± 0.50 0.009 ± 0.007 3.80 ± 4.48 
Mixed bottle/breastfeeding, ≥6 mo 95 0.28 ± 0.15 0.27 ± 0.13 0.17 ± 0.09 0.56 ± 0.24 27.01 ± 4.69 0.20 ± 0.19 0.74 ± 0.30 1.76 ± 0.51 0.008 ± 0.009 4.67 ± 7.80 
Exclusive breastfeeding, ≥6 mo 84 0.29 ± 0.14 0.27 ± 0.12 0.17 ± 0.08 0.60 ± 0.23 27.20 ± 4.03 0.22 ± 0.19 0.77 ± 0.30 1.79 ± 0.49 0.008 ± 0.008 4.10 ± 7.04 
Pd 
 
0.05 0.70 0.99 0.26 0.89 0.76 0.57 0.91 0.91 0.68 
                                
Iron supplementation 
                               
None 155 0.31 ± 0.17 0.28 ± 0.13 0.17 ± 0.08 0.59 ± 0.25 27.38 ± 4.09 0.20 ± 0.16 0.80 ± 0.38 1.78 ± 0.51 0.008 ± 0.007 3.91 ± 6.32 
Any 84 0.27 ± 0.14 0.26 ± 0.11 0.18 ± 0.10 0.68 ± 0.84 26.69 ± 5.01 0.24 ± 0.21 0.71 ± 0.30 1.78 ± 0.48 0.009 ± 0.010 4.82 ± 7.61 
Pb 
 
0.07 0.22 0.55 0.35 0.28 0.21 0.05 0.93 0.19 0.35 
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Table 4.1. Serum biomarkers of polyunsaturated fatty acidsa at 5 y by categories of sociodemographic characteristics in infancy and other 
fatty acids at 5 y among children from Santiago, Chile 
  
N-3 N-6 
Characteristics N 
ALA 
18:3(n-3) 
EPA 
20:5(n-3) 
DPA 
22:5(n-3) 
DHA 
22:6(n-3) 
LA 
18:2(n-6) 
GLA 
18:3(n-6) 
DGLA 
20:3(n-6) 
AA 
20:4(n-6) 
∆6-desaturase 
activity index 
(GLA/LA) 
∆5-desaturase 
activity index 
(AA/DGLA) 
Graffar indexe 
                               
Q1 (high SES) 50 0.29 ± 0.11 0.31 ± 0.14 0.17 ± 0.06 0.60 ± 0.25 27.85 ± 4.02 0.24 ± 0.19 0.90 ± 0.49 1.85 ± 0.56 0.009 ± 0.008 2.90 ± 3.58 
Q2 45 0.28 ± 0.14 0.26 ± 0.12 0.16 ± 0.07 0.65 ± 0.27 27.53 ± 3.79 0.22 ± 0.15 0.81 ± 0.30 1.83 ± 0.53 0.008 ± 0.006 3.35 ± 4.17 
Q3 57 0.31 ± 0.21 0.26 ± 0.12 0.17 ± 0.09 0.56 ± 0.22 26.50 ± 4.41 0.18 ± 0.17 0.70 ± 0.33 1.73 ± 0.42 0.007 ± 0.008 5.27 ± 8.32 
Q4 46 0.29 ± 0.15 0.26 ± 0.12 0.16 ± 0.08 0.74 ± 1.12 27.75 ± 4.78 0.20 ± 0.18 0.74 ± 0.30 1.81 ± 0.58 0.007 ± 0.006 4.32 ± 7.02 
Q5 (low SES) 41 0.31 ± 0.15 0.24 ± 0.10 0.19 ± 0.12 0.56 ± 0.25 26.04 ± 5.05 0.24 ± 0.20 0.70 ± 0.30 1.65 ± 0.37 0.010 ± 0.011 5.27 ± 9.05 
P, trendf 
 
0.44 0.007 0.31 0.86 0.13 0.89 0.01 0.06 0.56 0.12 
                                
5 y serum fatty acids (median, weight % of total fatty acids) 
                         
Total trans fatty acids 
                               
Q1 (1.58) 59 0.30 ± 0.14 0.28 ± 0.13 0.18 ± 0.08 0.75 ± 0.27 29.04 ± 4.40 0.27 ± 0.22 0.79 ± 0.31 1.95 ± 0.48 0.010 ± 0.010 4.13 ± 6.87 
Q2 (2.24) 60 0.31 ± 0.17 0.30 ± 0.14 0.17 ± 0.05 0.71 ± 0.98 28.02 ± 3.78 0.22 ± 0.18 0.83 ± 0.48 1.87 ± 0.56 0.008 ± 0.008 4.70 ± 7.62 
Q3 (2.88) 60 0.29 ± 0.15 0.25 ± 0.12 0.18 ± 0.08 0.56 ± 0.21 26.67 ± 4.06 0.18 ± 0.12 0.72 ± 0.34 1.70 ± 0.43 0.007 ± 0.005 5.01 ± 7.74 
Q4 (4.06) 60 0.29 ± 0.17 0.24 ± 0.10 0.16 ± 0.12 0.46 ± 0.18 24.86 ± 4.45 0.19 ± 0.17 0.74 ± 0.26 1.59 ± 0.45 0.008 ± 0.008 3.08 ± 4.47 
P, trendf 
 
0.53 0.008 0.43 <0.0001 <0.0001 0.02 0.13 <0.0001 0.33 0.25 
                                
Palmitoleic acid 16:1(n-7) 
                               
Q1 (1.07) 59 0.27 ± 0.15 0.29 ± 0.13 0.17 ± 0.09 0.79 ± 0.99 28.55 ± 4.97 0.23 ± 0.21 0.76 ± 0.47 1.89 ± 0.52 0.009 ± 0.011 4.51 ± 7.15 
Q2 (1.38) 60 0.29 ± 0.15 0.29 ± 0.14 0.18 ± 0.07 0.59 ± 0.23 28.31 ± 3.58 0.19 ± 0.17 0.77 ± 0.33 1.80 ± 0.49 0.007 ± 0.006 4.65 ± 7.39 
Q3 (1.64) 60 0.29 ± 0.18 0.24 ± 0.10 0.17 ± 0.07 0.57 ± 0.22 27.46 ± 4.12 0.21 ± 0.19 0.73 ± 0.32 1.81 ± 0.49 0.008 ± 0.008 4.51 ± 6.37 
Q4 (2.12) 60 0.33 ± 0.16 0.26 ± 0.12 0.18 ± 0.11 0.54 ± 0.22 24.26 ± 3.67 0.22 ± 0.14 0.82 ± 0.28 1.61 ± 0.46 0.009 ± 0.006 3.25 ± 6.30 
P, trendf 
 
0.05 0.07 0.83 0.05 <0.0001 0.95 0.44 0.001 0.60 0.26 
aExpressed as percentage of total fatty acids by weight. 
bWald test from linear regression models with each fatty acid as the outcome and an indicator variable for the characteristic as a predictor. 
cIncludes 7 children who were small for gestational age according to birth length. 
dχ2 score statistic from linear regression models with each fatty acid as the outcome and indicator variables for levels of the characteristic as predictors. 
eIndex of socioeconomic status that includes information on family structure, education and employment of the head of household, crowding and physical condition of the home, and ownership of the 
home, car, and household appliances (33). Higher values indicate lower socioeconomic status. 
fWald test from linear regression models with each fatty acid as the outcome and a variable representing category-specific medians of an ordinal characteristic introduced as a continuous predictor. 
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Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
5 years of age among children from Santiago, Chile 
 
          5 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
5 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
Overall 239 0.93 ± 0.08 0.70 ± 0.07 -0.23 ± 0.06 
  
             
N-3 
            
ALA (18:3 n-3) 
            
Q1 (0.12) 59 0.93 ± 0.16 0.68 ± 0.16 -0.25 ± 0.13 Reference 
Q2 (0.25) 60 0.64 ± 0.14 0.59 ± 0.12 -0.05 ± 0.13 0.30 (-0.08, 0.67) 
Q3 (0.34) 60 1.12 ± 0.16 0.76 ± 0.16 -0.36 ± 0.12 0.06 (-0.29, 0.41) 
Q4 (0.45) 60 1.05 ± 0.15 0.78 ± 0.15 -0.26 ± 0.11 0.05 (-0.30, 0.39) 
P, trendd 
 
0.29 0.54 0.56 0.94 
             
EPA (20:5 n-3) 
            
Q1 (0.12) 59 0.87 ± 0.14 0.71 ± 0.14 -0.16 ± 0.13 Reference 
Q2 (0.22) 60 0.90 ± 0.16 0.60 ± 0.15 -0.30 ± 0.11 -0.16 (-0.50, 0.18) 
Q3 (0.30) 60 1.10 ± 0.18 0.87 ± 0.15 -0.23 ± 0.12 -0.09 (-0.43, 0.25) 
Q4 (0.41) 60 0.86 ± 0.14 0.63 ± 0.15 -0.23 ± 0.13 -0.06 (-0.44, 0.32) 
P, trend 
 
0.84 0.95 0.77 0.84 
             
DPA (22:5 n-3) 
            
Q1 (0.11) 59 0.91 ± 0.14 0.88 ± 0.14 -0.02 ± 0.12 Reference 
Q2 (0.14) 60 0.74 ± 0.15 0.52 ± 0.16 -0.21 ± 0.11 -0.23 (-0.57, 0.10) 
Q3 (0.18) 60 0.93 ± 0.14 0.63 ± 0.16 -0.30 ± 0.14 -0.31 (-0.70, 0.08) 
Q4 (0.23) 60 1.15 ± 0.18 0.79 ± 0.14 -0.36 ± 0.12 -0.31 (-0.68, 0.07) 
P, trend 
 
0.18 0.93 0.05 0.13 
             
DHA (22:6 n-3) 
            
Q1 (0.32) 59 0.70 ± 0.15 0.72 ± 0.15 0.02 ± 0.12 Reference 
Q2 (0.48) 60 0.97 ± 0.15 0.62 ± 0.13 -0.35 ± 0.13 -0.37 (-0.74, -0.01) 
Q3 (0.62) 60 0.93 ± 0.15 0.87 ± 0.16 -0.07 ± 0.13 0.00 (-0.36, 0.35) 
Q4 (0.90) 60 1.12 ± 0.16 0.60 ± 0.15 -0.51 ± 0.10 -0.51 (-0.88, -0.13) 
P, trend 
 
0.09 0.73 0.004 0.03 
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Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
5 years of age among children from Santiago, Chile 
 
          5 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
5 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
N-6 
            
LA (18:2 n-6) 
            
Q1 (21.58) 59 0.92 ± 0.15 0.69 ± 0.15 -0.23 ± 0.10 Reference 
Q2 (26.06) 60 1.05 ± 0.15 0.80 ± 0.14 -0.25 ± 0.12 -0.07 (-0.40, 0.25) 
Q3 (28.99) 60 1.08 ± 0.16 0.81 ± 0.14 -0.27 ± 0.12 -0.08 (-0.40, 0.23) 
Q4 (32.02) 60 0.68 ± 0.15 0.50 ± 0.16 -0.18 ± 0.15 0.03 (-0.38, 0.44) 
P, trend 
 
0.40 0.49 0.84 0.95 
             
GLA (18:3 n-6) 
            
Q1 (0.07) 59 0.65 ± 0.14 0.58 ± 0.14 -0.06 ± 0.13 Reference 
Q2 (0.11) 60 0.90 ± 0.16 0.66 ± 0.15 -0.24 ± 0.14 -0.06 (-0.44, 0.32) 
Q3 (0.21) 60 0.85 ± 0.14 0.54 ± 0.16 -0.30 ± 0.11 -0.07 (-0.42, 0.29) 
Q4 (0.40) 60 1.33 ± 0.16 1.01 ± 0.15 -0.32 ± 0.11 -0.06 (-0.41, 0.29) 
P, trend 
 
0.004 0.03 0.20 0.80 
             
DGLA (20:3 n-6) 
            
Q1 (0.35) 59 0.73 ± 0.15 0.53 ± 0.15 -0.20 ± 0.12 Reference 
Q2 (0.71) 60 1.03 ± 0.15 0.77 ± 0.15 -0.26 ± 0.14 -0.06 (-0.41, 0.29) 
Q3 (0.88) 60 0.77 ± 0.14 0.62 ± 0.13 -0.15 ± 0.10 0.13 (-0.19, 0.46) 
Q4 (1.08) 60 1.20 ± 0.17 0.89 ± 0.16 -0.30 ± 0.13 0.05 (-0.31, 0.41) 
P, trend 
 
0.10 0.14 0.71 0.64 
             
AA (20:4 n-6) 
            
Q1 (1.17) 59 0.81 ± 0.14 0.61 ± 0.15 -0.19 ± 0.13 Reference 
Q2 (1.58) 60 0.94 ± 0.15 0.73 ± 0.14 -0.21 ± 0.12 0.00 (-0.41, 0.40) 
Q3 (1.93) 60 0.85 ± 0.17 0.60 ± 0.15 -0.25 ± 0.10 0.01 (-0.35, 0.38) 
Q4 (2.28) 60 1.13 ± 0.16 0.87 ± 0.16 -0.26 ± 0.14 -0.07 (-0.48, 0.35) 
P, trend 
 
0.19 0.35 0.68 0.78 
             
∆6-Desaturase index (GLA/LA) 
          
Q1 (0.002) 59 0.74 ± 0.16 0.60 ± 0.14 -0.13 ± 0.14 Reference 
Q2 (0.004) 60 0.85 ± 0.14 0.66 ± 0.14 -0.20 ± 0.13 0.01 (-0.37, 0.40) 
Q3 (0.008) 60 0.84 ± 0.15 0.55 ± 0.16 -0.29 ± 0.11 -0.02 (-0.39, 0.34) 
Q4 (0.016) 60 1.30 ± 0.16 0.99 ± 0.14 -0.31 ± 0.11 -0.02 (-0.38, 0.35) 
P, trend 
 
0.009 0.04 0.32 0.87 
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Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
5 years of age among children from Santiago, Chile 
 
          5 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
5 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
∆5-Desaturase index (AA/DGLA) 
          
Q1 (1.54) 59 0.95 ± 0.16 0.66 ± 0.15 -0.29 ± 0.11 Reference 
Q2 (1.96) 60 1.02 ± 0.16 0.80 ± 0.14 -0.22 ± 0.14 0.08 (-0.27, 0.43) 
Q3 (2.43) 60 0.82 ± 0.15 0.67 ± 0.15 -0.15 ± 0.12 0.08 (-0.27, 0.43) 
Q4 (4.64) 60 0.94 ± 0.16 0.68 ± 0.16 -0.26 ± 0.12 -0.01 (-0.34, 0.32) 
P, trend   0.94 0.86 0.91 0.72 
aAccording to the World Health Organization Growth Reference 2007 (31) for children ages 5-19 y. 
bEstimates are from growth curves created using mixed effects linear regression models with BMI-for-age Z score as 
the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms 
for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age 
slopes to account for within-child correlation of repeated BMI measurements. 
cAdjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle 
feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), total serum trans fatty acids, palmitoleic 
acid, and serum concentrations of the PUFA measured in infancy. In addition, all n-3 PUFA are adjusted for LA and 
total long-chain n-6 PUFA, while all n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long-chain 
PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic 
spline terms. 
dFrom mixed effects linear regression models with Z score as the outcome and a variable representing medians of 
PUFA quartiles introduced as a continuous predictor. 
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Table 4.3. Serum biomarkers of polyunsaturated fatty acidsa at 10 y by categories of sociodemographic characteristics in infancy and 
other fatty acids at 10 y among children from Santiago, Chile 
  
N-3 N-6 
Characteristics N 
ALA 
18:3(n-3) 
EPA 
20:5(n-3) 
DPA 
22:5(n-3) 
DHA 
22:6(n-3) 
LA 
18:2(n-6) 
GLA 
18:3(n-6) 
DGLA 
20:3(n-6) 
AA 
20:4(n-6) 
∆6-desaturase 
activity index 
(GLA/LA) 
∆5-desaturase 
activity index 
(AA/DGLA) 
Overall 418 0.42 ± 0.17 0.26 ± 0.14 0.21 ± 0.06 0.65 ± 0.22 30.99 ± 4.26 0.20 ± 0.17 1.18 ± 0.30 3.18 ± 0.88 0.007 ± 0.006 2.92 ± 1.87 
                                
Infancy sociodemographic characteristics 
                             
Sex 
                               
Female 198 0.44 ± 0.18 0.25 ± 0.15 0.21 ± 0.06 0.66 ± 0.22 31.46 ± 4.50 0.21 ± 0.18 1.15 ± 0.27 3.10 ± 0.87 0.007 ± 0.006 2.81 ± 0.96 
Male 220 0.40 ± 0.16 0.27 ± 0.13 0.22 ± 0.06 0.64 ± 0.22 30.57 ± 4.00 0.19 ± 0.16 1.20 ± 0.32 3.24 ± 0.89 0.006 ± 0.006 3.02 ± 2.41 
Pb 
 
0.05 0.37 0.14 0.48 0.03 0.32 0.08 0.10 0.59 0.23 
                                
Birth length 
                               
Average for gestational agec 279 0.42 ± 0.17 0.27 ± 0.14 0.21 ± 0.06 0.65 ± 0.21 30.87 ± 4.31 0.18 ± 0.13 1.18 ± 0.30 3.14 ± 0.83 0.006 ± 0.005 2.91 ± 2.15 
Large for gestational age 139 0.42 ± 0.17 0.25 ± 0.13 0.22 ± 0.07 0.66 ± 0.24 31.22 ± 4.17 0.24 ± 0.23 1.18 ± 0.31 3.26 ± 0.96 0.008 ± 0.008 2.94 ± 1.14 
Pb 
 
0.78 0.11 0.37 0.61 0.42 0.002 0.99 0.21 0.005 0.87 
                                
Birth weight 
                               
Average for gestational age 305 0.42 ± 0.16 0.27 ± 0.14 0.21 ± 0.06 0.65 ± 0.21 31.02 ± 4.17 0.18 ± 0.14 1.17 ± 0.29 3.19 ± 0.86 0.006 ± 0.005 2.97 ± 2.09 
Large for gestational age 113 0.43 ± 0.20 0.23 ± 0.11 0.21 ± 0.06 0.64 ± 0.24 30.90 ± 4.52 0.25 ± 0.23 1.21 ± 0.33 3.15 ± 0.92 0.008 ± 0.008 2.78 ± 1.07 
Pb 
 
0.75 0.002 0.81 0.62 0.81 0.001 0.32 0.74 0.001 0.23 
                                
Breastfeeding 
                               
Breastfeeding <6 mo 148 0.43 ± 0.17 0.25 ± 0.14 0.21 ± 0.07 0.66 ± 0.22 30.72 ± 4.10 0.22 ± 0.15 1.17 ± 0.31 3.21 ± 0.86 0.007 ± 0.005 3.16 ± 2.87 
Mixed bottle/breastfeeding, ≥6 mo 147 0.41 ± 0.15 0.27 ± 0.14 0.22 ± 0.06 0.65 ± 0.20 31.08 ± 4.41 0.19 ± 0.17 1.17 ± 0.30 3.19 ± 0.87 0.006 ± 0.006 2.88 ± 0.97 
Exclusive breastfeeding, ≥6 mo 116 0.42 ± 0.19 0.27 ± 0.13 0.21 ± 0.06 0.64 ± 0.23 31.12 ± 4.26 0.20 ± 0.20 1.22 ± 0.30 3.11 ± 0.93 0.006 ± 0.006 2.66 ± 0.90 
Pd 
 
0.69 0.71 0.65 0.78 0.67 0.30 0.30 0.68 0.26 0.05 
                                
Iron supplementation 
                               
None 205 0.42 ± 0.18 0.25 ± 0.12 0.21 ± 0.06 0.63 ± 0.22 30.97 ± 4.38 0.19 ± 0.17 1.17 ± 0.29 3.11 ± 0.87 0.006 ± 0.006 2.78 ± 0.98 
Any 213 0.42 ± 0.17 0.27 ± 0.15 0.22 ± 0.06 0.67 ± 0.22 31.01 ± 4.16 0.21 ± 0.17 1.19 ± 0.31 3.24 ± 0.89 0.007 ± 0.006 3.05 ± 2.44 
Pb 
 
0.91 0.14 0.03 0.11 0.93 0.20 0.68 0.14 0.25 0.13 
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Table 4.3. Serum biomarkers of polyunsaturated fatty acidsa at 10 y by categories of sociodemographic characteristics in infancy and 
other fatty acids at 10 y among children from Santiago, Chile 
  
N-3 N-6 
Characteristics N 
ALA 
18:3(n-3) 
EPA 
20:5(n-3) 
DPA 
22:5(n-3) 
DHA 
22:6(n-3) 
LA 
18:2(n-6) 
GLA 
18:3(n-6) 
DGLA 
20:3(n-6) 
AA 
20:4(n-6) 
∆6-desaturase 
activity index 
(GLA/LA) 
∆5-desaturase 
activity index 
(AA/DGLA) 
Graffar indexe 
                               
Q1 (high SES) 71 0.42 ± 0.16 0.26 ± 0.13 0.21 ± 0.07 0.62 ± 0.21 30.81 ± 3.98 0.22 ± 0.20 1.16 ± 0.33 3.15 ± 0.93 0.008 ± 0.008 3.07 ± 2.07 
Q2 82 0.44 ± 0.23 0.28 ± 0.15 0.21 ± 0.07 0.64 ± 0.20 31.27 ± 3.84 0.16 ± 0.12 1.17 ± 0.28 3.16 ± 0.76 0.005 ± 0.004 2.86 ± 1.00 
Q3 99 0.44 ± 0.15 0.25 ± 0.13 0.22 ± 0.05 0.70 ± 0.23 31.35 ± 4.05 0.22 ± 0.21 1.22 ± 0.27 3.24 ± 0.93 0.007 ± 0.007 2.74 ± 0.80 
Q4 83 0.39 ± 0.13 0.26 ± 0.13 0.21 ± 0.06 0.63 ± 0.20 30.89 ± 4.55 0.20 ± 0.15 1.19 ± 0.32 3.10 ± 0.86 0.007 ± 0.005 2.72 ± 0.83 
Q5 (low SES) 83 0.41 ± 0.17 0.25 ± 0.14 0.22 ± 0.07 0.64 ± 0.24 30.52 ± 4.85 0.20 ± 0.15 1.16 ± 0.30 3.22 ± 0.90 0.006 ± 0.005 3.26 ± 3.40 
P, trendf 
 
0.22 0.41 0.24 0.95 0.42 0.81 0.95 0.78 0.70 0.62 
                                
10 y serum fatty acids (median, weight % of total fatty acids) 
                         
Total trans fatty acids 
                               
Q1 (1.11) 104 0.46 ± 0.20 0.27 ± 0.14 0.22 ± 0.06 0.72 ± 0.25 32.47 ± 4.08 0.22 ± 0.20 1.22 ± 0.29 3.44 ± 0.95 0.007 ± 0.006 2.93 ± 0.98 
Q2 (1.45) 105 0.42 ± 0.16 0.26 ± 0.14 0.22 ± 0.06 0.69 ± 0.22 31.38 ± 4.23 0.19 ± 0.17 1.23 ± 0.33 3.23 ± 0.83 0.006 ± 0.006 3.01 ± 3.01 
Q3 (1.82) 105 0.43 ± 0.19 0.26 ± 0.12 0.21 ± 0.06 0.62 ± 0.18 31.26 ± 4.12 0.19 ± 0.17 1.19 ± 0.26 3.09 ± 0.88 0.006 ± 0.006 2.70 ± 0.91 
Q4 (2.46) 104 0.37 ± 0.12 0.25 ± 0.14 0.20 ± 0.06 0.57 ± 0.18 28.84 ± 3.85 0.21 ± 0.15 1.08 ± 0.30 2.95 ± 0.79 0.007 ± 0.005 3.04 ± 1.78 
P, trendf 
 
0.0002 0.48 0.003 <0.0001 <0.0001 0.77 0.0001 <0.0001 0.44 0.80 
                                
Palmitoleic acid 16:1(n-7) 
                               
Q1 (0.97) 104 0.39 ± 0.18 0.29 ± 0.14 0.21 ± 0.06 0.67 ± 0.22 33.33 ± 4.38 0.21 ± 0.18 1.09 ± 0.30 3.49 ± 0.99 0.007 ± 0.006 3.35 ± 0.97 
Q2 (1.29) 105 0.41 ± 0.20 0.26 ± 0.13 0.20 ± 0.06 0.70 ± 0.24 32.09 ± 3.62 0.18 ± 0.15 1.10 ± 0.28 3.23 ± 0.88 0.006 ± 0.005 3.27 ± 3.01 
Q3 (1.67) 105 0.42 ± 0.14 0.28 ± 0.16 0.22 ± 0.07 0.65 ± 0.20 30.82 ± 3.24 0.20 ± 0.17 1.23 ± 0.31 3.18 ± 0.81 0.006 ± 0.006 2.83 ± 1.69 
Q4 (2.29) 104 0.46 ± 0.16 0.22 ± 0.10 0.22 ± 0.06 0.57 ± 0.20 27.70 ± 3.60 0.21 ± 0.18 1.31 ± 0.26 2.81 ± 0.69 0.008 ± 0.007 2.22 ± 0.65 
P, trendf 
 
0.002 0.0001 0.39 <0.0001 <0.0001 0.62 <0.0001 <0.0001 0.05 <0.0001 
aExpressed as percentage of total fatty acids by weight. 
bWald test from linear regression models with each fatty acid as the outcome and an indicator variable for the characteristic as a predictor. 
cIncludes 7 children who were small for gestational age according to birth length. 
dχ2 score statistic from linear regression models with each fatty acid as the outcome and indicator variables for levels of the characteristic as predictors. 
eIndex of socioeconomic status that includes information on family structure, education and employment of the head of household, crowding and physical condition of the home, and ownership of the 
home, car, and household appliances (33). Higher values indicate lower socioeconomic status. 
fWald test from linear regression models with each fatty acid as the outcome and a variable representing category-specific medians of an ordinal characteristic introduced as a continuous predictor. 
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Table 4.4. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
10 years of age among children from Santiago, Chile 
  
    10 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
Overall 418 1.03 ± 0.06 0.73 ± 0.05 -0.31 ± 0.03 
  
             
N-3 
            
ALA (18:3 n-3) 
            
Q1 (0.27) 104 0.64 ± 0.11 0.46 ± 0.09 -0.18 ± 0.07 Reference 
Q2 (0.37) 105 1.01 ± 0.10 0.65 ± 0.10 -0.36 ± 0.08 -0.14 (-0.32, 0.04) 
Q3 (0.44) 105 0.96 ± 0.11 0.64 ± 0.11 -0.32 ± 0.06 -0.13 (-0.31, 0.05) 
Q4 (0.57) 104 1.53 ± 0.11 1.16 ± 0.11 -0.37 ± 0.07 -0.13 (-0.31, 0.05) 
P, trendd 
 
<0.0001 <0.0001 0.07 0.22 
             
EPA (20:5 n-3) 
            
Q1 (0.11) 104 0.98 ± 0.12 0.71 ± 0.11 -0.26 ± 0.07 Reference 
Q2 (0.21) 105 1.00 ± 0.11 0.61 ± 0.11 -0.39 ± 0.06 -0.12 (-0.30, 0.05) 
Q3 (0.28) 105 1.07 ± 0.12 0.80 ± 0.11 -0.27 ± 0.07 0.02 (-0.18, 0.21) 
Q4 (0.42) 104 1.09 ± 0.10 0.78 ± 0.09 -0.31 ± 0.07 -0.11 (-0.29, 0.07) 
P, trend 
 
0.42 0.43 0.94 0.43 
             
DPA (22:5 n-3) 
            
Q1 (0.15) 104 0.89 ± 0.10 0.63 ± 0.09 -0.26 ± 0.06 Reference 
Q2 (0.19) 105 1.00 ± 0.12 0.64 ± 0.11 -0.36 ± 0.07 -0.06 (-0.24, 0.12) 
Q3 (0.23) 105 1.21 ± 0.11 0.91 ± 0.11 -0.30 ± 0.06 -0.04 (-0.22, 0.15) 
Q4 (0.29) 104 1.04 ± 0.12 0.73 ± 0.11 -0.31 ± 0.08 -0.11 (-0.32, 0.10) 
P, trend 
 
0.25 0.29 0.81 0.36 
             
DHA (22:6 n-3) 
            
Q1 (0.43) 104 1.13 ± 0.11 0.67 ± 0.11 -0.45 ± 0.07 Reference 
Q2 (0.57) 105 0.98 ± 0.10 0.67 ± 0.09 -0.31 ± 0.07 0.06 (-0.14, 0.26) 
Q3 (0.68) 105 0.93 ± 0.11 0.80 ± 0.10 -0.13 ± 0.06 0.25 (0.05, 0.45) 
Q4 (0.90) 104 1.10 ± 0.12 0.76 ± 0.12 -0.34 ± 0.07 0.11 (-0.11, 0.34) 
P, trend 
 
0.95 0.51 0.26 0.31 
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Table 4.4. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
10 years of age among children from Santiago, Chile 
  
    10 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
N-6 
            
LA (18:2 n-6) 
            
Q1 (25.96) 104 1.09 ± 0.11 0.72 ± 0.10 -0.37 ± 0.08 Reference 
Q2 (29.92) 105 1.22 ± 0.11 0.90 ± 0.12 -0.32 ± 0.07 0.07 (-0.14, 0.28) 
Q3 (32.59) 105 0.96 ± 0.11 0.68 ± 0.11 -0.27 ± 0.07 0.06 (-0.17, 0.28) 
Q4 (35.77) 104 0.87 ± 0.11 0.60 ± 0.10 -0.27 ± 0.06 -0.08 (-0.32, 0.17) 
P, trend 
 
0.09 0.28 0.27 0.58 
             
GLA (18:3 n-6) 
            
Q1 (0.06) 104 1.05 ± 0.10 0.81 ± 0.10 -0.24 ± 0.07 Reference 
Q2 (0.11) 105 0.83 ± 0.11 0.51 ± 0.11 -0.33 ± 0.07 -0.08 (-0.27, 0.10) 
Q3 (0.20) 105 1.14 ± 0.12 0.78 ± 0.10 -0.37 ± 0.08 -0.12 (-0.31, 0.07) 
Q4 (0.37) 104 1.12 ± 0.11 0.81 ± 0.11 -0.31 ± 0.07 -0.09 (-0.27, 0.10) 
P, trend 
 
0.23 0.38 0.62 0.46 
             
DGLA (20:3 n-6) 
            
Q1 (0.85) 104 0.68 ± 0.11 0.43 ± 0.10 -0.25 ± 0.07 Reference 
Q2 (1.08) 105 0.94 ± 0.11 0.64 ± 0.11 -0.30 ± 0.06 0.03 (-0.16, 0.21) 
Q3 (1.27) 105 1.10 ± 0.11 0.78 ± 0.10 -0.31 ± 0.06 0.04 (-0.14, 0.22) 
Q4 (1.55) 104 1.42 ± 0.11 1.05 ± 0.11 -0.37 ± 0.08 0.07 (-0.15, 0.29) 
P, trend 
 
<0.0001 <0.0001 0.26 0.53 
             
AA (20:4 n-6) 
            
Q1 (2.23) 104 1.33 ± 0.11 0.88 ± 0.11 -0.44 ± 0.07 Reference 
Q2 (2.81) 105 0.89 ± 0.10 0.59 ± 0.11 -0.30 ± 0.07 0.15 (-0.05, 0.35) 
Q3 (3.37) 105 1.03 ± 0.11 0.76 ± 0.10 -0.27 ± 0.07 0.20 (0.01, 0.39) 
Q4 (4.19) 104 0.89 ± 0.12 0.67 ± 0.11 -0.22 ± 0.07 0.22 (0.00, 0.44) 
P, trend 
 
0.03 0.37 0.02 0.06 
             
∆6-Desaturase index (GLA/LA) 
            
Q1 (0.002) 104 1.00 ± 0.10 0.79 ± 0.10 -0.22 ± 0.07 Reference 
Q2 (0.004) 105 0.88 ± 0.12 0.54 ± 0.10 -0.34 ± 0.07 -0.13 (-0.32, 0.06) 
Q3 (0.006) 105 1.10 ± 0.12 0.75 ± 0.11 -0.35 ± 0.07 -0.14 (-0.32, 0.05) 
Q4 (0.012) 104 1.16 ± 0.11 0.84 ± 0.11 -0.32 ± 0.07 -0.11 (-0.30, 0.08) 
P, trend 
 
0.11 0.27 0.44 0.44 
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Table 4.4. Changes in BMI-for-age Z scoresa by serum biomarkers of polyunsaturated fatty acids at 
10 years of age among children from Santiago, Chile 
  
    10 y - 16 y 
Fatty acid quartile 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference 
in change 
(95% CI)c 
∆5-Desaturase index (AA/DGLA) 
           
Q1 (1.79) 104 1.52 ± 0.11 1.14 ± 0.11 -0.39 ± 0.07 Reference 
Q2 (2.42) 105 1.13 ± 0.10 0.76 ± 0.10 -0.37 ± 0.07 0.00 (-0.20, 0.20) 
Q3 (3.00) 105 0.86 ± 0.11 0.57 ± 0.11 -0.29 ± 0.06 0.04 (-0.15, 0.22) 
Q4 (3.80) 104 0.63 ± 0.11 0.44 ± 0.10 -0.19 ± 0.07 0.05 (-0.16, 0.26) 
P, trend   <0.0001 <0.0001 0.03 0.56 
aAccording the World Health Organization Growth Reference 2007 (31) for children ages 5-19 y 
bEstimates are from growth curves created using mixed effects linear regression models with BMI-for-age Z score as 
the outcome, and predictors that included indicator variables for each PUFA quartile, a linear term for age, and 
interaction terms between the quartiles and age. All models included random intercepts to account for within-child 
correlations of repeated BMI measurements. 
cAdjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle 
feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), total serum trans fatty acids, palmitoleic 
acid, and serum concentrations of the main exposure PUFA measured in infancy. In addition, all n-3 PUFA are 
adjusted for LA and total long-chain n-6 PUFA, while all n-6 PUFA are adjusted for ALA and total long-chain n-3 
PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear 
and restricted cubic spline terms. 
dFrom mixed effects linear regression models with Z score as the outcome and a variable representing medians of 
PUFA quartiles introduced as a continuous predictor. 
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Table 4.5. Changes in BMI-for-age Z scoresa according to changes in serum biomarkers of 
polyunsaturated fatty acids at 5 and 10 years of age among children from Santiago, Chile 
    
10 y - 16 y 
Quartile of fatty acid change 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference in 
change 
(95% CI)c 
Overall 141 0.97 ± 0.10 0.67 ± 0.10 -0.30 ± 0.06 
  
             
N-3 
            
ALA (18:3 n-3) 
            
Q1 (-0.10) 35 0.69 ± 0.20 0.48 ± 0.18 -0.21 ± 0.13 Reference 
Q2 (0.07) 35 0.64 ± 0.17 0.43 ± 0.16 -0.21 ± 0.11 -0.03 (-0.35, 0.29) 
Q3 (0.18) 36 1.01 ± 0.19 0.61 ± 0.21 -0.41 ± 0.13 -0.18 (-0.51, 0.16) 
Q4 (0.37) 35 1.55 ± 0.18 1.17 ± 0.21 -0.38 ± 0.11 -0.21 (-0.55, 0.14) 
P, trendd 
 
0.0007 0.01 0.20 0.18 
             
EPA (20:5 n-3) 
            
Q1 (-0.20) 35 0.96 ± 0.20 0.71 ± 0.20 -0.26 ± 0.10 Reference 
Q2 (-0.07) 35 0.83 ± 0.20 0.68 ± 0.22 -0.15 ± 0.11 0.18 (-0.11, 0.46) 
Q3 (0.05) 36 1.14 ± 0.19 0.89 ± 0.18 -0.26 ± 0.13 0.00 (-0.32, 0.31) 
Q4 (0.16) 35 0.95 ± 0.17 0.41 ± 0.19 -0.53 ± 0.13 -0.32 (-0.64, 0.00) 
P, trend 
 
0.75 0.47 0.08 0.04 
             
DPA (22:5 n-3) 
            
Q1 (-0.07) 35 1.04 ± 0.19 0.79 ± 0.17 -0.25 ± 0.11 Reference 
Q2 (0.02) 35 0.91 ± 0.19 0.56 ± 0.18 -0.34 ± 0.14 -0.08 (-0.41, 0.25) 
Q3 (0.07) 36 1.02 ± 0.19 0.50 ± 0.21 -0.52 ± 0.11 -0.27 (-0.56, 0.02) 
Q4 (0.13) 35 0.93 ± 0.20 0.84 ± 0.23 -0.09 ± 0.10 0.12 (-0.23, 0.47) 
P, trend 
 
0.79 0.96 0.70 0.88 
             
DHA (22:6 n-3) 
            
Q1 (-0.38) 35 0.85 ± 0.20 0.61 ± 0.18 -0.24 ± 0.11 Reference 
Q2 (-0.08) 35 1.02 ± 0.20 0.51 ± 0.23 -0.51 ± 0.13 -0.14 (-0.49, 0.21) 
Q3 (0.14) 36 0.86 ± 0.19 0.69 ± 0.17 -0.17 ± 0.12 0.24 (-0.11, 0.59) 
Q4 (0.41) 35 1.16 ± 0.18 0.87 ± 0.21 -0.29 ± 0.11 -0.07 (-0.43, 0.29) 
P, trend 
 
0.34 0.28 0.81 0.87 
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Table 4.5. Changes in BMI-for-age Z scoresa according to changes in serum biomarkers of 
polyunsaturated fatty acids at 5 and 10 years of age among children from Santiago, Chile 
    
10 y - 16 y 
Quartile of fatty acid change 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference in 
change 
(95% CI)c 
N-6 
            
LA (18:2 n-6) 
            
Q1 (-1.64) 35 1.05 ± 0.16 0.61 ± 0.18 -0.44 ± 0.13 Reference 
Q2 (1.65) 35 1.11 ± 0.19 0.78 ± 0.19 -0.33 ± 0.13 -0.04 (-0.39, 0.31) 
Q3 (5.22) 36 0.96 ± 0.19 0.75 ± 0.20 -0.22 ± 0.10 0.04 (-0.33, 0.41) 
Q4 (9.67) 35 0.78 ± 0.22 0.55 ± 0.22 -0.23 ± 0.11 -0.03 (-0.43, 0.37) 
P, trend 
 
0.26 0.79 0.17 0.98 
             
GLA (18:3 n-6) 
            
Q1 (-0.19) 35 1.13 ± 0.19 0.83 ± 0.20 -0.29 ± 0.11 Reference 
Q2 (-0.04) 35 1.18 ± 0.20 0.81 ± 0.22 -0.37 ± 0.11 -0.20 (-0.52, 0.11) 
Q3 (0.04) 36 0.73 ± 0.21 0.44 ± 0.21 -0.29 ± 0.14 -0.12 (-0.45, 0.21) 
Q4 (0.15) 35 0.86 ± 0.16 0.61 ± 0.16 -0.26 ± 0.12 -0.07 (-0.37, 0.22) 
P, trend 
 
0.15 0.23 0.77 0.67 
             
DGLA (20:3 n-6) 
            
Q1 (-0.06) 35 0.55 ± 0.20 0.39 ± 0.21 -0.16 ± 0.12 Reference 
Q2 (0.24) 35 1.12 ± 0.17 0.83 ± 0.16 -0.28 ± 0.11 -0.10 (-0.41, 0.21) 
Q3 (0.46) 36 1.06 ± 0.19 0.77 ± 0.21 -0.30 ± 0.10 -0.06 (-0.35, 0.24) 
Q4 (0.93) 35 1.16 ± 0.19 0.69 ± 0.21 -0.47 ± 0.15 -0.29 (-0.62, 0.04) 
P, trend 
 
0.06 0.43 0.11 0.09 
             
AA (20:4 n-6) 
            
Q1 (0.45) 35 1.38 ± 0.20 0.79 ± 0.21 -0.59 ± 0.12 Reference 
Q2 (1.17) 35 0.94 ± 0.19 0.81 ± 0.20 -0.13 ± 0.12 0.56 (0.22, 0.90) 
Q3 (1.53) 36 0.73 ± 0.16 0.49 ± 0.15 -0.24 ± 0.10 0.40 (0.10, 0.70) 
Q4 (2.17) 35 0.85 ± 0.21 0.61 ± 0.23 -0.24 ± 0.13 0.51 (0.11, 0.90) 
P, trend 
 
0.05 0.42 0.06 0.03 
             
∆6-Desaturase index (GLA/LA) 
            
Q1 (-0.009) 35 1.11 ± 0.18 0.76 ± 0.21 -0.35 ± 0.12 Reference 
Q2 (-0.002) 35 1.44 ± 0.22 1.06 ± 0.23 -0.38 ± 0.10 -0.16 (-0.48, 0.15) 
Q3 (0.000) 36 0.47 ± 0.16 0.37 ± 0.17 -0.10 ± 0.12 0.05 (-0.28, 0.38) 
Q4 (0.005) 35 0.88 ± 0.17 0.51 ± 0.16 -0.38 ± 0.12 -0.16 (-0.47, 0.15) 
P, trend 
 
0.14 0.21 0.86 0.39 
 
             
 158 
Table 4.5. Changes in BMI-for-age Z scoresa according to changes in serum biomarkers of 
polyunsaturated fatty acids at 5 and 10 years of age among children from Santiago, Chile 
    
10 y - 16 y 
Quartile of fatty acid change 
(median, weight % of total FA) 
N 
10 y BMI-for-
age Z score 
(mean ± SE)b 
16 y BMI-for-
age Z score 
(mean ± SE) 
Change in BMI-
for-age Z score 
(mean ± SE)b 
Adjusted difference in 
change 
(95% CI)c 
∆5-Desaturase index (AA/DGLA) 
           
Q1 (-2.08) 35 1.30 ± 0.20 0.76 ± 0.23 -0.54 ± 0.13 Reference 
Q2 (0.23) 35 1.24 ± 0.17 0.86 ± 0.19 -0.37 ± 0.13 0.17 (-0.21, 0.54) 
Q3 (0.81) 36 0.95 ± 0.18 0.73 ± 0.17 -0.22 ± 0.09 0.33 (0.01, 0.65) 
Q4 (1.62) 35 0.40 ± 0.19 0.33 ± 0.19 -0.06 ± 0.11 0.64 (0.27, 1.02) 
P, trend 
 
0.005 0.28 0.008 0.003 
aAccording to the World Health Organization Growth Reference 1007 (31) for children ages 5-19 y. 
bEstimates are from growth curves created using mixed effects linear regression models with BMI-for-age Z score as 
the outcome, and predictors that included indicator variables for each PUFA change quartile, a linear term for age, 
and interaction terms between the quartiles and age. All models included random intercepts to account for within-
child correlations of repeated BMI measurements. 
cAdjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle 
feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), change in total serum trans fatty acids, 
change in palmitoleic acid, and serum concentrations of the main exposure PUFA measured in infancy. In addition, 
all n-3 PUFA are adjusted for change in LA and total long-chain n-6 PUFA, while all n-6 PUFA are adjusted for 
change in ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for change in their precursor 
PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms. 
dFrom mixed effects linear regression models with Z score as the outcome and a variable representing medians of 
PUFA change quartiles introduced as a continuous predictor. 
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Supplemental Table 4.1. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 5 years of age among children from Santiago, Chile, stratified by 
weight status at 5 years 
 
5 y - 16 y change in BMI-for-age Z 
score (mean ± SE)b 
Adjusted difference in 5 y - 16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 5 y 
N 
Overweight/ 
obesee at 5 y 
Normal 
weight at 5 y 
Overweight/ 
obese at 5 y 
Overall 134 0.07 ± 0.07 105 -0.60 ± 0.09 
    
  
   
 
   
    
N-3 
 
   
 
   
    
ALA (18:3 n-3) 
 
   
 
   
    
Q1 (0.14/0.11) 33 -0.11 ± 0.11 26 -0.43 ± 0.26 Reference Reference 
Q2 (0.25/0.25) 40 0.36 ± 0.13 20 -0.86 ± 0.18 0.56 (0.22, 0.91) -0.47 (-1.17, 0.23) 
Q3 (0.33/0.35) 30 0.04 ± 0.18 30 -0.74 ± 0.13 0.34 (-0.08, 0.77) -0.13 (-0.71, 0.44) 
Q4 (0.44/0.47) 31 -0.10 ± 0.15 29 -0.43 ± 0.16 0.14 (-0.24, 0.53) -0.01 (-0.59, 0.56) 
P, trendf 
 
0.70 
 
>0.99 0.67 0.94 
P, interactiong 0.84 0.85 
  
   
 
   
    
EPA (20:5 n-3) 
            
Q1 (0.12/0.11) 33 0.11 ± 0.17 26 -0.51 ± 0.18 Reference Reference 
Q2 (0.22/0.22) 33 -0.14 ± 0.13 27 -0.49 ± 0.19 -0.24 (-0.66, 0.18) 0.02 (-0.53, 0.57) 
Q3 (0.30/0.30) 33 0.17 ± 0.12 27 -0.72 ± 0.18 0.01 (-0.40, 0.43) -0.09 (-0.60, 0.42) 
Q4 (0.40/0.41) 35 0.12 ± 0.16 25 -0.69 ± 0.20 -0.07 (-0.53, 0.40) 0.14 (-0.42, 0.70) 
P, trend 
 
0.68 
 
0.37 0.98 0.71 
P, interaction 0.34 0.77 
             
DPA (22:5 n-3) 
 
   
 
   
    
Q1 (0.11/0.11) 34 0.18 ± 0.13 25 -0.31 ± 0.20 Reference Reference 
Q2 (0.14/0.13) 38 -0.07 ± 0.14 22 -0.44 ± 0.16 -0.35 (-0.74, 0.04) 0.21 (-0.38, 0.80) 
Q3 (0.18/0.18) 32 -0.02 ± 0.19 28 -0.64 ± 0.20 -0.40 (-0.85, 0.04) -0.08 (-0.70, 0.54) 
Q4 (0.23/0.23) 30 0.20 ± 0.12 30 -0.93 ± 0.16 -0.03 (-0.45, 0.39) -0.39 (-0.93, 0.16) 
P, trend 
 
0.71 
 
0.01 0.96 0.07 
P, interaction 0.02 0.17 
  
   
 
   
    
DHA (22:6 n-3) 
 
   
 
   
    
Q1 (0.34/0.32) 40 0.19 ± 0.14 19 -0.35 ± 0.21 Reference Reference 
Q2 (0.49/0.47) 34 -0.02 ± 0.14 26 -0.77 ± 0.22 -0.27 (-0.70, 0.16) -0.14 (-0.80, 0.52) 
Q3 (0.64/0.60) 32 0.31 ± 0.16 28 -0.49 ± 0.18 0.02 (-0.44, 0.47) 0.21 (-0.28, 0.71) 
Q4 (0.92/0.87) 28 -0.29 ± 0.12 32 -0.71 ± 0.14 -0.57 (-1.03, -0.11) 0.01 (-0.58, 0.61) 
P, trend 
 
0.03 
 
0.38 0.03 0.63 
P, interaction 0.54 0.07 
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Supplemental Table 4.1. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 5 years of age among children from Santiago, Chile, stratified by 
weight status at 5 years 
 
5 y - 16 y change in BMI-for-age Z 
score (mean ± SE)b 
Adjusted difference in 5 y - 16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 5 y 
N 
Overweight/ 
obesee at 5 y 
Normal 
weight at 5 y 
Overweight/ 
obese at 5 y 
 
N-6 
            
LA (18:2 n-6) 
            
Q1 (22.09/21.46) 32 -0.11 ± 0.11 27 -0.36 ± 0.18 Reference Reference 
Q2 (25.84/26.18) 33 0.12 ± 0.15 27 -0.70 ± 0.16 0.31 (-0.11, 0.72) -0.48 (-0.99, 0.04) 
Q3 (28.99/28.96) 30 0.01 ± 0.15 30 -0.53 ± 0.18 0.20 (-0.19, 0.59) -0.38 (-0.89, 0.13) 
Q4 (31.98/32.29) 39 0.21 ± 0.16 21 -0.90 ± 0.22 0.41 (-0.02, 0.84) -0.85 (-1.55, -0.15) 
P, trend 
 
0.16 
 
0.11 0.08 0.02 
P, interaction 0.03 0.004 
  
   
 
   
    
GLA (18:3 n-6) 
 
   
 
   
    
Q1 (0.07/0.06) 41 0.18 ± 0.13 18 -0.63 ± 0.27 Reference Reference 
Q2 (0.11/0.12) 36 0.10 ± 0.15 24 -0.75 ± 0.21 0.02 (-0.33, 0.38) 0.00 (-0.74, 0.74) 
Q3 (0.19/0.22) 33 -0.12 ± 0.14 27 -0.51 ± 0.17 -0.18 (-0.61, 0.24) 0.30 (-0.29, 0.90) 
Q4 (0.44/0.39) 24 0.05 ± 0.15 36 -0.56 ± 0.14 -0.09 (-0.46, 0.28) 0.38 (-0.25, 1.00) 
P, trend 
 
0.42 
 
0.61 0.48 0.08 
P, interaction 0.37 0.07 
  
   
 
   
    
DGLA (20:3 n-6) 
 
   
 
   
    
Q1 (0.50/0.22) 39 -0.03 ± 0.11 20 -0.54 ± 0.25 Reference Reference 
Q2 (0.71/0.70) 34 0.08 ± 0.17 26 -0.70 ± 0.22 0.18 (-0.22, 0.59) -0.10 (-0.84, 0.64) 
Q3 (0.86/0.68) 34 0.13 ± 0.12 26 -0.49 ± 0.16 0.18 (-0.15, 0.51) 0.15 (-0.65, 0.94) 
Q4 (1.10/1.05) 27 0.12 ± 0.19 33 -0.66 ± 0.14 0.13 (-0.34, 0.60) 0.05 (-0.63, 0.74) 
P, trend 
 
0.40 
 
0.83 0.40 0.75 
P, interaction 0.51 0.85 
             
AA (20:4 n-6) 
            
Q1 (1.17/1.17) 35 0.03 ± 0.16 24 -0.51 ± 0.21 Reference Reference 
Q2 (1.58/1.57) 34 0.09 ± 0.14 26 -0.60 ± 0.19 0.14 (-0.35, 0.63) 0.02 (-0.60, 0.63) 
Q3 (1.91/1.95) 36 0.02 ± 0.10 24 -0.64 ± 0.19 0.11 (-0.30, 0.51) 0.01 (-0.60, 0.62) 
Q4 (2.25/2.29) 29 0.15 ± 0.20 31 -0.64 ± 0.17 0.21 (-0.31, 0.73) -0.08 (-0.76, 0.60) 
P, trend 
 
0.76 
 
0.62 0.49 0.83 
P, interaction 0.57 0.56 
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Supplemental Table 4.1. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 5 years of age among children from Santiago, Chile, stratified by 
weight status at 5 years 
 
5 y - 16 y change in BMI-for-age Z 
score (mean ± SE)b 
Adjusted difference in 5 y - 16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 5 y 
N 
Overweight/ 
obesee at 5 y 
Normal 
weight at 5 y 
Overweight/ 
obese at 5 y 
 
∆6-Desaturase index (GLA/LA) 
         
Q1 (0.002/0.003) 41 0.17 ± 0.14 18 -0.82 ± 0.29 Reference Reference 
Q2 (0.004/0.004) 35 0.11 ± 0.15 25 -0.61 ± 0.19 0.05 (-0.33, 0.42) 0.35 (-0.39, 1.09) 
Q3 (0.007/0.008) 35 -0.10 ± 0.13 25 -0.52 ± 0.18 -0.22 (-0.60, 0.16) 0.58 (-0.15, 1.31) 
Q4 (0.018/0.016) 23 0.08 ± 0.15 37 -0.54 ± 0.14 -0.04 (-0.44, 0.37) 0.59 (-0.08, 1.26) 
P, trend 
 
0.60 
 
0.47 0.73 0.07 
P, interaction 0.38 0.12 
             
∆5-Desaturase index (AA/DGLA) 
        
Q1 (1.60/1.51) 32 -0.06 ± 0.14 27 -0.56 ± 0.17 Reference Reference 
Q2 (2.00/1.95) 31 0.37 ± 0.18 29 -0.82 ± 0.16 0.52 (0.09, 0.95) -0.38 (-0.85, 0.10) 
Q3 (2.45/2.41) 36 0.04 ± 0.13 24 -0.44 ± 0.20 0.06 (-0.31, 0.43) -0.01 (-0.56, 0.54) 
Q4 (3.54/5.74) 35 -0.06 ± 0.13 25 -0.56 ± 0.21 -0.05 (-0.43, 0.33) -0.14 (-0.71, 0.43) 
P, trend 
 
0.34 
 
0.72 0.21 0.94 
P, interaction 0.40 0.45 
aAccording the World Health Organization Growth Reference 2007 (31) for children ages 5-19 y. 
bEstimates are from growth curves created using mixed effects linear regression models with BMI-for-age Z score as 
the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms 
for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age 
slopes to account for within-child correlations of repeated BMI measurements. 
cAdjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle 
feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), total serum trans fatty acids, palmitoleic 
acid, and serum concentrations of the main exposure PUFA measured in infancy. In addition, all n-3 PUFA are 
adjusted for LA and total long-chain n-6 PUFA, while all n-6 PUFA are adjusted for ALA and total long-chain n-3 
PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear 
and restricted cubic spline terms. 
dBMI-for-age Z score at 5 y ≤1. 
eBMI-for-age Z at 5 y score >1. 
fFrom mixed effects linear regression models with Z score as the outcome and a variable representing medians of 
PUFA quartiles introduced as a continuous predictor. 
gFrom mixed effects linear regression models with an indicator for overweight/obesity as a predictor and cross-
product terms between the indicator and all other predictors in the model. 
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Supplemental Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 10 years of age among children from Santiago, Chile, stratified by 
weight status at 10 years 
 
10 y - 16 y change in BMI-for-age Z score 
(mean ± SE)b 
Difference in 10 y -16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 10 y 
N 
Overweight/ 
obesee at 10 y 
Normal 
weight at 10 y 
Overweight/ 
obese at 10 y 
Overall 190 -0.07 ± 0.05 228 -0.51 ± 0.05 
    
  
   
 
   
    
N-3 
 
   
 
   
    
ALA (18:3 n-3) 
 
   
 
   
    
Q1 (0.26/0.28) 60 0.03 ± 0.08 44 -0.46 ± 0.09 Reference Reference 
Q2 (0.37/0.37) 48 -0.07 ± 0.09 57 -0.61 ± 0.11 -0.09 (-0.33, 0.14) -0.15 (-0.41, 0.12) 
Q3 (0.43/0.44) 49 -0.14 ± 0.09 56 -0.48 ± 0.08 -0.16 (-0.39, 0.08) -0.07 (-0.33, 0.19) 
Q4 (0.55/0.57) 33 -0.15 ± 0.10 71 -0.48 ± 0.09 -0.11 (-0.36, 0.14) 0.00 (-0.24, 0.24) 
P, trendf 
 
0.11 
 
0.77 0.27 0.68 
P, interactiong 0.19 0.28 
  
   
 
   
    
EPA (20:5 n-3) 
        
    Q1 (0.11/0.10) 53 -0.11 ± 0.08 51 -0.42 ± 0.10 Reference Reference 
Q2 (0.21/0.20) 48 -0.19 ± 0.09 57 -0.55 ± 0.08 -0.05 (-0.28, 0.17) -0.10 (-0.36, 0.16) 
Q3 (0.28/0.29) 42 0.09 ± 0.09 63 -0.51 ± 0.09 0.22 (-0.02, 0.47) -0.06 (-0.34, 0.22) 
Q4 (0.45/0.39) 47 -0.06 ± 0.10 57 -0.52 ± 0.10 0.05 (-0.19, 0.29) -0.14 (-0.41, 0.13) 
P, trend 
 
0.38 
 
0.64 0.40 0.40 
P, interaction 0.35 0.24 
         
    DPA (22:5 n-3) 
 
   
 
       Q1 (0.14/0.15) 53 -0.03 ± 0.08 51 -0.51 ± 0.08 Reference Reference 
Q2 (0.19/0.19) 49 -0.12 ± 0.10 56 -0.57 ± 0.10 -0.08 (-0.31, 0.15) -0.04 (-0.31, 0.23) 
Q3 (0.23/0.23) 43 -0.10 ± 0.09 62 -0.43 ± 0.08 -0.08 (-0.34, 0.19) 0.04 (-0.22, 0.29) 
Q4 (0.29/0.28) 45 -0.04 ± 0.10 59 -0.51 ± 0.10 -0.04 (-0.33, 0.24) -0.12 (-0.41, 0.18) 
P, trend 
 
0.98 
 
0.80 0.80 0.52 
P, interaction 0.87 0.78 
  
   
 
   
    
DHA (22:6 n-3) 
 
   
 
   
    
Q1 (0.41/0.44) 44 -0.23 ± 0.10 60 -0.62 ± 0.09 Reference Reference 
Q2 (0.58/0.56) 46 -0.04 ± 0.08 59 -0.51 ± 0.09 0.17 (-0.08, 0.43) -0.01 (-0.31, 0.29) 
Q3 (0.68/0.68) 57 0.03 ± 0.08 48 -0.33 ± 0.09 0.23 (-0.05, 0.50) 0.21 (-0.10, 0.52) 
Q4 (0.91/0.90) 43 -0.09 ± 0.10 61 -0.52 ± 0.10 0.16 (-0.16, 0.48) 0.08 (-0.24, 0.39) 
P, trend 
 
0.40 
 
0.43 0.45 0.61 
P, interaction 0.94 0.83 
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Supplemental Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 10 years of age among children from Santiago, Chile, stratified by 
weight status at 10 years 
 
10 y - 16 y change in BMI-for-age Z score 
(mean ± SE)b 
Difference in 10 y -16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 10 y 
N 
Overweight/ 
obesee at 10 y 
Normal 
weight at 10 y 
Overweight/ 
obese at 10 y 
N-6 
        
    LA (18:2 n-6) 
 
   
    
    Q1 (26.24/25.66) 47 0.01 ± 0.09 57 -0.68 ± 0.11 Reference Reference 
Q2 (29.98/29.74) 38 -0.18 ± 0.12 67 -0.40 ± 0.08 -0.18 (-0.46, 0.11) 0.40 (0.09, 0.70) 
Q3 (32.54/32.66) 53 -0.03 ± 0.08 52 -0.53 ± 0.09 0.01 (-0.26, 0.28) 0.20 (-0.11, 0.51) 
Q4 (35.79/35.71) 52 -0.11 ± 0.08 52 -0.42 ± 0.09 -0.25 (-0.55, 0.05) 0.16 (-0.21, 0.54) 
P, trend 
 
0.52 
 
0.12 0.20 0.54 
P, interaction 0.11 0.19 
  
   
 
       GLA (18:3 n-6) 
 
   
 
   
    
Q1 (0.06/0.07) 47 -0.04 ± 0.10 57 -0.39 ± 0.09 Reference Reference 
Q2 (0.11/0.11) 56 -0.14 ± 0.08 49 -0.54 ± 0.10 -0.11 (-0.34, 0.12) -0.16 (-0.45, 0.13) 
Q3 (0.21/0.19) 45 0.04 ± 0.10 60 -0.65 ± 0.09 0.02 (-0.24, 0.28) -0.21 (-0.47, 0.05) 
Q4 (0.40/0.34) 42 -0.11 ± 0.08 62 -0.44 ± 0.09 -0.14 (-0.39, 0.10) -0.04 (-0.30, 0.22) 
P, trend 
 
0.85 
 
0.96 0.45 0.93 
P, interaction 0.87 0.56 
  
   
 
   
    
DGLA (20:3 n-6) 
 
   
 
   
    
Q1 (0.85/0.86) 63 -0.06 ± 0.09 41 -0.55 ± 0.09 Reference Reference 
Q2 (1.07/1.08) 50 -0.16 ± 0.09 55 -0.43 ± 0.09 -0.10 (-0.35, 0.15) 0.25 (0.01, 0.50) 
Q3 (1.27/1.27) 43 -0.03 ± 0.07 62 -0.51 ± 0.09 0.03 (-0.19, 0.25) 0.20 (-0.07, 0.46) 
Q4 (1.53/1.56) 34 -0.01 ± 0.11 70 -0.54 ± 0.10 0.12 (-0.16, 0.39) 0.18 (-0.11, 0.46) 
P, trend 
 
0.64 
 
0.80 0.29 0.55 
P, interaction 0.61 0.79 
         
    AA (20:4 n-6) 
        
    Q1 (2.20/2.23) 36 -0.14 ± 0.11 68 -0.60 ± 0.07 Reference Reference 
Q2 (2.81/2.80) 53 -0.09 ± 0.08 52 -0.52 ± 0.11 0.10 (-0.17, 0.36) 0.08 (-0.21, 0.38) 
Q3 (3.34/3.38) 48 -0.03 ± 0.09 57 -0.47 ± 0.10 0.12 (-0.15, 0.39) 0.22 (-0.05, 0.48) 
Q4 (4.28/4.18) 53 -0.04 ± 0.08 51 -0.40 ± 0.10 0.12 (-0.20, 0.44) 0.25 (-0.07, 0.57) 
P, trend 
 
0.46 
 
0.10 0.56 0.10 
P, interaction 0.54 0.41 
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Supplemental Table 4.2. Changes in BMI-for-age Z scoresa by serum biomarkers of 
polyunsaturated fatty acids at 10 years of age among children from Santiago, Chile, stratified by 
weight status at 10 years 
 
10 y - 16 y change in BMI-for-age Z score 
(mean ± SE)b 
Difference in 10 y -16 y change 
(95% CI)c 
Fatty acid quartile (median, 
normal weight/overweight, 
weight % of total FA) 
N 
Normal 
weightd at 10 y 
N 
Overweight/ 
obesee at 10 y 
Normal 
weight at 10 y 
Overweight/ 
obese at 10 y 
 
∆6-Desaturase index (GLA/LA) 
         
Q1 (0.002/0.002) 49 -0.07 ± 0.09 55 -0.35 ± 0.09 Reference Reference 
Q2 (0.004/0.004) 54 -0.05 ± 0.09 51 -0.65 ± 0.10 -0.04 (-0.28, 0.20) -0.26 (-0.54, 0.03) 
Q3 (0.007/0.006) 46 -0.03 ± 0.09 59 -0.59 ± 0.09 -0.03 (-0.27, 0.21) -0.21 (-0.48, 0.06) 
Q4 (0.014/0.012) 41 -0.14 ± 0.10 63 -0.44 ± 0.09 -0.16 (-0.43, 0.10) -0.04 (-0.32, 0.24) 
P, trend 
 
0.53 
 
0.93 0.23 0.67 
P, interaction 0.62 0.25 
             
∆5-Desaturase index (AA/DGLA) 
         
Q1 (1.85/1.77) 29 0.09 ± 0.10 75 -0.57 ± 0.08 Reference Reference 
Q2 (2.42/2.39) 40 -0.14 ± 0.09 65 -0.51 ± 0.10 -0.24 (-0.49, 0.01) 0.11 (-0.14, 0.37) 
Q3 (2.99/3.02) 57 -0.14 ± 0.09 48 -0.45 ± 0.09 -0.29 (-0.53, -0.04) 0.23 (-0.01, 0.48) 
Q4 (3.94/3.72) 64 -0.03 ± 0.08 40 -0.45 ± 0.10 -0.16 (-0.45, 0.13) 0.12 (-0.18, 0.42) 
P, trend 
 
0.76 
 
0.30 0.58 0.32 
P, interaction 0.34 0.27 
aAccording the World Health Organization Growth Reference 2007 (31) for children ages 5-19 y 
bEstimates are from growth curves created using mixed effects linear regression models with BMI-for-age Z score as 
the outcome, and predictors that included indicator variables for each PUFA quartile, a linear term for age, and 
interaction terms between the quartiles and age. All models included random intercepts to account for within-child 
correlations of repeated BMI measurements. 
cAdjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle 
feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), total serum trans fatty acids, palmitoleic 
acid, and serum concentrations of the main exposure PUFA measured in infancy. In addition, all n-3 PUFA are 
adjusted for LA and total long-chain n-6 PUFA, while all n-6 PUFA are adjusted for ALA and total long-chain n-3 
PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear 
and restricted cubic spline terms. 
dBMI-for-age Z score at 10 y ≤1 
eBMI-for-age Z score at 10 y >1 
fFrom mixed effects linear regression models with Z score as the outcome and a variable representing medians of 
PUFA quartiles introduced as a continuous predictor. 
gFrom mixed effects linear regression models with an indicator for overweight/obesity as a predictor and cross-
product terms between the indicator and all other predictors in the model. 
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Chapter 5. Conclusions 
 
Summary of main findings 
This dissertation expands current understanding of PUFA nutrition in Latin American 
settings, and helps to clarify the relations between these nutrients and the development of 
cardiometabolic disease risk in childhood. 
In chapter 2, we identified sociodemographic, anthropometric, and dietary predictors of 
adipose tissue PUFA concentrations among a group of parents and their school-age children 
from 9 Mesoamerican countries. Mean adipose LA and ALA weight percentages across 
participants from all countries were comparable those in populations from mostly high-income 
countries (1). However, levels among participants from some countries were much lower which 
may indicate heterogeneity of intake throughout the region. Furthermore, although we 
determined that characteristics such as height, BMI, and smoking status were related to specific 
PUFA biomarkers in children and adults, the strongest predictor of all PUFA was country of 
origin. This is consistent with a study of plasma PUFA in participants from multiple European 
countries (2) and likely represents differences in diet and lifestyle. We also found that the type of 
cooking oil used in the home was a significant predictor of both essential and long-chain PUFA, 
despite low levels of preformed long-chain PUFA in vegetable oils. This is consistent with 
results from previous studies in Costa Rica (3,4) and a trial of sunflower and soyabean oils in 
Colombia (5). High adipose ALA among canola and soyabean oil users and low levels of all 
PUFA in palm oil users are consistent with the PUFA content of these oils in Latin American 
 171 
countries (6–8). High LA among participants who used soyabean oil are consistent with previous 
analyses from Costa Rica (3). High long-chain n-3 PUFA among canola oil users is consistent 
with high ALA levels in canola oil; however, these participants also had among the highest 
levels of long-chain n-6 PUFA. The reason for this is uncertain. Other dietary correlates of 
adipose tissue PUFA differed somewhat between adults and children, and were generally less 
strongly predictive of these biomarkers than cooking oil type. 
In chapter 3, we investigated associations between adipose tissue PUFA biomarkers and 
MetS in the same Mesoamerican population. Among adults, ALA was inversely associated with 
MetS which is in line with previous studies of adipose tissue PUFA (9–11). ALA could be 
protective against MetS through enhancement of membrane fluidity and glucose transport as a 
result of its incorporation into cell membranes (12). Unexpectedly, EPA was positively 
associated with MetS. This is consistent with a Costa Rican study that measured PUFA in 
adipose tissue (11) but inconsistent with evidence for protective associations between EPA and 
multiple MetS components (13,14). Adipose tissue EPA may not reflect levels of this PUFA in 
plasma membranes which could be directly related to MetS (15). This association may also be 
specific to Mesoamerican populations. DGLA and the D6D activity index were both positively 
associated with MetS. The association with DGLA is consistent with many (16–19) but not all 
(20,21) previous studies, and associations between D6D and MetS have also been described 
(22,23). The association with D6D activity may be mediated by its effect on DGLA levels in 
tissue, or D6D and DGLA may exert independent effects. ALA was not associated with 
metabolic score among children, which is consistent with the small number of existing studies 
(24–26). The effects of ALA may be cumulative from childhood, or ALA could only be related 
to extreme metabolic dysregulation and the association was not apparent with a continuous 
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metabolic score. DPA was positively associated with metabolic score in children, while EPA and 
DHA were not associated. Our results in conjunction with those of previous investigations (24–
33) do not consistently indicate a protective effect of long-chain n-3 PUFA on metabolic health 
in childhood. Finally, LA, DGLA, AA, and the D6D and D5D activity indices were all positively 
associated with waist circumference. This may indicate that n-6 PUFA generally have 
adipogenic effects in childhood (34). 
In chapter 4, we assessed the relations between serum PUFA in middle childhood and 
BAZ change through adolescence in a cohort of Chilean children. DHA at 5 y of age was 
inversely associated with BAZ change between ages 5 and 16 y, which is consistent with a few 
cross-sectional studies (24,35,36) but inconsistent with two previous longitudinal studies (37,38) 
and trials of DHA+EPA (27) or DHA supplements (28). DHA could reduce weight gain by 
promoting satiety (39) or upregulating oxidation of fatty acids and downregulating lipogenesis 
(40). Serum AA at 10 y of age and change in AA between ages 5 and 10 y were positively 
associated with BAZ change from ages 10 to 16 y. AA is the precursor for the eicosanoid 
prostacyclin, which promotes differentiation of preadipocytes into adipocytes (34) and thus could 
promote adipogenesis. Most studies have not found similar associations, including two 
longitudinal investigations (37,38). Discrepancies could be related to differences in AA levels 
among different populations. Alternatively, AA at age 10 y was inversely associated with BAZ at 
10 y, and our finding may reflect this rather than an effect of AA on subsequent BAZ change. 
Change in the D5D activity index was also positively associated with subsequent BAZ change, 
despite prior evidence for an inverse association (41). This finding may also have been driven by 
an inverse association with baseline BAZ. Neither ALA nor LA were associated with BAZ 
change in the entire sample, though LA at 5 y of age was inversely associated with BAZ change 
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among children with overweight or obesity. LA (37) and ALA (38) have each been inversely 
associated with weight change in previous investigations, and discrepancies may be related to 
differences in intake levels or unmeasured confounding by other aspects of diet. 
Our results were generally inconsistent between the analyses of PUFA and MetS and 
adiposity. In particular, specific long-chain n-3 PUFA were positively associated with MetS but 
inversely associated with BAZ change; DGLA was strongly associated with MetS among adults 
but not related to BAZ change, while AA was positively associated with BAZ change but not 
related to MetS. One possible explanation may be that the results from chapter 3 are biased by 
reverse causation, whereas those from chapter 4 are not. There may also be effect modification 
by region of the associations between PUFA and cardiometabolic risk (42), possibly due to 
differences between the study populations in terms of genetic background or dietary context. 
One of the strengths of this dissertation is the use of objective biomarkers to measure 
PUFA status, which are not subject to recall bias or systematic errors from the determination of 
nutrient composition of foods. Adipose tissue and serum concentrations of specific PUFA are 
correlated with dietary measures (1). In particular, adipose tissue fatty acids are the gold standard 
biomarkers of fatty acid status because they reflect long-term intake (1), and these biomarkers 
have not been widely used in pediatric research. The family design of the study in chapters 2 and 
3 allowed us to examine associations separately in adults and children within the same 
population. In chapter 4, the prospective design greatly limits the possibility of reverse causation 
and allowed us to examine associations between PUFA and adiposity at multiple developmental 
periods. Finally, this work as a whole provides new information on PUFA nutrition and its 
relation to early-life cardiometabolic risk in populations where these associations have not been 
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well-characterized, and where both low PUFA intake (43) and chronic disease (44) are of public 
health concern. 
Among the limitations of this dissertation is the cross-sectional design of the 
Mesoamerican study, which prevents causal inference. Because of this, we cannot rule out the 
possibility that reverse causation might explain some of the findings in chapter 3 if, for example, 
metabolic dysregulation affects desaturase activity. The study population was not intended to be 
representative of any particular group, which may limit the generalizability of our findings. The 
relatively small number of children in the study population could have limited statistical power. 
In the Chilean cohort, most covariates were only measured in infancy, so there may be residual 
confounding of the associations by childhood characteristics. Some of the results may be related 
in part to cross-sectional associations between serum PUFA and BAZ, which could be subject to 
reverse causation. Finally, serum fatty acids are responsive to short-term intake, so the use of a 
single serum PUFA measurement might misclassify individuals with respect to their habitual 
diet. 
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Public health implications and future directions 
The state of PUFA nutrition in Latin America is poorly characterized, but available 
evidence suggests that intake of these nutrients is inadequate (43,45,46). In addition, the burden 
of chronic disease in the region is large and growing (44), in conjunction with a high prevalence 
of early-life risk factors such as childhood obesity (47) and metabolic dysregulation (48). As the 
nutrition transition continues in many of these countries, identifying dietary targets for 
prevention of cardiometabolic diseases is crucial to reduce their impact on population health. 
Improving PUFA nutrition is a potentially promising avenue for intervention, but little is known 
about the sociodemographic and dietary patterning of PUFA status in Latin America, or the 
relations between PUFA and cardiometabolic risk in childhood. This dissertation contributes to 
knowledge in these areas, which is essential to the design and implementation of adequate 
interventions. 
In chapter 2, we found that country of origin was a substantial source of variation in 
adipose tissue PUFA concentrations. This suggests that there is heterogeneity in intake of PUFA 
across different populations within Latin America, and emphasizes the need for further 
surveillance efforts in order to identify groups who may be at risk of inadequate intake. Our 
sample size did not allow for extensive within-country analyses; future work in this area could 
clarify the mechanisms driving the differences between countries and inform the design of 
policies or interventions targeting the specific causes of low PUFA status in places such as El 
Salvador and Honduras. This should involve studies with larger sample sizes from specific 
countries, and potentially measurement of single nucleotide polymorphisms (SNPs) that have 
previously been identified as being associated with tissue PUFA levels in order to determine the 
extent to which between-country differences are influenced by genetics and environment. Our 
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findings corroborate those from previous studies in Latin American contexts (3–5) that suggest 
that the type of vegetable oil used for cooking in the home is a primary dietary determinant of 
PUFA intake and status. In a trial of soyabean and sunflower cooking oils conducted in Bogotá, 
Colombia, the use of high-PUFA oils increased blood levels of long-chain PUFA as well as 
essential PUFA, and switching to this type of oil was feasible and acceptable for most families 
(5). Our results and those from this trial suggest that interventions designed to promote 
replacement of palm oil with canola or soyabean oils high in LA and ALA could be effective at 
increasing PUFA status in Mesoamerican populations, and warrants studying their effects in 
future randomized trials. Nevertheless, interventions should be tailored to national dietary and 
cultural contexts; the selection of adequate replacement oils should take into consideration issues 
such as accessibility and cost, acceptability, and the trans fat content of specific types of oils 
within different countries. 
Our finding that ALA is inversely associated with MetS among Mesoamerican adults 
should be investigated further. Our results are in agreement with a study conducted in Costa Rica 
(11) and may indicate that increasing ALA intake in this population would help to combat the 
development of MetS and resulting cardiometabolic diseases. A protective effect of ALA against 
coronary heart disease may be greatest when intake of long-chain n-3 PUFA is low (49). This 
indicate that increasing ALA intake in Latin American populations with low fish consumption 
could be especially important for cardiometabolic health. Moreover, we did not find that any 
long-chain n-3 PUFA were protective against MetS among either adults or children; in fact, EPA 
and DPA were positively associated with MetS and metabolic score, respectively. The 
mechanisms behind these unexpected associations are speculative, but the results may suggest 
that long-chain n-3 PUFA would not be effective targets for intervention against MetS among 
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Mesoamerican adults or children. Nevertheless, our study was cross-sectional and our results 
could be explained by reverse causation. While our findings provide preliminary evidence that 
ALA intake is a more important target than long-chain n-3 PUFA for intervening on MetS, 
confirmation with longitudinal designs would provide stronger evidence for causality. If the 
association were confirmed in longitudinal studies, it would further underscore the need to 
conduct trials of interventions designed to increase ALA intake, possibly through choice of 
cooking oils. 
In the Chilean cohort, DHA was inversely associated with BAZ change. This finding is 
not consistently supported by existing studies, and requires further investigation with 
longitudinal observational investigations or randomized trials. If future studies also find evidence 
for a protective effect of DHA on adiposity in childhood, it will be important to determine what 
types of interventions could feasibly increase DHA status in areas where fish availability is low, 
and could be sustainable in the long-term given decreasing global fish stocks (50). 
The positive association of serum AA and BAZ gain could be consistent with our finding 
from chapter 3 that LA, AA, and DGLA were positively associated with waist circumference 
among Mesoamerican children. AA serves as a precursor to prostacyclin, an eicosanoid that 
promotes differentiation of preadipocytes into adipocytes and thus may promote adipogenesis in 
early life (34). LA and DGLA are precursors in the synthesis of AA and could operate through 
this effect of prostacyclin. Most studies of PUFA and measures of adiposity among children have 
not found similar associations, so our results should be tested through replication of these 
analyses in other longitudinal studies. However, the possibility of a positive association between 
n-6 PUFA and adiposity in childhood is worth investigating, particularly given that some 
populations in Latin America may be at heightened risk of developing insulin resistance as a 
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result of adiposity (51,52). The effect of n-6 PUFA on obesity in children is important to 
consider in the design of interventions intended to increase n-3 PUFA consumption, since LA 
and ALA co-occur in many of their dietary sources. For example, this may suggest that canola 
oil is a healthier choice than soyabean oil, given its comparatively lower LA content. 
In summary, the research in this dissertation indicates that PUFA status of different 
populations within Latin America is heterogeneous, and is related to the type of vegetable oil 
used for cooking at home. In children, PUFA status is related to metabolic dysregulation and 
adiposity, and thus could have effects on long-term cardiometabolic health. Further studies in 
pediatric populations are needed, both to confirm the associations we found between specific 
PUFA and cardiometabolic risk factors and to investigate dietary interventions that would affect 
PUFA status in this region. Nevertheless, our results indicate that nutrition with regard to PUFA 
is plausibly related to cardiometabolic health in childhood, and that it is worth pursuing as a 
means of reducing the public health burden of chronic disease. 
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